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This work elucidates the properties of human colon mucosa in ulcerative colitis (UC) on the 
protein level. We developed an optimized sample preparation method of colon mucosa biopsies 
for bottom-up proteomics. This method applies a lysis buffer of 8M urea, 5% sodium 
deoxycholate, and 100 mM TEAB. It showed superior reproducibility and identification 
numbers. With this method, we acquired the to-date deepest proteome data set from colon 
mucosa biopsies with more than 8,000 quantified proteins. The investigated states comprise 
active UC, remission from UC, and healthy controls. We performed enrichment analyses of GO 
annotations among differently abundant proteins.  
We observed increased abundances among proteins related to the immune system and to protein 
processing in the endoplasmic reticulum (ER) in active UC compared to healthy controls. 
Lower abundant are metallothioneins, fibrillary collagens, bile acid transport proteins, carbonic 
anhydrases, and proteins related to nutrient, energy, and xenobiotic metabolism.  
In general, the remission state seems to be a blend of healthy and diseased state. We 
characterized the remission state based on the proteins that were significantly different 
abundant in remission compared to active UC and/or healthy controls. A small fraction of these 
proteins (associated functions: hormones, vitamins, lipoproteins, muscle) is higher abundant in 
remission than in both active UC and healthy controls. Most proteins (associated functions: 
immune system, protein processing, collagen) show similar abundances in remission as in 
healthy controls. About one fourth of the remission abundances (associated functions: nutrient 
and energy metabolism, PPAR signaling) was between those in active UC and healthy controls 
and significantly different from both. Approximately one eighth of the proteins was at similar 
levels as in active UC (associated functions: immunoglobulins, metallothioneins, prostaglandin 
metabolism). Protein abundances that are not at equal levels as in healthy controls may 
contribute to relapses and symptoms in remission.  
In addition to improving our understanding of UC, our findings have some clinical implications. 
Several functions apart from the inflammation could be readily addressable with medication. 
For instance, late metabolites such as the ketone body β-hydroxybutyrate could potentially 
circumvent some impairments in the nutrient metabolism and thereby ameliorate the energy 
deficiency in colonocytes. It may furthermore lead to metallothionein induction.  
Our results have implications for the use of biomarkers in UC. The abundance changes of the 
routinely used calprotectin proteins and lactotransferrin are representative for only a small 
minority of differently abundant proteins. An additional assessment of more representative 
proteins may be useful. We furthermore present a model for the prediction of the 1-year-
outcome that could bring great benefit for clinical decision-making.      
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1.1 Inflammatory Bowel Disease 
Ulcerative colitis (UC) and Crohn’s disease (CD) share clinical manifestations. Hence, they are 
often summarized as inflammatory bowel disease (IBD), even though they are distinct 
pathophysiological entities.[3] Both diseases are chronic inflammatory intestinal disorders, but 
they differ in the location and nature of the inflammatory changes.[4] UC presents with 
continuous, non-transmural (i.e. limited to epithelial lining) inflammation of the mucosa that is 
limited to the large intestine. In 95% of the cases UC affects the rectum, from where it can 
extend to more proximal parts of the large intestine in a continuous and circumferential 
manner.[5] CD on the other hand presents with transmural (i.e. it affects the entire bowel wall) 
and discontinuous inflammation that can affect all segments of the gastrointestinal tract from 
mouth to anus.[6] UC is less prone to complications than CD and its course is in many patients 
comparatively mild.[3] 
1.1.1 Epidemiology and role of environmental factors 
At the turn of the 21st century IBD has become a global disease.[7] The worldwide burden of 
IBD is increasing over time.[8] After the prevalence in North America and Western Europe 
increased since the mid of the 20th century [3, 9], the incidence in these regions has by now 
stabilized.[5, 7] The incidence in newly industrialized countries that are becoming more 
westernized is still increasing.[7] For instance in China, IBD has changed from being rare to 
now being responsible for one fourth of the occupied gastroenterological and colorectal surgical 
hospital beds.[10] When IBD is newly diagnosed in a population, UC precedes CD and appears 
with a higher incidence.[3]  
The highest annual incidence for UC is 24.3 per 100 000 person-years in Europe, 19.2 per 
100,000 person-years in North America, and 6.3 per 100 000 person-years in Asia (see Figure 
1).[8] The highest prevalence values were reported for Europe (505 per 100 000 in Norway) 
and North America (286 per 100,000 in the USA).[11] The peak-age for disease onset is 30-40 
years [11, 12] with a slight gender predominance that rests with men.[12, 13] The highest 
annual incidence for CD is 12.7 per 100,000 person-years in Europe, 20.2 per 100,000 person-
years in North America, and 5.0 per 100,000 person-years in Asia and the Middle East.[8] Like 
for UC, the highest reported prevalence values for CD are in Europe (322 per 100,000 in 
Germany) and North America (319 per 100,000 in Canada).[8] 
Relatives of IBD patients and Jewish populations show a higher rate of developing CD and 
UC.[14] Genome analyses identified 200 risk loci, of which most contribute to both ulcerative 
colitis and Crohn’s disease.[11] However, around 10 % of IBD can be explained by genetic 




Figure 1 - Worldwide incidences of the IBD forms UC and CD. Used with permission from [7] 
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Both diseases are disorders of modern societies. The incidence of IBD increased strongly since 
the mid of the 20th century[3, 9], for which environmental factors are primarily responsible.[9] 
A possible explanation is that the body is not properly adapted to the rapid environmental 
changes. In an attempt to adjust to those changes with altered neuronal and endocrine responses 
a complex disruption of homeostasis occurs.[9, 17] Associations with IBD have been shown 
for several, seemingly unrelated, environmental factors. Most supported by evidence are 
associations of IBD with smoking and the enteric bacterial flora.[9]  
The role of smoking in IBD is ambiguous, as it has protective effects in UC, but increases the 
risk of developing CD and worsens its clinical course.[9] Former smoking has been identified 
as a strong risk factor for UC development, while active smoking decreases the risk to develop 
the disease and the severity of the disease course.[11] The mechanisms for the differential 
effects are not clear. However, many components of cigarette smoke possibly have 
immunomodulatory effect, and nicotine inhibits both innate and adaptive immune 
responses.[18] 
Evidence suggests that both forms of IBD result from an inappropriate immune reaction to 
intestinal microbes[19], probably to those that form the normal enteric flora.[9] The role of the 
microbiota is supported by the observation that most animal models of IBD do not develop 
inflammation, if the animals are kept in a germ-free environment.[20] It is further supported by 
beneficial effects of antibiotics on CD and to a lesser degree also on UC.[9] Increasing hygiene 
in developed countries and the resulting decreased microbial burden are believed to contribute 
to the rising prevalence of IBD.[21] 
Further factors associated with IBD are stress, diet, drugs (primarily oral contraceptives and 
nonsteroidal anti-inflammatory drugs), latitude (IBD more common in North than in the South 
of Europe and North America), intestinal permeability, appendectomy (negative association 
with UC), occupation, as well as social, economic and educational status.[9] 
1.1.2 Pathogenesis of IBD 
UC has a complex and not fully understood pathogenesis that involves genetic factors, 
environmental influences, epithelial barrier defects, and a dysregulated immune response.[9, 
11, 22]  
The gastrointestinal (GI) tract has a mean surface of 32 m2, of which 2 m2 belong to the large 
intestines.[23] The highest bacterial populations in humans occur in the large intestines and 
reach 1012 bacteria/cm3. The bacterial flora of the large intestines comprises more than 1,000 
species. The compositions vary from person to person.[24] As a result of the GI tract’s large 
contact area with bacteria and their high number and variety, the GI tract is a central site to the 
immune system. In the healthy GI tract, the innate and the adaptive immune systems are 
balanced in complex interactions with the bacterial flora. Environmental factors trigger a 
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disruption of this balance in genetically susceptible individuals, which results in the intestinal 
inflammation observed in IBD.[22] These environmental factors transiently break the mucosal 
barrier, trigger an immune reaction, or alter the balance between pathogenic and beneficial 
microbes.[25] 
Findings from human genetics, animal models, basic science and clinical trials indicate that UC 
and CD are heterogeneous diseases, in which various genetic abnormalities cause T cells to 
react overly aggressive to commensal bacterial flora. It is widely believed that the manifestation 
of IBD results when four different components intersect: An (1) overly aggressive T cell 
response to a (2) subset of commensal bacteria and (3) triggering environmental factors cause 
the onset or reactivation of the disease in (4) genetically susceptible individuals (see Figure 
2).[25] 
 
Figure 2 - Four components lead to IBD. Used with permission from [25]  
The UC pathogenesis has traditionally been identified as a TH2-like disease, while CD has been 
linked to TH1 cells. More recently, a role of an imbalance between TH17 cells and regulatory T 
(Treg) cells in IBD has been suggested.[22, 26] TH2, TH1 and TH17 cells are effector T helper 
(TH) cells and subgroups of CD4+ T cells. They secrete characteristic cytokines. The cytokines 
secreted by TH2 cells comprise interleukin-4, 5, and 13, whereas TH1 cells secrete interferon-γ 
and TNF-α and TH17 cells secrete interleukin-17. As effector T helper cells, TH2, TH1 and TH17 
cells are crucial in protecting the host from pathogens and from excessive entry of luminal 
bacteria, but their proper regulation is a prerequisite for maintaining intestinal immune 
homeostasis.[19]  
Specific hypotheses suggest roles in the IBD pathogenesis for persistent infections with specific 
pathogens, dysbiosis, mucosal barrier dysfunctions, and defective microbial clearance.[25] 
 
11 
A role of persistent infections with specific pathogens was suggested for various bacteria. 
Mycobacterium avium paratuberculosis was the first bacterium implicated as an IBD pathogen 
possibly causing CD.[27, 28] Subsequently further potential IBD pathogens were suggested, 
including Adherent-Invasive Escherichia coli (AIEC) and various Helicobacter species. AIEC 
is particularly of interest, because it can strongly stimulate the secretion of TNF-α, which is a 
key cytokine in IBD.[28] The risk for the development of both UC and CD is increased in 
patients who experienced episodes of Salmonella or Campylobacter gastroenteritis.[29] The 
“cold chain hypothesis” suggests that domestic refrigeration is a risk factor for CD due to 
psychrotrophic bacteria, which can grow slowly at low temperatures, e.g. Yersinia 
enterocolitica, Listeria monocytogenes, and Clostridium botulinum.[30] A role in the IBD 
pathogenesis has furthermore been suggested for fungi (Saccharomyces cerevisiae, Candida 
albicans) and viruses (especially cytomegalovirus (CMV), but also parvovirus B19, norovirus, 
and Epstein–Barr virus). On the contrary, in line with the “IBD hygiene hypothesis” a lack of 
exposure to helminthic parasites may predispose to CD development.[31, 32] Further research 
is necessary to attribute a causative role of specific pathogens to the IBD pathogenesis, because 
it is often unknown whether a pathogen associated with IBD causes the disease, or whether the 
disease causes conditions that are suitable for proliferation of the respective pathogen.[28]  
Dysbiosis describes a state of imbalance between aggressive and beneficial microbes, which 
could lead to intestinal conditions that trigger chronic inflammation in susceptible hosts. An 
over-representation of commensal bacteria such as Escherichia coli, Bacteroides, Enterococcus 
and Klebsiella species seems to favor inflammation, whereas Lactobacillus and 
Bifidobacterium species probably have protective effects.[25, 33] Dietary components can alter 
the intestinal bacterial composition. For instance, non-absorbable carbohydrates like inulin and 
fructose oligosaccharides support the growth of the beneficial Bifidobacterium and 
Lactobacillus species. Iron, which is a common food additive in Western diets, enhances the 
growth and virulence of intracellular bacteria.[28] A role of iron in IBD is further supported by 
the finding that supplementation with iron enhances inflammation in rats with dextran sulfate 
sodium (DSS)-induced colitis.[34] 
A dysfunction of the mucosal barrier could increase the uptake of luminal antigens and 
adjuvants, which could in turn overwhelm the suppressive capacities of the mucosal immune 
system.[25] The mucus layer in healthy individuals consists of two substructures, one tightly 
adherent inner layer that is mostly sterile, and a loosely adherent outer layer that is good for 
microbial growth. In IBD, particularly CD, an increase of bacteria associated with the adherent 
mucus layer occurs, e.g. mucosa-associated Escherichia coli.[35] An alternative mechanism is 
that an impairment of repair capabilities in the epithelium could potentiate damage from 
infections and agents like NSAIDs. One hypothesis is that IBD results from such damage and 
a subsequent failure to down-regulate the resulting immune reaction.[25] 
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Defective microbial clearance (i.e. defective bacterial killing) is a possible factor in the 
pathogenesis of CD.[25] This is supported by the finding that approximately one-third of CD 
patients have loss-of-function mutation in the NOD2 (synonym: CARD15) gene. Nucleotide-
binding oligomerization domain 2 (NOD2) is an intracellular receptor for muramyl dipeptides, 
which is a component of bacterial peptidoglycan. Upon activation, NOD2 leads to NF-κB-
dependent pro-inflammatory cytokine expression[36], α-defensin expression[37], and possibly 
killing of intracellular bacteria.[25, 38] 
NOD2 was the first susceptibility gene identified for CD. Further genes associated with CD are 
related to autophagy, which is a process for clearing unnecessary components. Among those 
genes are for instance those coding for Autophagy-related protein 16-1 (ATG16L1)[39] and 
Immunity-related GTPase family M protein (IRGM).[19, 40] Among the gene loci associated 
with UC are human leukocyte antigen (HLA) and several that contribute to the mucosal barrier 
function, e.g. the genes coding for Cadherin-1 (CDH1) and Hepatocyte nuclear factor 4-alpha 
(HNF4A).[11, 41] Genetic associations with both UC and CD have been shown for multiple 
genes of the interleukin-23–TH17 pathway, which is crucial for the function of TH17 cells. The 
interleukin-23–TH17 pathway mediates intestinal inflammation and defense against microbes. 
The genes coding for Interleukin-23 receptor (IL23R), Interleukin-12 subunit beta (IL12B) and 
Signal transducer and activator of transcription 3 (STAT3) are associated with both UC and 
CD, whereas the gene coding for C-C chemokine receptor type 6 (CCR6) is associated only 
with CD.[19, 42] 
1.1.3 Pathophysiology of Ulcerative Colitis 
Infiltration of innate immune cells (neutrophils, macrophages, cytotoxic T cells, dendritic cells) 
and adaptive immune cells (B cells and T cells, especially pro-inflammatory T cell subgroups) 
into the intestinal lamina propria is the hallmark of active IBD. The increased number and an 
activation of these immune cells result in elevated secretion of pro-inflammatory cytokines 
(TNF-α, interleukin-1β, interleukin-6, interleukin-12, interleukin-23) and chemokines. The 
increased chemokine levels cause further infiltration of leukocytes, leading to a sustained cycle 
of inflammation.[19] 
Tumor necrosis factor (TNF) is a dominant cytokine in ulcerative colitis.[43, 44] It is also 
referred to as TNF-α. However, this specification became obsolete, because the term TNF-β for 
the cytokine lymphotoxin (LT) was abandoned after its two forms LT-α and LT-β were 
identified.[45] Macrophages, monocytes and neutrophils secrete TNF in ulcerative colitis.[46-
48] The TNF signaling is complex, but the known signaling pathways involve Tumor necrosis 
factor receptor 1 (TNFR1) or Tumor necrosis factor receptor 2 (TNFR2), see Figure 3. 
Unstimulated TNFR1 is associated with silencer of death domain (SODD), which is released 
upon TNF binding. This allows binding of another death domain containing protein, TNFR-
associated death domain protein (TRADD). TRADD then recruits two further proteins, receptor 
interacting protein-1 (RIP1) and TNFR-associated factor 2 (TRAF2).[49] The complex is then 
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internalized[50] and the TRADD-RIP1-TRAF2 complex gets released from TNFR1. The 
TRADD-RIP1-TRAF2 interacts with further proteins in the cell, eventually resulting effects 
like mediation of cell survival and pro-inflammatory signals through NF-κB and Activator 
protein 1 (AP-1) and apoptosis through caspase 3. The signaling by TNFR2 is less well defined, 
but seems to involve TRAFs. TNFR2 can further activate endothelial/epithelial tyrosine kinase 
(Etk), which has functions in cell adhesion, migration, survival and proliferation. In endothelial 
cells, TNFR2, Etk, and vascular endothelial growth factor receptor 2 (VEGFR2) form a 
complex upon activation by TNF. In this complex, Etk and VEGFR2 phosphorylate one 
another, which results in phosphatidylinositol‐3 kinase (PI3K) activation.[49] 
 
Figure 3 - TNF signaling pathways. Used with permission from [49] 
Many inflammatory effects of TNF result from its effects on the vascular endothelium and 
endothelial leukocyte interactions. Following stimulation by TNF, endothelial cells present 
adhesion molecules for leukocytes such as E-selectin, intercellular adhesion molecule 1 
(ICAM1) and vascular adhesion molecule 1 (VCAM1).[49] TNF furthermore induces the 
secretion of chemokines such as monocyte chemoattractant protein-1 (MCP1),[51] interleukin-
8 (IL8),[52] and C-X-C motif chemokine 10 (CXCL10).[49, 53, 54] The adhesion molecules 
and chemokines facilitate the recruitment of different leukocyte populations. TNF furthermore 
induces cyclooxygenase-2 (COX2; synonym Cyclooxygenase-2, Prostaglandin G/H synthase 
2, PTGS2), leading to increased levels of prostaglandin I2 (PGI2; synonym prostacyclin). This 
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causes vasodilation and thereby an increased local blood flow, leading to the inflammation 
features redness (rubor) and heat (calor). TNF causes swelling (tumor) through enhancing 
vascular permeability, leading to an increased trans-endothelial passage of fluids and 
macromolecules from blood vessels into the tissue. TNF is crucial for the normal immune 
response to bacteria, viruses and parasites, but an excessive production can be harmful.[49]  
Naïve CD4+ T cells in secondary lymphoid organs (Peyer’s patches and mesenteric lymph 
nodes) differentiate to regulatory T cells (e.g. Treg) or helper T cells (e.g. TH1, TH2, TH17), 
depending on the surrounding cytokine milieu and the antigen-presenting cells (see Figure 4). 
The activated CD4+ cells then migrate to the lamina propria, where they execute effector 
functions.[19] A transformation imbalance between TH17 and Treg cells may play an important 
role in IBD. Treg cells effectively repair damaged tissue, but in the presence of interleukin-6 
and/or interleukin-23 they transform into TH17 cells. A transformation of TH17 to Treg cells was 
not reported. The colon mucosa of UC and CD patients shows increased TH17 cells[55] and 
higher levels of the TH17 cytokine interleukin-17, but decreased Treg cells.[56] 
TH17 cells are crucial mediators in both UC and CD.[57] The interleukin-23–TH17 pathway is 
central to the function of TH17 cells and contributes to the sustained inflammation. Activated 
antigen-presenting cells (primarily dendritic cells, monocytes and macrophages) secrete 
interleukin-23.[19, 58] Interleukin-23 is as a member of the interleukin-12-type cytokine family 
and is a heterodimer of interleukin-12 subunit beta (IL12B, which it has in common with 
interleukin-12) and interleukin-23 subunit alpha (IL23A). Interleukin-23 signals to TH17 cells 
by triggering the dimerization of interleukin-12 receptor subunit beta-1 (IL12RB1) and 
interleukin-23 receptor (IL23R), which together form the interleukin-23 receptor complex.[59] 
The interleukin-23 receptor complex signals through the JAK-STAT pathway.[19, 59] Most 
Signal Transducer and Activator of Transcription (STAT)-activating cytokine receptors do not 
have intrinsic tyrosine kinase activity. They instead recruit proteins from the Janus kinase 
(JAK) family that provide them with tyrosine kinase activity. In mammalian cells the JAK 
family contains the four proteins JAK1, JAK2, JAK3, and Tyrosine kinase 2 (TYK2).[60] The 
interleukin-23 receptor complex recruits JAK2 (Interleukin-23 receptor) and TYK2 
(Interleukin-12 receptor subunit beta-1), which enables it to phosphorylate predominantly 
STAT3 and to a lesser degree STAT1, STAT4, and STAT5.[59] Phosphorylated STATs form 
homo- and heterodimers, which are rapidly transported to the nucleus. There they bind to target 
promoters and increase the transcription from those promoters.[60] The transcriptional 
activation results in increased proliferation and/or survival of TH17 cells[61] and mediates 
intestinal inflammation.[19] TH17 cells attract neutrophils and induce the release of anti-
microbial peptides from epithelial cells. Among the TH17 cytokines are interleukin-17A, 
interleukin-17F, interleukin-22, and TNF-α.[26] In addition to its functions related to TH17 
cells, interleukin-23 also restrains the activity of regulatory T cells and reduces their 




Figure 4 - The intestinal immune system and the role of T cell differentiation. Used with permission from [19] 
Besides TH2 and TH17 cells, Natural Killer T cells that secrete interleukin-13 and TH9 cells that 
secrete interleukin-9 contribute to the UC pathophysiology.[11, 63, 64] The contribution of the 
various cell types to the UC pathophysiology is subject to ongoing debate and research. 
Nitric oxide (NO) is a diffusible messenger for cell-cell communication throughout the body. 
In the gastrointestinal mucosa, NO regulates perfusion, microvascular and epithelial 
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permeability, and immune processes. It has been associated with the initiation and maintenance 
of inflammation in IBD. Nitric oxide synthases (NOSs) produce NO from arginine. The 
constitutively expressed NOSs endothelial NOS and neuronal NOS produce NO in nanomolar 
amounts, while the inducible NOS (NOS2) produces micromolar NO quantities. Specific 
cytokines, microbes, and bacterial compounds induce iNOS.[65] The microbes that induce 
NOS2 include the enteroinvasive bacteria Escherichia coli, Salmonella and Shigella[65, 66], 
and NO has a direct antimicrobial effect.[67] This suggest a role of NO in the antimicrobial 
defense. However, sustained NOS2 overexpression and the resulting NO increase may be 
detrimental.[65] Increased levels of NOS2 and NO have been detected in UC tissue.[68-72] 
Histamine is another small molecule messenger that is produced from an amino acid[73] and is 
a pro-inflammatory mediator.[74] Histidine decarboxylase produces histamine through α-
decarboxylation from L-histidine.[73] In addition to its role in inflammation, histamine is 
involved in gastric acid secretion, bone loss, sleep regulation, food intake control, and 
schizophrenia.[73, 75-78] The known histamine receptors H1, H2, H3 and H4 are G protein-
coupled receptors.[73] H1, H2 and H3 can be found in the gut.[74] Histamine N-
methyltransferase (HNMT) and diamine oxidase (amiloride binding protein 1, ABP1, AOC1) 
degrade histamine. A polymorphism in ABP1 is associated with UC severity[79] and histamine 
content is increased in UC colon mucosa.[80, 81] These findings indicate a role of histamine in 
the UC pathophysiology. Gut mast cells are probably a major source of the histamine in UC 
colon mucosa.[79, 81, 82] 
The most prominent feature of UC is the intestinal inflammation, but the pathophysiology 
comprises a wide range of further aspects. Peroxisome proliferator-activated receptor gamma 
(PPAR-γ) is reduced in colonic epithelial cells of UC patients.[11, 83] PPAR-γ is a member of 
the nuclear receptor superfamily and a ligand dependent transcription factor. Its ligands include 
hormones, vitamins, endogenous metabolites, dietary compounds and synthetic drugs.[84] Four 
isoforms of PPAR-γ exist. PPAR-γ1 is expressed in ubiquitously, PPAR-γ2 is found mainly in 
adipose tissue, PPAR-γ3 is expressed in macrophages, large intestine, and white adipose tissue, 
and PPAR-γ4 can be found in endothelial cells.[84] PPAR-γ controls the expression of very 
many genes and is a key transcriptional regulator of lipid and glucose metabolism.[84-86] 
PPAR-γ agonists furthermore reduce the activation of macrophages[87] and decrease the 
cytokine secretion from myeloid cells[88] in vitro, and they attenuate colitis in mice in vivo.[89, 
90] In macrophages PPAR-γ activation reduces the expression of inducible nitric oxide 
synthase (NOS2), matrix metalloproteinase-9 (MMP9, synonym Gelatinase B), and scavenger 
receptor class A (SR-A, synonyms CD204, Macrophage scavenger receptor types I and II, 
MSR1), partly by antagonizing the transcriptional induction by NF-κB, AP-1 and STAT1.[87] 
A mechanism for this was shown in Caco-2 cells. In these cells, the PPAR-γ agonist 15d-PGJ2 
inhibits the immune-response induced degradation of NF-κB inhibitor alpha (IκBα). This 
results in an inhibition of the promotor activity of nuclear factor-κB (NF-κB), because IκBα 
inhibits the nuclear translocation and subsequent DNA-binding of NF-κB.[90] PPAR-γ is of 
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interest to dietary research, because of findings that the anti-inflammatory properties of PPAR-
γ ligands in food may be beneficial to human health.[84] 
An energy deficiency of colonocytes seems to occur in colonocytes in UC. Short chain fatty 
acid (SCFA), especially butyrate[91], are the major energy source for colonocytes. Bacteria 
generate SCFA by fermentation from dietary fibers.[92] The oxidation of butyrate to carbon 
dioxide and ketone bodies is decreased in UC. The energy generation in UC is shifted to 
increased glucose and glutamine oxidation.[91] Monocarboxylate transporter 1 (SLC16A1, 
MCT1) is a transporter of butyrate and its expression is decreased in HT-29 upon treatment 
with the pro-inflammatory cytokines TNF interferon-γ. This indicates that the impairment is 
rather a result than the initial cause of the inflammation. In addition to its nutritional role, 
butyrate promotes the formation of Treg cells, which suppress inflammatory processes.[92] Its 
metabolite beta-hydroxybutyrate, a ketone body, furthermore acts as an endogenous histone 
deacetylase inhibitor. The resulting increased gene transcription of FOXO3A, encoding for 
Forkhead box protein O3, and MT2, encoding for metallothionein 2, increases the protection 
from oxidative stress.[93] 
The involvement of metallothioneins (MTs) in IBD is not limited to metallothionein 2 and has 
been suspected for several members of the MT superfamily. Even though MTs are rapidly 
upregulated in inflammation and are hence classified as acute phase proteins, most studies 
report a decreased abundance of MTs in UC compared to healthy controls.[94] Human 
metallothioneins are heavy metal binding proteins that have a low molecular weight, are 
cysteine-rich, and a majority is clustered on chromosome 16. They bind heavy metals of the 
International Union of Pure and Applied Chemistry (IUPAC) groups of chemical elements 11, 
e.g. Cd2+, Zn2+, Hg2+, and 12, e.g. Cu+, Ag+ and Au+. MTs regulate the heavy metal metabolism 
and protect against toxic heavy metal ions.[95] Zinc ions have various roles in inflammation, 
including anti-inflammatory properties. MTs, together with other compounds like vitamin E, 
ascorbate and superoxide dismutase (SOD1), also protect against reactive oxygen species 
(ROS). Neutrophils and macrophages produce ROS as a defense mechanism to kill bacteria and 
parasites, but ROS are also cytotoxic to host cell. ROS cause oxidative DNA damage, oxidative 
protein damage and lipid peroxidation, and they can destabilize tight junctions, thereby 
increasing permeability.[94] 
Further contributing factors in UC colon mucosa include, but are not limited to:  
• collagen degradation by matrix metalloproteinases (MMPs)[96] 
• decreased carbonic anhydrase abundances[97] 
• epithelial ER stress and the related unfolded protein response (UPR)[98] 
• mitochondrial dysfunction[99] 
• decrease of xenobiotic metabolism[100] 
• decrease of bile acid transporter expression[101] 
 
18 
• increased noradrenaline content[102] 
• changed expression of steroid metabolism enzymes[103, 104] 
1.1.4 Symptoms and clinical presentation of Ulcerative Colitis 
Blood in the stool is the hallmark symptom of UC and is reported by more than 90% of the 
patients.[5, 105] A symptom of extensive active UC is chronic diarrhea with rectal bleeding or 
at least visible blood. UC symptoms further comprise crampy abdominal pain, rectal 
urgency[105], incontinence, increased frequency of bowel movements, mucus discharge and 
nocturnal defecations.[6, 11] Irritation from diarrhea can cause skin tags and anal fissures in 
UC.[11] Systemic symptoms of UC include weight loss, fever, tachycardia, nausea, 
vomiting[105], anemia and fatigue. 
Extraintestinal manifestations (EIMs) occur in approximately one third of the UC patients and 
can precede an IBD diagnosis.[11, 106] Anatomical structures affected by EIMs of UC include 
skin, joints, eyes, mouth, liver and lung.[11] The most common EIMs in UC are peripheral 
arthritis (21%, joints), aphthous stomatitis (4%, mouth), uveitis (4%, eye), and primary 
sclerosing cholangitis (4%, liver).[107] 
The clinical course in UC comprises phases of exacerbation and remission, which occur either 
spontaneous or as a response to treatment or intercurrent illnesses.[5] Up to 15% of the patients 
present initially with severe illness.[105]  
UC is classified based on the disease extend (see Figure 5).[108, 109] The clinical presentation 
tends to vary depending on this. Urgency and tenesmus (a sensation of incomplete evacuation) 
seem to predominate in patients with proctitis, whereas bloody diarrhea and abdominal pain are 
probably more prominent in pancolitis. Paradoxical constipation occurs in up to 10% of the 




Figure 5 - Disease extend of UC according to Montreal Classification. Illustration by Jill K Gregory, used with 
permission from ©Mount Sinai Health System 
Further classification is based on the disease severity. The various clinical disease activity 
indices usually return the classifications mild, moderate, and severe. Examples are the Mayo 
Score[110], Lichtiger Score[111], Simple Clinical Colitis Activity Index[112], Ulcerative 
Colitis Endoscopic Index of Severity (UCEIS)[11, 113], and Ulcerative Colitis Disease Activity 
Index (UCDAI).[114] These scores assess the frequency and severity of symptoms (including 
EIMs) and endoscopic findings.[11] The Geboes Index[115], Nancy index[116],  Robarts 
Histopathology index (RHI)[117], and Modified Riley Score (MRS)[118] assess histological 
features. 
Clostridium difficile infections among UC patients are a growing problem, because they can 
precipitate flares and are associated with increased mortality, hospitalization rates and resource 
utilization.[11, 119, 120]  
1.1.5 Treatment 
The treatment aim in UC is to achieve remission. Remission can be defined as the resolution of 
clinical symptoms and as the endoscopic mucosa healing, which do not necessarily correlate 
well with each other.[11, 121-123] The resolution of clinical symptoms is important for the 
patients’ quality of life. However, endoscopic mucosa healing must be assessed independently 
of this, because mucosal healing is associated with improved long-term clinical remission, 
corticosteroid-free clinical remission and decreased risk of colectomy.[124] The treatment 
options comprise topical and systemic administration of drugs as well as surgery. Optimized 
treatment approach algorithms in the form of flow charts help in choosing an appropriate 















5-aminosalicylic acid (5-ASA, synonyms Mesalazine, Mesalamine) drugs are the first-line 
treatment of mild and moderate ulcerative colitis.[11] The mechanism of action of 5-ASA is 
poorly understood. It is believed that it decreases the production of pro-inflammatory 
prostaglandins and leukotrienes from the cyclooxygenase and lipoxygenase pathways.[125-
127] 5-ASA probably exerts further effects over PPAR-γ, as it was shown that 5-ASA increases 
PPAR-γ expression, promotes its translocation from the cytoplasm to the nucleus, and changes 
its conformation, which increases the binding of coactivators and the activation of a 
peroxisome-proliferator response element-driven gene.[128] 5-ASA may further have 
antioxidant properties and act as a radical scavenger.[129] 5-ASA efficacy is not dependent on 
systemic absorption and redistribution to the colon mucosa, but rather on the effects resulting 
from topical concentrations. However, after oral ingestion 5-ASA is rapidly absorbed by the 
small intestine; hence, approaches were developed to enhance topical drug concentrations in 
the colon.[130] Common approaches to achieve high 5-ASA concentrations in the colon are 
tablet and microgranule formulations that release the 5-ASA at the desired sites (often by 
coating), prodrugs that contain an azo bond and release 5-ASA upon cleavage by bacterial 
azoreductases in the colon, and the use of suppositories or enemas. Enemas may be gels, liquids, 
or aerosols.[131]  
Glucocorticoids 
Glucocorticoids (GCs) can be given to patients with mild to moderate disease who do not 
respond or do not reach remission under 5-ASA treatment.[11] Intravenous GCs are the 
mainstay of conventional therapy of severe ulcerative colitis of any extend.[132, 133] 
Oral GCs are readily absorbed and transported with the blood, where they are mainly bound to 
corticosteroid binding globulin (CBG, SERPINA6) and to a lesser extend to albumin (ALB). 
GCs diffuse passively through cell membranes and bind to the intracellular glucocorticoid 
receptor (GR). GR is, like the previously discussed PPAR-γ, a nuclear receptor. Accordingly, 
it primarily functions as transcription factor.[134] These genomic effects are the classical 
actions of glucocorticoid signaling. GRs can homodimerize upon binding of a ligand and 
subsequently bind to glucocorticoid response elements of GC target genes. The bound GR 
modulates the transcription of the respective gene.[135] In addition to this, GR can change the 
gene transcription in several other ways.[135-138] One mechanism of significance for the use 
of GCs as anti-inflammatory agents is that GR interact (“tether”) with other transcription 
factors, which are DNA-bound to their respective response elements. This can cause 
enhancement or repression of transcription. GR interacts in such way with NF-κB and AP-1 
and decreases the expression of their target genes.[136, 138] This contributes to the anti-
inflammatory effects of GCs.[135] Genomic effects from GR would be expected after a few 
hours, because the transcription and translation are time-consuming. However, evidence 
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suggests that GCs have effects that occur within minutes and non-genomic mechanisms are 
proposed for those. One of these mechanisms is an interaction of GR with signal transduction 
pathways.[135] Another hypothesis is that rapid GC effects result from physicochemical 
interactions with cell membranes.[139]  
GCs affect all major systems of the body.[140] The diversity of effects reflects in diverse side 
effects, which are a concern in GC treatments with a duration of more than one week.[141] The 
side effects of prolonged GC treatment include weight gain, hyperglycemia, osteoporosis, 
hypertension, dyslipidemia, glaucoma, and psychiatric and cognitive disturbances.[142] 
GCs can exert their effects either systemically or topically. The administration for topical 
effects can be either rectal, e.g. in the form of foams or enemas, or oral. Topical effects of oral 
GCs are achieved by using modified-release formulations of GCs with high first-pass liver 
metabolism, such as budesonide-multimatrix and prolonged release beclomethasone 
dipropionate. They are a first-line treatment of patients with mild to moderate UC who do not 
reach remission with 5-ASA.[11]  
Thiopurines 
The thiopurines azathioprine (AZA) and 6-mercaptopurine (MP) are used for remission 
maintenance in UC patients.[11] 
The first step in the metabolism of AZA is its conversion to MP. However, both AZA and MP 
are prodrugs. Multiple enzymes are involved in the metabolism to their active metabolite 6-
thioguanine nucleotide (6TGN).[143] 6TGN exerts its immunosuppressive effects mainly by 
inactivating Rac1, which is a small GTPase and an important intracellular mediator with impact 
on the fate of T cells. The inactivation of Rac1 by 6TGN induces T cell apoptosis and impairs 
the interaction of T cells with antigen-presenting cells. In addition to this mechanism, a small 
proportion of 6TGN is incorporated into the DNA instead of guanine. This activates the 
mismatch repair system and eventually leads to cell death.[144] 
Biologics 
The biologics applied in the UC treatment are antibodies targeting TNF and an integrin, 
respectively.[11, 145] They are effective at inducing and maintaining remission in moderate 
and severe UC.[11] 
The TNF antibodies infliximab, adalimumab and golimumab are used in the treatment of 
UC.[11, 146] They bind to TNF and thereby block the interactions with its receptors. As 
described earlier, TNF is a major mediator of inflammation in UC, accordingly the inhibition 
of its effects result in decreased inflammation. However, the exact molecular mechanisms 
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involved in anti-TNF treatment are still a matter of debate, because these molecules have effects 
in addition to blocking TNF.[146] In addition to the soluble TNF acting as a ligand, its precursor 
form transmembrane TNF (mTNF) can act as a receptor that is activated upon binding of the 
TNF antibodies. This is believed to contribute further to the anti-inflammatory effects of TNF 
antibodies.[146, 147] 
The antibody vedolizumab is directed against α4β7 integrin. α4β7 integrin is a glycoprotein 
that B and T cells present on their cell surface.[148] It interacts with mucosal addressin-cell 
adhesion molecule 1 (MAdCAM-1), which is preferentially expressed in the intestinal tract and 
associated lymphoid tissues, but is not detected in the majority of other tissues, including those 
with mucosal surfaces.[149] The interaction between α4β7 integrin and MAdCAM-1 facilitates 
the lymphocyte recruitment to intestinal tissue.[148, 149] The binding of vedolizumab to α4β7 
integrin prevents this.[148]  
The development of biologics improved the health outcomes in IBD drastically, and 
accordingly their use has been increasing. For instance, one US study showed that the 
proportion of UC outpatients using biologics increased from 5.1% in 2007 to 16.2% in 2015. 
However, with an increased use not only in UC (for instance the proportion of CD patients 
using biologics increased in the same study from 21.8% to 43.8%), the expensive biologics 
have a considerable impact on the health care costs of IBD.[150] 
Surgery 
Surgery is indicated in patients with refractory UC, perforation, uncontrolled bleeding, steroid 
dependence, colorectal carcinoma, or dysplastic lesions that are not amenable to endoscopic 
removal.[11, 151] It can also be necessary when the disease impairs the patient’s quality of life 
significantly or when the patient is not compliant.[151] Despite the progresses in medical 
treatment, surgery is needed in 15%-35% of the UC patients.[151-153] The gold standard and 
most commonly performed surgery is restorative proctocolectomy with ileal pouch-anal 
anastomosis (RP-IPAA), which comprises a total resection of the colon and upper rectum, a 
construction of a pouch from the end of the small intestine, and the attachment of that pouch to 
the anus.[11, 151, 154] The most common postoperative issue after RP-IPAA is pouchitis. 
Pouchitis is an inflammatory condition of the ileal pouch, of which at least one episode occurs 
in up to 46% of the RP-IPAA patients.[11] 
1.1.6 Clinical outcome 
The clinical outcomes in IBD are not clearly defined and there is little agreement on the 
endpoints.[155] One of the well-known studies on outcomes in UC is the IBSEN study. The 
IBSEN study applied four predefined curves to describe the disease progression (Figure 
8).[156] 59% of the 420 patients in the study who did not undergo surgery experienced a decline 
of disease severity (Figure 8, curve 1). 31% of these patients experienced chronic relapsing 
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symptoms (Figure 8, curve 4) and 9% chronic continuous symptoms (Figure 8, curve 3). The 
disease severity increased for only 1% of the patients (Figure 8, curve 2).  
 
Figure 8 - Predefined curves describing the disease progression in the IBSEN study. Used with permission from 
[156] 
The UC treatment according to the medical step-up approach uses 5-ASA and local GCs in 
mild disease manifestations and additional oral GC, immunomodulator and biological therapy 
in moderate to severe disease.[157] Conversely, the top-down approach uses 
immunomodulators and anti-TNF agents early in the disease. While no studies are published 
on the top-down therapy in UC, it can induce long term clinical remission of CD.[158]  
Good biomarkers for predicting the disease progression at UC onset would support clinicians 
in tailoring individualized therapies. For instance, the top-down treatment approach may be 
most beneficial in patients with a predicted severe disease course.[159] An optimized, 
personalized treatment starting at disease onset may change the course of the disease.[160] 
Accordingly, the demand is high for biomarkers that can predict the disease progression in IBD. 
Some progress has been made in this area. Biomarkers have been suggested for predicting 
outcomes in CD.[159] It was furthermore shown that normalized mucosal TNF mRNA can 
predict an increased duration of remission in both UC and CD.[161, 162] However, there still 








Proteomics is the scientific discipline that investigates the proteome. The proteome can be 
defined as the entire protein content of a cell, tissue or organism. 
1.2.1 Value of proteomics 
Proteins are the major functional units of every cell. Hence, knowledge about the abundance 
and the state of proteins are crucial for our understanding of physiological and 
pathophysiological processes. However, the determination of protein abundances is 
challenging. 
The measurement of messenger RNA (mRNA) abundances in great depth is comparably easy, 
because mRNA can be amplified. mRNA is the template for protein translation. Hence, mRNA 
abundances are routinely measured in transcriptomics as surrogates for protein abundances. 
The use of this approach however is limited, because the abundances of mRNA and protein 
correlate poorly.[163-165] This poor correlation results from varying rates of the translation 
from a given amount of mRNA and of the degradation of proteins, see Figure 9.[165] 
 
Figure 9 - The translation and degradation of proteins, and factors that contribute to a poor correlation between 
mRNA and protein abundances. Used and modified with permission from [165] 
The translational efficiency is defined as the number of completed protein translations per 
mRNA molecule and time. Translational efficiencies differ between mRNA molecules, which 
directly influences the mRNA-protein correlation.[165] One factor that influences the 
translation rate are the properties of the mRNA itself. The secondary mRNA structure is 
variable in eukaryotes and influences translation.[166, 167] The mRNA codon sequence in 
dependence of transfer RNA (tRNA) levels can further influence the transcription rate.[168] 
The distribution of the mRNA within the cell, e.g. localization in the nucleus, changes its access 
to ribosomes for translation.[165] Small RNA (sRNA) can induce target mRNA cleavage and 
destabilization without cleavage, inhibit protein translation, and induce histone modifications 
that silence further transcription.[169, 170] While mRNA degradation or reduced transcription 
do not cause poor correlation between mRNA and protein levels because the mRNA levels 
decrease as well, inhibition of translation can contribute to decreased correlation. The 
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translation is facilitated by ribosomes, which are built from ribosomal RNA (rRNA), and 
modulated by further proteins. Most such effects result from regulation at the stages of 
initiation.[171-173] Regulation of elongation and termination contribute as well.[174, 175] A 
study in yeast found a hundred-fold range of translational efficiency in the same sample 
between different genes, and changes in translational efficiency upon starvation were found for 
roughly one-third of the genes.[176] 
The individual rates of protein degradation are the most important post-translational influence 
on the mRNA-protein correlation. The half-life of a protein depends on factors including its 
intrinsic stability, posttranslational modifications (PTMs, e.g. ubiquitination), its last N-
terminal amino acid (N-end rule), and protein localization.[165, 177] Protein secretion further 
decreases the correlation, because secreted protein that leave the sample tissue escape the 
quantification, while proteins translated and secreted elsewhere can enter the sample 
tissue.[165] 
Beside the advantage of measuring the abundance of proteins instead of a surrogate, proteomics 
can identify and quantify PTMs. PTMs are changes of covalent bonds in proteins after 
translation. They are not encoded in the mRNA and for this reason not accessible to 
transcriptomics. Most PTMs are introduced enzymatically by the respective cell or organism. 
The term PTM summarizes diverse chemical reactions. These include the covalent attachment 
of various inorganic and organic groups/molecules (including other proteins and lipids), 
formation of disulfide bridges between cysteines, other chemical modifications on amino acids 
(e.g. deamidation of glutamine/asparagine, hydroxylation of proline, isomerization), and 
proteolytic cleavage at peptide bonds. Protein phosphorylytion can arguably be considered one 
of the most important regulatory mechanisms. PTMs in proteins can influence their activity 
state, localization, and stability, can modify the interaction with other proteins, and make major 
structural contributions.[178] 
1.2.2 History of proteomics 
The first studies that can be categorized as proteome investigation were published in 1975.[179-
182] These beginnings of proteomics were dominated by two-dimensional gel electrophoresis 
(2-DE) of proteins. These techniques separated and visualized proteins, but the proteins could 
not be identified due to the lack of sensitive sequencing techniques, which were necessary 
because of the limited loading capacity in gel electrophoresis. The first major method for 
protein sequencing was the Edman degradation[183], but the identification of the electroblotted 
proteins became only possible in the 1980s with the emergence of microsequencing 
procedures.[179, 184] 
The proteomics field has since experienced major developments. Sequencing has essentially 
been replaced by mass spectrometry (MS) approaches. Most commonly, bottom-up approaches 
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are applied. In bottom-up approaches, the proteins are enzymatically cleaved into peptides, 
which are subsequently identified by high-resolution tandem-MS.  
Electrophoresis of the proteins is today only an optional step to reduce sample complexity and 
commonly omitted. Gel electrophoresis is no longer mandatory, because the peptides resulting 
from the protein digestion are usually separated by low-pH reversed-phase liquid 
chromatography (LC) before they are subjected to mass spectrometry analysis. Furthermore, 
when an additional reduction of the sample complexity is desired, other fractionation 
approaches such as high pH reversed-phase, strong cation exchange (SCX) or hydrophilic 
interaction chromatography (HILIC) are often preferred over gel electrophoresis. 
1.2.3 Basic sample preparation workflow in bottom-up proteomics 
The bottom-up proteome analysis of a given sample consists of three major steps: sample 
preparation, liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis, and 
computational analyses, see Figure 10. 
 
Figure 10 - Typical workflow for quantitative bottom-up proteomics. Used with permission from Joanna Kirkpatrick, 
Core Facility Proteomics, Leibniz Institute on Aging – Fritz Lipmann Institute (FLI) 
The purpose of the sample preparation in a bottom-up proteomics study is to convert the 
protein-containing sample of interest into a peptide solution for LC-MS/MS analysis. The first 
step of the sample preparation facilitates the lysis and homogenization of the cell or tissue 
sample as well as the solubilization and denaturation of the proteins. This can be accomplished 
with reagents and mechanical force. Among the reagents for this purpose are detergents and 
urea (see below). The mechanical disruption methods include grinding in liquid nitrogen[185], 
sonication, cell scraping, bead mills, gentle rocking, and French pressing.[186] The 
macroscopic appearance and properties of the sample help in selecting an appropriate 
mechanical disruption method. 
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Disulfide bonds occur between protein cysteines and can contribute to the tertiary structure of 
proteins. These bonds add additional complexity, the interpretation of the resulting mass 
spectrometry data is challenging, and the disulfide bonds can rearrange (so-called 
reshuffling).[187] The resulting data from linked peptides is furthermore not compatible with 
the standard computational approaches for bottom-up proteomics. Adjusted protocols can 
tackle these challenges and extensive research efforts are directed at disulfide proteomes.[187-
189] However, disulfide bonds are undesirable in general bottom-up proteomics. Hence, 
reducing agents like dithiothreitol (DTT) are added to reduce disulfide bonds to thiols, which 
are then alkylated with a reagent like iodoacetamide (IAA). This step serves to break the 
disulfide bonds and to prevent their reformation 
However, IAA can alkylate peptide N-termini and side-chain nitrogens in addition to the more 
reactive cysteine thiols, if given enough incubation time. The alkylation of these amino groups 
with IAA is termed overalkylation.[190] Overalkylation increases the sample complexity and 
peptides that are modified in such way would not be identified in computational analysis, unless 
specified as possible modification. Overalkylation furthermore introduces a possible bias with 
regard to peptide quantification. Quenching of excess IAA with additional DTT after alkylation 
is a suitable measure to avoid overalkylation.[191] 
The proteins are then enzymatically digested into peptides with enzymes, which cut at specific 
cleavage sites. Trypsin is the most commonly applied enzyme and cleaves the amino acid chain 
after the basic amino acids lysine and arginine. Lys-C cuts proteins after lysine as well, but 
tolerates higher urea concentrations. Hence, it can be applied for protein predigestion under 
harsher solubilization conditions, without introducing additional cleavage sites compared to 
tryptic digestion alone. See below for more detail. 
An optional step is the isobaric labelling of the resulting peptides. Isobaric labelling is a 
chemical peptide modification that attaches chemical groups of identical structure and total 
masses, but with different distributions of heavy and light isotopes. Each sample for one LC-
MS/MS run is labelled with a different mass tag and the samples are then mixed. The identical 
chemical properties and total masses of these mass tags make them indistinguishable in both 
the liquid chromatography and the mass spectrometer prior to fragmentation. The fragmentation 
in the collision cell however releases reporter ions of distinct masses. The relative intensities of 
the respective reporter ions reflect the proportion of peptide molecules originating from each 
sample. This approach can reduce the possible bias resulting from changes in the LC-MS/MS 
system between runs. 
After the digestion, and if applicable isobaric labelling, substances that would interfere with the 
LC-MS/MS analysis must be removed from the peptide solution. These substances include 
detergents and salts. The detergent removal methods vary depending on their chemical 
properties, and some need to be performed before the digestion (see below). Solid-phase 
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extraction methods are most commonly applied to remove hydrophilic contaminants and salts 
that are not compatible with mass spectrometry. 
In solid-phase extractions, the peptide solution flows over a solid stationary resin that retains 
the peptides. Salts are not retained and are washed away with the sample solvent and washing 
solutions. Elution buffer release the peptides from the resin. The desalting can either be a 
separate step or be included in a sample fractionation workflow. Pipette tips that contain a small 
bed of C18 sorbent are commonly applied when no fractionation is desired.  
Before the sample clean up with C18 pipette tips, the sample solution must be acidified with an 
ion-pairing agent like trifluoroacetic acid (TFA) or heptafluorobutyric acid (HFBA). The 
peptides get protonated under acidic conditions and carry positive charges. The conjugated 
bases of the ion pairing agents (i.e. trifluoroacetate and heptafluorobutyrate ions, respectively) 
are negatively charged. Ion pairing of peptides with TFA and HFBA, respectively, removes the 
overall positive charge of the peptides; hence, it increases the peptide hydrophobicity and 
thereby their affinity to the C18 sorbent. The C18 sorbent must be conditioned before use with 
an acetonitrile-water solution to improve peptide binding. Subsequent flushing with TFA (or 
HFBA) solution removes residual organic solvent. The peptide solution is then applied to the 
sorbent by repeated aspiration. During that, the peptides bind to the sorbent. The bound peptides 
are then repeatedly washed with TFA (or HFBA) solution and eventually eluted. The organic 
solvent in the elution buffer breaks the interactions between the peptides and the sorbent and 
thereby releases the peptides. Evaporation facilitates the removal of the organic solvent in the 
peptide solution. Reconstitution of the peptides in MS compatible acid solution and dilution to 
the desired peptide concentration give the peptide solution for LC-MS/MS analysis.  
1.2.4 Detergents for protein denaturation and solubilization 
Detergents are applied frequently in proteomics experiments because they denaturize proteins 
and increase their solubilization in lysis buffers. These properties improve the enzymatic 
digestion of sample proteins. The presence of detergents is especially beneficial for the 
digestion of hydrophobic proteins, e.g. transmembrane proteins.[192] Detergents can decrease 
the activity of proteolytic enzymes, which limits the applicable concentrations. 
Detergent molecules have both hydrophilic and lipophilic moieties. Hence, they can facilitate 
the interaction between lipophilic protein moieties and the water as solvent, which in turn 
increases the protein solubilization. Detergents can be further classified as anionic, cationic, 
zwitterionic and non-ionic according to their electrical charge. Anionic detergents carry 
negatively charged groups such as carboxylate (e.g. sodium deoxycholate, sodium laurate) or 
sulfate functions (e.g. sodium dodecyl sulfate). The positively charged groups in cationic 
detergents are most commonly quaternary ammonium groups (e.g. cetyltrimethylammonium 
bromide). Zwitterionic detergents carry equal numbers of negative and positive charges, 
resulting in a net zero charge. Non-ionic detergents contain no charged groups.  
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Detergents interfere with the liquid chromatography; hence, they need to be removed or 
degraded before injection into an LC-MS/MS system. Ionic detergents can have a fixed charge 
or their charge can be pH dependent. The removal of pH-dependent charges from detergents 
decreases their hydrophilicity and as a result their water solubility. Those detergents with pH-
dependent charges that show sufficiently low water solubility after charge removal, precipitate 
(i.e. transition to solid state), and present with higher density than water can be effectively 
removed by pH manipulation and subsequent centrifugation. Under these conditions, the 
respective detergent forms a pellet and the peptide solution can be separated from the detergent 
by pipetting. This procedure allows the removal of detergents with pH dependent charges after 
digestion, which is advantageous especially for membrane proteins.[192] If compatibility of 
the detergent with tandem mass tag (TMT) labelling is given, this furthermore allows for 
detergent removal after the differently labelled peptides are mixed. Alterations of the sample 
composition due to the detergent removal step would then not change the detected isotope 
ratios, except for particular cases such as contaminations with other TMT labelled peptides. 
Commonly applied methods for the removal of detergents with fixed charges need to be 
performed prior to protein digestion, e.g. protocols depending on filter-aided sample 
preparation (FASP)[193], protein precipitation[194], or polyacrylamide gel electrophoresis 
(PAGE). These methods have further disadvantages besides the loss of the potentially beneficial 
effects of detergents on the digestion. The additional, partially tedious, working steps prior to 
enzymatic digestion increase the risk of contaminations. Contaminations with proteins, e.g. 
keratin, from these steps undergo crucial parts of the sample preparation, i.e. reduction, 
alkylation, digestion, and labelling. Hence, these contaminants would appear as proteins of the 
respective samples. Furthermore, especially complex additional steps before mixing of the 
differently labelled peptides introduce the risk of producing artificial differences between 
samples. However, alternatives exist that allow the removal of detergents with fixed charges 
after digestion, e.g. Pierce Detergent Removal Spin Columns, which are packed with a 
proprietary resin.  
Many detergents have been applied in proteomics sample preparation. Anionic detergents are 
the most common choice. Due to its role in two-dimensional PAGE, sodium dodecyl sulfate 
(SDS) has been an important detergent in proteomics from the early days. SDS has this role in 
two-dimensional PAGE because it binds to all proteins in the ratio 1.4 g SDS / 1 g protein under 
the conditions used in electrophoresis. This results in the loss of all protein specificity in two-
dimensional PAGE, with the mobility becoming a measure of the molecular size alone.[195] 
An unbranched 12-C hydrocarbon tail constitutes the lipophilic part of SDS, while a sulfate 
group serves as the hydrophilic moiety. When in-solution digestion protocols gained increasing 
relevance, not the least due to progress in LC-MS/MS technology, the development of new 
detergent removal methods such as FASP[193] secured SDS a continuing significant role in 
proteomics sample preparations. 
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Besides detergents, urea has been commonly used for protein denaturation for more than a 
century.[196] Urea denatures proteins probably by direct interaction with the backbone and 
other hydrophobic protein moieties.[197, 198] An indirect effect from strengthening the water 
structure might contribute as well, probably to a minor degree.[198] 
The detergent choice is an important factor in optimizing both the reproducibility and the 
identification numbers in proteomics experiments. Even though general trends regarding the 
preferability of detergents exist, the different compositions of biological samples warrant 
individual optimization efforts. 
1.2.5 The endoproteinases trypsin and Lys-C in proteomics 
Endoproteinases are proteins that cleave peptide bonds within other proteins. Endoproteinases 
can be categorized according to their catalytic residue. The catalytic residues often are often in 
the side-chains of amino acids (e.g. alcoholic function in serine and threonine, cysteine thiols 
etc.). Metalloproteases utilize metal ions, most commonly zinc ions, as their catalytic residue. 
The most commonly applied endoproteinases in proteomics are serine proteases. 
Endoproteinases cleave peptide bonds usually either before or after one or several specific 
amino acids. Digest specificity, efficiency and reproducibility are prerequisites for reliable 
quantifications and identifications. The specificity is important in bottom-up proteomics 
because protein identifications in these experiments are based on the comparison of measured 
mass spectra with theoretical spectra that are derived from in-silico cleavages of known protein 
sequences. These in-silico cleavages are performed according to rules defined depending on 
the used endoproteinase. High digest efficiency decreases the sample complexity because it 
removes additional, often redundant, peptides that would result from missed cleavages. High 
digest efficiency can also contribute to high reproducibility. High digest reproducibility is 
important for quantification, because protein intensities in bottom-up experiments are derived 
from peptide intensities. 
The serine protease trypsin is the most commonly applied endoproteinase in proteomics. By the 
end of 2014, 96% of the deposited data at Global Proteome Machine Database (GPM DB) were 
from tryptic digestions.[199] Trypsin is a protease of the digestive system that appeared early 
in evolution. Trypsin stems from a common ancestor of both prokaryotes and eukaryotes.[200] 
Species-specific adaptations of trypsins, for factors such as temperature and substrates, increase 
the fitness of the respective organisms. In animals, trypsin can be found in both vertebrates and 
invertebrates.[201] The trypsin cleavage pattern is commonly simplified to cutting after (i.e. on 
the carboxyl side of) lysine and arginine, but not before proline. However, violations of this 
“Keil rule” occur with commercially available trypsin.[202] The tryptic cleavage pattern yields 
peptides in a favorable mass range for sequencing. The basic properties of arginine and lysine 
furthermore add a positive charge to all peptide C-termini, except for the protein C-terminal 
peptides. Due to this additional charge, the C-terminal fragments become accessible to mass 
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spectrometry as y-ions. Together with the b-ions from the N-terminal peptide fragments, this 
gives information-rich, easily interpretable peptide fragment spectra.[203] 
However, trypsin has some shortcomings. Tightly packed proteins can be resistant to tryptic 
cleavage, and the use of reagents to facilitate unfolding is limited because many such reagents 
inhibit trypsin activity. Furthermore, tryptic digestion is usually incomplete, with missed 
cleavages occurring especially at theoretical cleavage sites after lysine. The use of Lys-C in 
addition to trypsin can avoid these shortcomings.[204]  
Lys-C originates from Lysobacter enzymogenes[205] and is, like trypsin, a serine 
endoproteinase. Lys-C retains its activity in high urea concentrations (6-8 M). This allows a 
predigestion with Lys-C under maximized protein denaturation. After dilution, the resulting 
peptides can then be digested further with trypsin to yield the favorable tryptic cleavage pattern. 
This tandem-digestion approach results in improved proteolytic efficiency compared to the use 
of trypsin alone.[206] 
1.2.6 Data handling 
The first step in the computational analysis of mass spectrometry data in proteomics 
experiments is the protein identification and quantification. The protein identification is 
facilitated by matching the in-silico digestion of protein sequences, in accordance with the 
cleavage pattern of the applied protease, with the acquired mass spectra. The peptide bonds 
along the protein backbone break randomly in the collision cell of the mass spectrometer. The 
fragments resulting from collision-induced dissociation (CID) or higher-energy collisional 
dissociation (HCD) appear as b-ions (from the N-terminal side) and corresponding y-ions (from 
the C-terminal side). The peptide sequences can be determined from the mass differences 
between the various b-ions and y-ions, respectively, which correspond to the characteristic 
molecular weights of the respective amino acids. Leucine and isoleucine however are 
indistinguishable with this method. 
Multiple steps are necessary to identify differently abundant proteins from raw protein 
abundances. Perseus[207] is a comprehensive software solution for these tasks. Its flexibility 
allows to process proteomics data from very different experimental designs, and even non-
proteomics data. Perseus offers multiple data visualization tools. 
Enrichment analyses are one way to approach the challenging interpretation of comprehensive 
lists of protein abundance changes from proteomics experiments. Enrichment analyses 
determine which gene ontology (GO) terms are overrepresented among a specific group of 
proteins in comparison to the entire dataset. The gene ontology terms comprise for instance 
biological and molecular functions, cellular localization, pathways, and protein families. The 
enrichment of such terms among the differently abundant proteins can help to understand which 
role the respective ontologies play in the disease pathophysiology. Many of the challenges in 
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the interpretation of proteomics results arise from the high numbers of differently abundant 
proteins that a modern proteomics approach can identify especially in strong phenotypes. 
Alternative approaches to enrichment analyses include the focus on only the proteins with the 
highest abundance changes and the manual interpretation of extensive protein lists. However, 
the focus on only the highest abundance changes disregards large amounts of data and does not 
detect moderate changes that accumulate in one function or compartment. The manual 
interpretation of extensive protein lists is prone to be arbitrary and to be influenced by the 
background of the interpreting researcher.[208] 
In network analyses, interactions or functions that are retrieved from databases serve to create 
networks. These networks consist of nodes and edges that connect the nodes. Proteins in such 
analyses can have either role. For instance, when proteins serve as nodes they can be connected 
by edges that indicate known protein-protein interactions. When gene ontology terms serve as 
nodes, proteins can serve as edges. Network analyses can help to understand and visualize the 
interplay of proteins and biological functions that are subject to abundance changes. 
Cytoscape[209] and its plugin ClueGO[210] create and visualize networks from protein lists. 
ClueGO uses gene ontology terms as nodes and builds networks with the respective proteins as 
edges. 
1.2.7 Proteomics and protein biomarkers in Ulcerative Colitis 
Common aims of proteomics in the context of diseases are the elucidation of the disease 
pathophysiology and the finding of biomarkers. In a clinical setting, an improved understanding 
of the pathophysiology is advantageous because it can lead to new and improved treatment 
options and can help to understand the pathogenesis, which may help to prevent the disease.  
Biomarkers are measurable indicators of specific biological states. Clinically they are used in 
the diagnosis of diseases, in monitoring their activity, for guiding the therapy, to assess the 
therapeutic response, or to predict the disease progression.[211, 212] Efforts of biomarker 
discovery in UC with diagnostic purpose aimed to differentiate UC from CD or healthy 
controls. In the context of treatment the prediction and monitoring of responses to medication, 
especially biologics, are of interest.[212] Prediction of disease progression is of interest with 
regard to the intestinal inflammation, EIMs, complications, and relapses. Most potential clinical 
applications of proteomics are believed to require the assessment of multiple proteins. The 
rationale behind this is that a single protein has multiple functions in a cell and interacts with 
other proteins to exert these functions, and that as a result a change in the abundance of one 
protein may only be relevant when other protein abundances change as well.[212]  
The assessment of intestinal inflammation allows clinicians to adjust the treatment. Proteins 
that are measured in this assessment are often mediators of inflammation, e.g. cytokines and 
eicosanoids, or other compounds produced as a response to inflammation.[213] Such 
biomarkers of inflammation in UC are C-reactive protein (CRP), fecal lactotransferrin (LTF, 
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synonym: lactoferrin), and fecal calprotectin.[11, 214] CRP is useful in acute severe UC. A 
CRP over 45 mg/l on day 3 after hospital admission for severe colitis together with 3-8 
stools/day is predictive for colectomy.[105] Fecal biomarkers have a higher specificity for 
inflammation located in the intestines.[213] Fecal calprotectin seems to have the highest 
sensitivity and specificity for active inflammation.[11, 215, 216] It correlates with increased 
neutrophils in the intestines.[11] Calprotectin is a complex of protein S100A8 and protein 
S100A9. These markers are not specific for UC, because they only indicate the presence of 
inflammation (CRP) and intestinal inflammation (fecal biomarkers), respectively.[11, 105] 
However, fecal calprotectin and CRP can essentially exclude IBD in patients with irritable 
bowel syndrome (IBS) symptoms. The probability of having IBD is ≤ 1% in patients with low 
CRP or fecal calprotectin.[214] While many proteins used as biomarkers of inflammation are 
increased in this state, the serum biomarkers albumin, transferrin, α2 macroglobulin and Factor 
XII are decreased in the acute phase response.[213] Hypoalbuminemia occurs in severe UC and 
is a predictor for colectomy and poor response to biologics.[11, 217] 
The sample type choice for proteomics of UC follows usually one of three approaches. Colon 
mucosa is the main site of the disease manifestation and candidate biomarkers may be more 
concentrated, which reduces the chance of false discoveries.[212] Sample types from the site 
of inflammation are colon mucosa biopsies, the mucosal-luminal interface, and “proximal 
fluid”.[218-221] The second approach is the analysis of easily accessible body liquids. These 
sample types are most interesting for clinical application, because they are easy to obtain. For 
this reason, a blood test is usually the ultimate aim in biomarker discovery.[212] Such samples 
comprise blood, plasma, serum, and urine.[212, 222-225] The third approach is measuring of 
bacterial proteins. The bacteria population in the gut is involved in the UC pathogenesis and 
pathophysiology. Sample types for this purpose are feces and the mucosal-luminal 
interface.[212, 221, 226]  
Several studies show the potential of proteomics to elucidate pathophysiological processes. 
Different protein abundances found in UC compared to controls implicate roles of inflammation 
and tissue repair[227], mitochondrial dysfunction[218] and energy metabolism[228], amino 
acid metabolism (arginine and tryptophan)[229], cellular stress, and signal transduction.[212, 
228]   
Further results implicate that proteomics can facilitate biomarker discovery. The proteomes of 
UC patients and healthy controls show clear differences, which indicates feasibility of 
biomarker development for this purpose.[212, 228, 230] However, validation for clinical 
applications is necessary.[212] A panel of proteins can differentiate between UC and CD.[219] 
The prediction of the disease course and response to biologics or the monitoring of treatment 
response were not addressed by proteomics studies in UC.[212] While the obtained results are 
promising, many research questions remain unaddressed and none of the proteomic biomarkers 
is implemented in clinical daily use.[212, 231] 
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The studies applied different study designs and analytical approaches. This makes comparisons 
between studies difficult.[212] However, with different designs/approaches and their 
characteristics taken into account, e.g. ratio compression in TMT labelled samples compared to 
label-free MS analysis[232], the confirmation of results across different designs and analytical 




1.3 Aims of the thesis 
The overall hypothesis of this thesis is that through elucidating the properties of the proteome 
in ulcerative colitis, an improvement of our understanding of the pathophysiology in the active 
and the remission state will lead to further development through new treatment regimens and 
treatment options. We also hypothesize that a deep proteomic investigation of treatment naïve 
patients can lead to the identification of potential biomarker candidates.  
We pursued these hypotheses with the following intermediate aims: 
- Optimization of the sample preparation of colon mucosa biopsies for bottom-up 
proteomics 
- Identification of the most differently abundant proteins between active UC and healthy 
controls  
- Functional enrichment analyses of differently abundant proteins between UC and 
healthy controls 
- Characterization of the proteome in remission from UC as compared to active UC and 
healthy controls 
- Development of a prediction model for the 1-year outcome of UC severity  
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2 Materials and Methods 
2.1 Patient characteristics 
The colon mucosa biopsies from treatment-naïve and newly diagnosed UC patients were 
collected in Norway. Diagnosis of UC was based on criteria defined in the European Crohn and 
Colitis Organization (ECCO) guidelines.[105] Subjects undergoing a cancer screening 
examination without intestinal disease were included as healthy controls. The inflammation 
was evaluated during colonoscopy based on the ulcerative colitis disease activity index 
(UCDAI).[114] TNF mRNA was measured by real-time PCR. Geboes index values were 
determined during histological examination.[115]  
The patient characteristics can be summarized as follows: 
Table 1 - Characteristics of patients and healthy controls in paper I [1] 
 Number of 
Subjects 
Average 







UC onset active 6 48 (14) 1/5 9.5 (2) 2.6 (0.5) 14,188 (12390) 
Healthy controls 6 54 (10) 1/5 – 0 2933 (1084) 
 






Age (SD) Female/Male 
Average years 














(16.0) 5/9 7.4 (4.5) 
4800 




(16.7) 4/13 0 
14350 




(14.3) 5/10 - 
4500 
(2400) - - 
 
Table 3 - Characteristics of patients and healthy controls in paper IV 
1-year outcome Number of Subjects 
Average age 





Mild/Moderate 14 40.3 (20-62) 4/10 11,315 (4,600-31,700) 6.5 (3-13) 





2.2 Ethical approval and participation consent 
The study and the storage of biological material were approved under the number REK NORD 
2012/1349 by the Regional Committee of Medical Ethics of North Norway and the Norwegian 
Social Science Data Services. All enrolled subjects signed informed and written consent forms. 
2.3 Sample preparation 
Paper 1 (Method development) – Colon mucosa biopsies were homogenized in water. Protein 
concentration was determined with a bicinchoninic acid (BCA) assay. The homogenate was 
subsequently added to lysis buffers of the following compositions: 
- Sodium deoxycholate (5%), 8 M urea, 100 mM TEAB 
- Sodium dodecyl sulfate (1%), 8 M urea, 100 mM TEAB 
- Sodium laurate (5%), 5.7 M urea, 100 mM TEAB 
- Rapigest (0.25%), 8 M urea, 100 mM TEAB 
- Cetyltrimethylammonium bromide (1%), 8 M urea, 100 mM TEAB 
- N-methyldioctylamine (5%), 6 M urea, 100 mM TEAB 
- 8 M urea, 100 mM TEAB 
Protein solubilization was supported with MagNA Lyser treatment. The proteins were reduced 
with DTT and alkylated with IAA. Sodium dodecyl sulfate, cetyltrimethylammonium bromide 
and N-methyldioctylamine were removed by modified FASP methods before digestion. 
Rapigest was removed by acid induced cleavage after digestion. Sodium deoxycholate and 
sodium laurate were removed after digestion by acid precipitation. Predigestion was performed 
with Lys-C (enzyme:protein ratio 1:100) for 8 h, followed by digestion with trypsin 
(enzyme:protein ratio 1:20) for 16 h. The samples were desalted with C18 pipette tips and 
reconstituted in 0.1% formic acid. 
Paper 1 (Clinical samples) – Colon mucosa biopsies were added to the optimized lysis buffer 
(sodium deoxycholate 5%, 8 M urea. 100 mM TEAB) and homogenized by MagNA Lyser 
treatment. The protein content for each sample was determined by BCA assay. The proteins 
were reduced, alkylated, and digested as described above. A standard was produced by 
combining equal peptide amounts from each sample. The standard and the samples were 
labelled with TMTsixplex and afterwards combined. Desalting and reconstitution were 
performed as described above. 
Papers 2, 3 and 4 – The samples were treated as described for the clinical samples of paper 1 
up until the labelling step. A new standard was produced from all samples included in this 
experiment. After the samples and the standard were combined, the combined samples were 
subjected to high pH reversed-phase fractionation, yielding eight fractions each.   
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2.4 LC-MS/MS analyses 
Paper 1 – The peptides were analyzed with an EASY-LC system coupled to a qExactive mass 
spectrometer. Peptides were separated on a C18 column (2 µm, 100 Å, 50 µm, 50 cm) with a 
4-40% gradient of acetonitrile in 0.1% formic acid (FA) over 1 h. The first fixed mass was set 
to 120 m/z for the clinical samples. These were further subjected to two additional 1 h LC-
MS/MS analyses with inclusion lists with the purpose of acquiring better mass spectra for low 
confidence identifications and to identify and quantify peptides that were identified in one other 
samples as well. 
Paper 2, 3 and 4 – The fractions were analyzed with the instrument described above with a fixed 
first mass of 120 m/z and a gradient of 0% to 5% over 19 min, further to 30% at 180 min and 
to 100% at 200 min. 
2.5 Data handling 
Protein identification and quantification were performed with MaxQuant[233] by searching 
against fasta files from UniProt[234] that contain the human proteins. Methionine oxidation 
and N-term acetylation were set as variable modifications. The quantification method was label-
free for the method development and set to TMTsixplex for all clinical samples. 
The statistical analyses were performed and visualized with Perseus.[207, 235]  
For paper 1, the protein intensities were log2(x+1) transformed in Perseus, and batch corrected 
with the combat method.[236] The entries were filtered for the labels “potential contaminant”, 
“reverse” and “only identified by site”. The data was further analyzed by principal component 
analysis (PCA), and with the limma package, Cluster Profiler and revigo.[237, 238] 
For paper 2, the protein intensities were log(2) transformed and the standard intensities were 
subtracted from the corresponding sample intensities. The resulting intensities were Z-score 
transformed (matrix access: columns). Significantly different proteins were determined with a 
two-sample test. For functional analyses gene ontology terms were added from GOBP 
(biological process), GOMF (molecular function), GOCC (cellular component),[239] 
KEGG,[240] GSEA,[241] UniProt keywords,[234] InterPro,[242], Reactome,[243] and 
PROSITE.[244] Enrichment of proteins with increased and decreased, respectively, abundance 
was determined with a Fisher exact test. The network analyses were performed with the 
Cytoscape app ClueGO, applying the WikiPathways database.[245]  
For paper 3, the protein intensities were normalized as described for paper 2. ANOVA testing 
with subsequent post-hoc testing determined significant differences and their direction (i.e. 
increased or decreased abundance) between active UC, healthy controls, and UC remission. 
The proteins were assigned to groups according to this pattern. The GO annotations described 
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above were added and categorical enrichments within these groups were determined with a 
Fisher exact test. Network analyses were performed with the Cytoscape app ClueGO, for which 
the GOBP database was applied. 
For paper 4, the protein intensities were normalized as described for papers 2 and 3. All proteins 
with missing data were removed from the dataset. Statistical analyses and model development 
were performed with SIMCA P+ 15.0 (Umetrics, Sweden). Network analysis was performed 
with StringDB.[246]   
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3 Summary of results 
Paper I 
The Proteome of Ulcerative Colitis in Colon Biopsies from Adults ‐ Optimized Sample 
Preparation and Comparison with Healthy Controls [1] 
Armin Schniers, Endre Anderssen, Christopher Graham Fenton, Rasmus Goll, Yvonne Pasing, 
Ruth Hracky Paulssen, Jon Florholmen and Terkel Hansen 
PROTEOMICS – Clinical Applications 2017, 11(11-12):1700053. 
In this study, we investigated seven lysis buffers to optimize the sample preparation of colon 
mucosa biopsies. A lysis buffer of 5% sodium deoxycholate, 8 M urea, and 100 mM was 
superior in the tandem-digestion with Lys-C and trypsin, with high reproducibility and 
identification numbers. Interestingly, the proportion of identified transmembrane proteins was 
highest with the two cationic detergents. Our results indicate that sodium laurate and urea 
inhibit tryptic enzyme activity synergistically. 
For the investigation of clinical samples, 6 healthy controls and 6 UC patients at disease onset 
were included. A PCA separates clearly between the groups. 68 proteins were up- and 100 
proteins down-regulated for p < 0.05 and fold change (log base 2) > |0.7|. 
Proteins related to the immune system are of increased abundance in UC. Proteins related to 
anion transport, epithelial cell adhesion, and mucus production are decreased in active UC. 
Seven out of 11 quantified S100 proteins were significantly different abundant, with both 
increases and decreases in active UC compared to healthy controls. S100A8 and S100A9, which 
form the heterodimer calprotectin, S100A11, S100A12, and S100P are of increased abundance 
in UC. The abundances of S100A14 and S100A16 are decreased. 
 
 
Figure 11 - Comparison of detergents in proteomics of colon mucosa biopsies. (A) PCA shows grouping according 
to detergent properties and detergent removal method. CTAB = cetyltrimethylammonium bromide, NMDOA = 
N-methyldioctylamine, SDS = sodium dodecyl sulfate, SL = sodium laurate, SDC = sodium deoxycholate 




Ulcerative colitis: functional analysis of the in-depth proteome [2] 
Armin Schniers, Rasmus Goll, Yvonne Pasing, Sveinung Wergeland Sørbye, Jon Florholmen 
and Terkel Hansen 
Clin Proteomics 2019, 16:4. 
In this study, we investigated the functional changes in the proteomes of 17 UC patients at 
debut compared to 15 healthy controls. 
The proteome depth achieved in the analyses was enhanced compared to paper I by high pH 
reversed-phase fractionation of the samples and increased analysis time. This approach resulted 
in the deepest proteome of colon mucosa biopsies published to-date. 8562 proteins were 
identified, of which 6818 proteins were quantified in at least 70% of the samples. 321 proteins 
were of decreased and 275 increased abundance in active UC compared to healthy controls for 
S0=2 and false discovery rate (FDR) = 0.01 of the normalized values.  
Hierarchical clustering of the significantly different proteins revealed 3 protein clusters. The 
decreased proteins group in one cluster, while the increased proteins group in a major cluster 
of 247 and a minor cluster of 20 proteins. The minor cluster presents with a more pronounced 
abundance increase in a subgroup of UC patients. The proteins in this minor cluster include the 
calprotectin complex proteins S100A8 and S100A9 and further proteins related to neutrophils.    
The functional analysis of the dataset shows that proteins associated with metabolism of 
nutrients, energy, steroids, xenobiotics and carbonate are of decreased abundance in active UC. 
Decreased in active UC are furthermore metallothioneins, PPAR-inducible proteins, fibrillar 
collagens and proteins involved in bile acid transport. Increased abundances were found for 
proteins involved in immune response and protein processing in the endoplasmic reticulum, 
e.g. unfolded protein response and signal peptidase complex proteins. 
 
 
Figure 12 - Functional network of proteins with significantly decreased abundance in active UC compared to healthy 





The proteome of ulcerative colitis in remission – functional differences in comparison with 
healthy controls and the active disease 
Armin Schniers, Rasmus Goll, Sveinung Wergeland Sørbye, Jon Florholmen and Terkel Hansen 
 
In this study, we investigated how protein abundances in UC remission relate to those in healthy 
controls and active UC. We included 14 patients in deep remission from UC, 17 patients with 
active UC, and 15 healthy controls. 6775 proteins were quantified in over 70% of the samples. 
631 proteins were differently abundant in remission compared to active UC, healthy controls, 
or both. 39 (6%) of these proteins were higher abundant in remission than in healthy controls 
and active UC. 359 (57%) proteins showed similar abundances in remission as in healthy 
controls. 82 proteins (13%) had a similar abundance in remission as in active UC. 151 (24%) 
of the protein abundances in remission lay in between healthy control and active UC 
abundances. These results show that the UC remission proteome is in most parts a combination 
of the proteomes of active UC and of healthy controls, with more similarity to healthy controls 
(see Figure 13). 
The functions that return in remission to abundance levels as in healthy controls include the 
increased abundances of immune processes (except for immunoglobulins) and protein 
processing in the ER observed in active UC, as well as the decreased levels of fibrillary 
collagens. The abundances of proteins that are involved in nutrient, energy and xenobiotics 
metabolism or are associated with PPAR signaling increase in remission significantly compared 
to active UC. However, they remain lower than in healthy controls.  
Metallothioneins remain in remission at similarly decreased levels as in active UC, and most 
immunoglobulins remain at similarly increased abundances. These persistent changes may 
contribute to symptoms and relapses in UC remission. 
 
 
Figure 13 - Exploratory analysis of the proteome in UC remission, active UC, and healthy controls. (A) The scatter 
plots of averaged abundances and corresponding Pearson correlations show that the proteome in remission is 
more similar to healthy controls than to active UC. (B) The separation of remission (yellow) and healthy (green) 
from active UC (violet) and the overlap between remission UC and healthy controls after hierarchical clustering 




Prediction of the 1-year outcome for Ulcerative Colitis from the proteomic profile of 
treatment naïve patients  
Armin Schniers, Rasmus Goll, Sveinung Wergeland Sørbye, Hans Stenlund, Jon Florholmen 
and Terkel Hansen 
 
In this article, we present a model to predict the one-year outcome for UC patients from biopsies 
obtained at disease onset. This final model takes into account the 50 most important proteins 
and separates clearly between mild/moderate and severe outcomes. 
Fibrinogens (FGA, FGB and FGG) are at the core in a network of the 50 most important 
proteins. Fibrinogens have pro-inflammatory properties in several diseases, e.g. multiple 
sclerosis, Alzheimer’s disease, rheumatoid arthritis, kidney fibrosis and several types of 
cancer.[247] The network core is connected to clusters with functions in splicing, protein 
translation and mitochondria. An independent network has functions in gut permeability and 
contains two Rab proteins, Rab13 and Rab22A. Both proteins are involved in 
inflammation.[248] Mistargeting of Rab13 to basolateral sites has been shown in patients with 
CD.[249] 
The prediction of the disease development at disease onset would be useful in the clinical 
decision-making. Knowledge that the disease will take a severe course may for instance warrant 
an early treatment escalation. However, the prediction model needs further validation. To 
establish clinical applications it would furthermore be necessary to show a benefit of the 
respective treatment adjustments. 
In conclusion, our study indicates that a protein network with fibrinogens at its core is important 
for the course of UC. This improves our understanding of the disease pathophysiology and 




Figure 14 - Partial least squares regression analysis (PLS) (2A) and principal component analysis (PCA) (2B) of 
samples taking into account the 50 most important proteins for separating mild or moderate outcome from severe 
outcome. Blue circles represent samples with mild or moderate outcome after one year; red diamonds represent 





4.1 Advanced Systems Biology Analysis of Early events and Clinical 
Outcomes in Inflammatory Bowel Disease (ASIB) study 
The present project is part of the ASIB study. The ASIB study is an international multicenter 
and multiregional study of IBD. It is a multi-omics study and comprises projects that investigate 
genomic, transcriptomic, proteomic, metabolomic and lipidomic patterns in IBD patients. The 
ASIB study is coordinated by Professor Jon Florholmen and funded by UiT – The Artic 
University of Norway and Helse Nord RHF. 
The study includes a biobank, which currently holds colon mucosa biopsies from about 100 UC 
patients at disease debut and further samples from patients in UC remission, from CD patients, 
and from healthy controls. The study aims to include in total 340 IBD patients. 
The clinical samples are central to the project. One strength of the study is that all omics in this 
study investigate samples from the same patients and healthy controls, which makes the direct 
comparison of different omics in the same patients possible. In this regard, for instance the 
correlation between mRNA and protein abundance changes or between enzymes and their 
respective metabolites are of interest. The enrolled patients and the disease manifestation are 
well characterized. The same evaluators perform the characterization of a particular patient over 
time, because changing evaluators could entail differences in the characterization. The biobank 
is centralized in one department, which maximizes the control over the sample handling. A 
current limitation of the ASIB biobank is the lack of other sample types than colon mucosa 
biopsies. This limitation has been recognized and the collection of additional sample types such 
as feces and blood is being planned. 
The biobank is relatively large for the characteristics of containing biopsies and of originating 
from untreated patients, but not particularly large when considering only the total number of 
patients. The clinicians optimize the treatment depending on their evaluation for each patient. 
Accordingly, the treatment is not randomized. This is necessary to ensure best possible care for 
each patient, but complicates the evaluation of the study results. The biopsy collection within 
Norway entails that the enrolled patients show little spread of ethnicity. While this has some 
advantages because the limitation of non-disease related differences simplifies the 
interpretation of the results, the lack of different ethnicities is also a major limitation of the 
study. 
Despite some important limitations, the ASIB study design is well tailored for answering a 
range of so far unresolved issues regarding IBD and the combination of omics disciplines is 




In this project, we investigated proteomes in biopsies from UC patients and healthy controls. 
We included patients with active inflammation at disease onset to investigate the proteome 
properties of the disease without treatment. In this group, we included patients with different 
1-year outcomes to build a model to predict the disease progression. We further included 
samples from patients in remission from UC to investigate how the remission state compares 
to the active disease and healthy controls. The control samples were taken from healthy subjects 
in cancer screening examinations. The subject characterizations are comprehensive and include 
clinical, endoscopic and histologic scores. 
We aimed to select samples with age and gender subject characteristics that were similar 
between groups we aimed to compare. However, the age is skewed towards a higher age in 
controls compared to UC patients, which reflects that colon cancer screening is less common 
in young subjects. The average age of patients in remission is higher than in patients at disease 
onset, reflecting that the disease onset of the patients in remission was on average 7.4 years 
before the biopsy was obtained. It was not possible to avoid age differences between the groups 
with the available samples entirely. However, the ages between the groups overlap strongly and 
the highest difference in average age between two groups (12.5 years) is moderate. 
Additionally, as opposed to the disease/healthy states, we did not observe grouping according 
to age in PCAs, which indicates that age has comparably little effect on the proteome. While a 
reduction of the differences in the average age would have been desirable, the present 
differences are acceptable. 
The gender ratios female/male are similar between the compared groups. However, the number 
of male subjects exceeds the number of female subjects. An equal distribution between the 
genders would have been preferable, but was not achievable with the samples available in the 
biobank without creating larger differences between the groups. Considering the study aims, 
we deemed similarity between the groups to have a higher priority and had to accept the low 
female/male ratio. 
The biopsies were obtained in Norwegian hospitals. Accordingly, the ethnicities and life-styles 
of the subjects reflect the Norwegian society. This can in principal entail results that are not 
transferable to other populations. This consideration would favor a more diverse study group. 
On the other hand, a comparably uniform study group, such as the one we investigated, may 
reduce noise in the data and lead to more results that are meaningful. While the present biobank 
did not leave a choice between these options, it can also be argued that the advantages of a low 
spread in factors such as ethnicity and life-styles outweigh the disadvantages for the aims of 
the present study. However, possible differences in UC manifestations depending on ethnicity 
or life-style would be an attractive topic for future studies. 
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The average TNF mRNA and average Geboes index at disease onset were considerably lower 
for patients with a mild or moderate 1-year outcome than for those with a severe outcome. This 
was not avoidable in planning the experiments. ln line with the previously described 
characteristics, more similarity between both groups would be advantageous. However, both 
TNF mRNA and Geboes index values overlap between the outcomes, and the model described 
in paper IV separates between the outcomes regardless of the TNF mRNA and Geboes index 
values. 
In conclusion, the selection of biopsies was suitable and optimized for answering the questions 




4.3 Sample preparation of colon mucosa biopsies for proteomics 
Our sample preparation approach aimed to achieve optimal protein denaturation, solubilization 
and extraction. This resulted in quite high concentration of both urea and detergent. A possible 
drawback of this approach is that denaturing conditions can also impair the digestion efficiency 
of enzymes. The use of a tandem digestion with Lys-C followed by trypsin helps to tackle this, 
because Lys-C can tolerate denaturing conditions better than trypsin. The idea behind the 
tandem digestion is that it allows the predigestion under strongly denaturing conditions, e.g. 6 
M urea, to introduce first cleavages by Lys-C into proteins, which yields peptides that are 
soluble under less denaturing conditions. Subsequent sample dilution to less denaturing 
condition, e.g. ≤1 M urea, restores conditions compatible with tryptic digestion. 
Sodium laurate (SL) has a 12-C carbon tail and a terminal carboxylate function; hence, it can 
be viewed as the carboxylate analog of SDS. It is the sodium salt of lauric acid, a fatty acid. 
The carboxylate function remains deprotonated under pH conditions common for enzymatic 
digestion, but can be quantitatively protonated by acidification. Protonation causes a loss of the 
negative charge and hence decreases the hydrophilicity, causing the precipitation from aqueous 
solutions. SL can subsequently be removed by centrifugation, which allows the detergent 
removal after enzymatic digestion. SL has been studied as a detergent for sample preparation 
in proteomics. SL has some favorable solubilization properties, but 1% SL inhibits trypsin 
activity already by 20%.[250]  
Sodium deoxycholate (SDC) has repeatedly been shown to be a favorable detergent in lysis 
buffers for proteomics experiments.[251] SDC is the sodium salt of the bile acid deoxycholic 
acid. As such, SDC has a sterane skeleton that contributes to its hydrophobic properties. The 
major hydrophilic moiety of SDC is the carboxylate function in the side-chain at 24-position. 
Little decrease of trypsin activity is observed for 1% SDC, and an activity of 77.4% was still 
determined in 10% SDC solution.[252] 
Rapigest is an anionic, acid cleavable detergent. The negative charge in Rapigest rests on a 
sulfonate group. This detergent contains a cyclic acetal. The acetal is stable under the lysis and 
digestion conditions, but degrades under acidic condition. The degradation products do not 
interfere with LC-MS/MS analysis. Rapigest is a patented surfactant and marketed at 
comparably high cost specifically for the use in proteomics. However, other detergents 
repeatedly outperformed Rapigest in sample preparation studies for proteomics.[251, 253] 
Cationic detergents like cetyltrimethylammonium bromide (CTAB) have been applied in 
PAGE as an alternative to SDS.[254] However, unlike SDS the cationic detergents did not gain 
a major role in in-solution digestion protocols for proteomics. Many cationic detergents are 
quaternary ammonium ions. CTAB is the bromide salt of a quaternary ammonium. Its nitrogen 
carries a positive charge, as it has four bonds – 3 to methyl groups and one to a hexadecyl group. 
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Furthermore, primary, secondary, or tertiary amines can be protonated to acquire positive 
charges and thereby detergent properties. 
The use of 5% SDC and 8 M urea in the lysis buffer gave the best results in terms of 
identification numbers and reproducibility. Especially the reproducibility of the method with 
regard to both the identity and the amount of extracted proteins is essential in projects 
concerning quantitative analyses from clinical samples. Our finding confirms previous studies 
that identify SDC as a preferable detergent. However, these studies used SDC in other settings, 
i.e. without urea and/or not in the context of Lys-C trypsin tandem digestion.[251, 252, 255] 
SDS was inferior to SDC, both in reproducibility and average protein identification number. 
For FASP methods, the detergent removal before digestion removes the possible advantage of 
increased solubilization due to the detergent. The more tedious sample processing furthermore 
introduce a potential source for contaminations and bias, which may explain the decreased 
reproducibility. On the other hand, these samples still benefit from the denaturation introduced 
to the sample during lysis and additionally from the removal of potentially interfering 
compounds. Beside this, the respective detergent can no longer interfere with the enzyme 
activities. The evaluation of the FASP method is further complicated by the variability of 
available FASP filters in material and shape, which is believed to influence the results and may 
contribute to the performance differences of FASP between laboratories. 
The high numbers of missed cleavages and the low identification numbers with SL confirm 
previous findings that SL impairs tryptic activity. However, the additional presence of urea 
seems to potentiate this effect. It is clear from our results that SL is not suitable for an approach 
that applies urea in addition. However, it seems to be inferior to SDC in other protocols as 
well.[251] 
Cationic detergents were clearly inferior to SDC. However, they had the interesting property of 
identifying a higher proportion of transmembrane proteins than any of the other tested detergent 
(not a higher absolute number though). The applied FASP method and filter material might be 
a cause for the inferiority. Considering that transmembrane proteins are of great biological 
interest, the development of an alternative approaches for the removal of cationic detergents 
could be promising. Spin columns with an appropriate resin may be a promising approach. 
An interesting observation is that in a PCA not only the samples treated with the same detergent 
grouped together, but that they were also closer together the more similar the applied detergents 
were chemically and in their removal method. Accordingly, cationic detergents group 
separately from anionic detergent, and detergents removed with FASP before digestion group 
separately from detergents removed by acid induced cleavage or acid precipitation. 
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The study shows that the additional use of a detergent compared to urea alone can improve the 
Lys-C trypsin tandem digestion significantly. The study however does not compare the 
performance in the use of detergents with or without urea. Preliminary results comparing SDC 
with or without urea showed a higher identification number with urea. However, the difference 
was not as pronounced as in the comparison of urea with or without SDC. We did not confirm 
this with further replicates and did not acquire results for the performance of other detergents 
without urea. Future studies could elucidate these issues. 
In conclusion, SDC is overall superior to the other tested detergents. The enhanced proportion 
of transmembrane proteins with the use of cationic detergents is of potential interest, but further 




4.4 Increased protein abundances in active UC 
The method developed in paper I made it possible to extract and analyze proteins with good 
yields in a reproducible manner. The developed protocol was further used to investigate the 
proteome of colon biopsies at different stages of UC, however with the addition of a 
pre-fractionation step by high pH reversed-phase spin cartridges.  
Proteins with increased abundance in active UC compared to healthy controls show, as 
expected, an enrichment for immune system processes and, more surprisingly, protein 
processing in the endoplasmic reticulum (ER). 
Most proteins of increased abundance in active UC return in remission fully (219 proteins) to 
levels as in healthy controls (healthy controls ≈ remission < active UC). 16 return only partially 
(healthy controls < remission < active UC) and 32 proteins remain at levels as in active UC 
(healthy controls < remission ≈ active UC). Immunoglobulin domains are predominant among 
these 48 proteins that do not return to levels as observed in healthy controls.  
4.4.1 Immune system 
The inflammation reflects in the proteome mainly with increased abundances of immune 
system proteins, but also decreases of anti-inflammatory processes can promote inflammation. 
Proteins of increased abundance that participate in inflammation are associated with 
phagocytes, T cells, and B cells. These proteins include inducible nitric oxide synthase (NOS2) 
that produces nitric oxide, metalloproteinases that degrade collagen, and immunoglobulins. 
Decreased abundances we found that might contribute to the inflammation are those of 
histamine degrading enzymes. A lack of these enzymes likely contributes to the increased 
histamine levels observed in UC tissue.[80] These findings are in agreement with current 
knowledge on the UC pathophysiology. 
Remarkable is that a group of 20 proteins (minority cluster) related to neutrophils follows a 
different abundance pattern than most other proteins with increased abundance in UC. 
Interestingly, these proteins include the biomarker proteins of the calprotectin complex 
(S100A8, S100A9) and lactotransferrin, which are widely applied as fecal biomarkers. The 
abundance of these proteins shows a marked increase in a subset of UC samples compared to 
other UC samples (see Figure 15A-1). This abundance pattern is representative for only few 
proteins and the abundances between active UC and healthy controls overlap for these proteins, 
which is not the case for several proteins of the majority clusters (see Figure 15B). These 
findings suggest that assessing only the proteins from the minority cluster gives an incomplete 
picture and that an additional assessment of the majority cluster proteins such as CD38, 





Figure 15 - Profile plots of relative abundances for significantly different abundant proteins in active UC (UC) 
compared to healthy controls (H). (A) Hierarchical clustering returned the protein clusters 1-3. The proteins of 
increased abundance in active UC form the minor cluster 1, which includes the biomarkers calprotectin and 
lactotransferrin, and the major cluster 2, which contains the majority of proteins of increased abundance. Cluster 3 
contains proteins of decreased abundance in active UC compared to healthy controls. (B) Abundance changes of 
proteins from groups 2 (CD38) and 3 (HMGCS2, SLC26A2), selected based on magnitude of fold change and p-
value, in comparison with the calprotectin complex proteins S100A8 and S100A9. The calprotectin complex proteins 
present with high average abundance changes, but the relative abundances overlap between active UC and healthy 
controls (e.g. H7 presents with higher calprotectin abundance than UC16). The higher consistency of abundance 
changes for the presented group 2 and 3 proteins could be appealing for clinical applications. Modified from [2] 
The abundances of the minority protein cluster correlate with the histological neutrophil 
assessment, but not strongly with fecal calprotectin levels. A factor that may contribute to the 
low correlation between biopsy calprotectin with fecal calprotectin is that biopsies represent 
only a small fraction of the colon, while fecal calprotectin can accumulate from different areas. 




In deep remission from UC, most immune system proteins return to levels as observed in 
healthy controls. The exception are immunoglobulins, which remain increased in remission 
compared to healthy controls. Most immunoglobulins remain at levels as in active UC. Only a 
minority decreases their abundance in UC remission significantly compared to active UC, but 
also their abundances remain higher than in healthy controls. These findings indicate that the 
immune system activity is mostly contained in the state of deep remission, with the exception 
of immunoglobulins. 
4.4.2 Protein processing 
Proteins related to protein processing in the endoplasmic reticulum (ER) are of increased 
abundance in active UC compared to healthy controls. The increased abundances observed for 
protein processing comprise chaperones that are related to unfolded protein response (UPR), 
e.g. disulfide isomerases that rearrange S-S bonds in proteins, and signal peptidase complex 
proteins, which cleave the N-terminal signal peptides from maturing proteins.  
The UPR leads to an increase in protein folding capacity, increased protein degradation in the 
ER, and a decreased global protein synthesis.[256] As the term indicates the UPR is induced 
by unfolded proteins, but as shown in yeast it also has housekeeping functions in the absence 
of stress conditions in accommodating increased synthesis of cytokines.[257] Unfolded 
proteins, e.g. mucin-2 (MUC2), and the UPR in immune cells and intestinal epithelial cells are 
believed to be involved in the IBD pathophysiology. The UPR has ambiguous effects. In 
intestinal epithelial cells, the UPR effectors can support the cell function and prevent 
inflammation.[256] On the other hand, the UPR modulates cytokine production, e.g. by 
activating the pro-inflammatory transcription factors NF-κB and AP-1.[258]  
Interestingly, protein processing in the ER was the only major function beside the immune 
system we found strongly enriched among proteins of increased abundance. This may give 
ground for giving it increased attention in its function in the UC pathophysiology. One 
important limitation of our studies with regard to UPR is that they assess the protein abundances 
in the complete biopsies. For UPR proteins, the cell type-resolved abundances are of interest 
due to the ambiguous functions of the UPR in epithelial cells and immune cells. Without such 
data, it is not possible to determine how the total UPR comes into place, i.e. whether immune 
cell UPR, epithelial cell UPR, or both are of increased abundance in active UC. 
The abundance of protein processing proteins decreases under remission to abundances similar 
to healthy controls. With regard to UPR in immune cells, this is consistent with the finding of 
immune cell proteins returning in remission to abundances as in healthy controls. A return of 
epithelial cell UPR could result from a decrease of unfolded proteins, but could also imply a 
decreased effect of its anti-inflammatory effects in these cells. However, as we did not design 
our studies to differentiate between epithelial cell UPR and immune cell UPR, further research 
is necessary to assess the abundance changes in different cell types. 
 
56 
4.5 Decreased protein abundances in active UC 
We observe decreased abundances in active UC compared to healthy controls predominantly 
in proteins related to metabolism, binding, and transport of small chemical compounds. 
Changes in these functions do not present with an equally obvious phenotype as the 
inflammation associated with increased immune system protein abundances. However, most of 
the significant abundance changes we found between active UC and healthy controls are in fact 
abundance decreases in UC (321 abundances were decreased in UC of in total 596 differently 
abundant proteins). This shows that the UC pathophysiology has manifold aspects beyond the 
obvious immune system activation. 
Interestingly, most decreased abundances observed in active UC do not return in remission fully 
to levels as observed in healthy controls. In our studies, 50 protein abundances remain in 
remission at a similar level as in active UC (healthy controls > remission ≈ active UC), while 
135 abundances increase significantly in remission, but show abundances between healthy 
controls and active UC (healthy controls > remission > active UC). 140 proteins return to levels 
as in healthy controls (healthy controls ≈ remission > active UC). This is remarkable, because 
most proteins of increased abundance in active UC return in remission to levels as in healthy 
controls, with the exception of immunoglobulins. 
In conclusion, our findings imply that decreased protein abundances have a major role in the 
pathophysiology of active UC, and that they could be dominant in the pathophysiology of UC 
in remission. 
4.5.1 Nutrient and energy metabolism 
Proteins involved in the utilization of nutrients are of decreased abundance in active UC 
compared to healthy controls in processes ranging from the transport within the cell, over 
degradation processes and the citric acid cycle, up to the electron transport chain in the 
mitochondria. The nutrients with associated decreased metabolic protein abundances are fatty 
acids including the SCFA butyrate, ketone bodies, and amino acids (valine, leucine, isoleucine, 
and tryptophan). Fatty acids depend, due to their low solubility, on fatty acid binding proteins 
(FABPs) for their intracellular transport. We observe decreased abundances in active UC 
compared to healthy controls for FABP1, FABP2, FABP4, and FABP5. Our results suggest 
that the decreased transport and metabolic capacities jointly impair the utilization of fatty acids. 
Butyrate is the major energy source for colonocytes. Previous studies observed an impaired 
utilization of butyrate. Based on this, an energy deficiency was suggested as a factor in the UC 
pathophysiology. Besides, colonocytes convert a fraction of the butyrate to the ketone body β-
hydroxybutyrate;[91] hence, the butyrate metabolism is intertwined with the ketone body 
metabolism. β-hydroxybutyrate is like other ketone bodies an energy source, but it also acts as 
an endogenous histone deacetylase inhibitor. The histone deacetylase inhibition by 
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β-hydroxybutyrate leads to increased acetylation at the promoters of FOXO3A and MT2 and 
to increased transcription of these genes. Accordingly, treatment of mice with 
β-hydroxybutyrate provides protection from oxidative stress.[93] Previous studies applied 
SCFA including butyrate to treat patients with UC, but the results are inconclusive.  
We believe that treatment with β-hydroxybutyrate could be a more promising approach, 
because our results suggest that the conversion of butyrate to β-hydroxybutyrate is impaired. 
Furthermore, our data shows decreased levels of the above-mentioned metallothionein-2 (MT2) 
in active UC. MT2 is among 50 proteins that remain in remission at similarly decreased levels 
as in active UC (H > R ≈ UC), whereas most other proteins are of significantly different 
abundance in remission compared to active UC. Our results indicate that MT2 abundances are 
non-responsive to current treatment in remission. Treatment with β-hydroxybutyrate could be 
an elegant approach to restore MT2 abundances to levels as in healthy controls and 
simultaneously improve the colonocyte nutrition. β-hydroxybutyrate has previously shown 
promising results and safety in the treatment of other pathological conditions.[259, 260] 
However, it should be noted and carefully considered that the role of metallothioneins in IBD 
is highly controversial[94], see the section on metallothioneins below. 
The citric acid cycle (synonyms tricarboxylic acid cycle, TCA cycle, and Krebs cycle) is a 
metabolic pathway that oxidizes acetyl-CoA to two equivalents CO2 and in turn reduces three 
equivalents NAD+ to NADH and one equivalent FAD to FADH2, and converts one equivalent 
GDP to GTP. Acetyl-CoA for the TCA cycle is supplied by the degradation of a wide range of 
nutrients, including fatty acids, ketone bodies, carbohydrates, and amino acids. Accordingly, 
the TCA cycle is central for the utilization of these nutrients. The NADH and FADH2 produced 
in the TCA cycle are further processed in the electron transport chain (ETC) to produce easily 
usable chemical energy in form of ATP. The decreased levels of proteins associated with the 
TCA cycle and the ETC suggest impaired ATP production capabilities with little nutrient 
specificity, which occur in addition to the impairments of more nutrient specific metabolic 
pathways.  
In remission, we observe increased abundances compared to active UC for proteins that are 
involved in the nutrient and energy metabolism. However, the abundances remain significantly 
below those in healthy controls (healthy controls > UC remission > active UC). This suggests 
that the proposed energy deficiency in active UC is only partially resolved in the remission 
state. For this reason, it seems likely that it continues to influence the clinical presentation and 
development of UC in the remission state. 
4.5.2 Peroxisome proliferator-activated receptor 
Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors that are stimulated 
by small lipophilic ligands. They have major regulatory roles in energy homeostasis and energy 
metabolism. PPARs have protective or detrimental effects in a range of different 
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pathophysiological conditions, including anti-inflammatory properties of PPAR-α and 
PPAR-γ.[84] Colonic epithelial cells express PPAR-γ. Activation of these receptors by the 
agonist 15d-PGJ2 inhibits the activation of nuclear factor-κB in an IκB-α–dependent way. It 
thereby decreases the expression of cytokines in colon cancer cell lines. Inflammation in IBD 
mouse models decreased upon treatment with thiazolidinedione agonists of PPAR-γ.[90] 5-
ASA, which is widely used in IBD, is believed to exert some of its effects through PPAR-
γ.[128] 
Our results show decreases of proteins related to PPAR signaling in active UC compared to 
healthy controls. This includes proteins that are involved in the transport of ligands to PPARs, 
especially the previously mentioned FABPs, and proteins whose expression PPARs increase. 
These findings suggest an impaired PPAR signaling in active UC. Accordingly, our findings 
support that PPAR agonists could be promising agents for the treatment of active UC.[90] 
We further show that proteins associated with PPAR signaling increase significantly in 
remission compared to active UC, but remain at decreased abundances compared to healthy 
controls (healthy controls > UC remission > active UC). This implies that the impaired PPAR 
signaling is not fully resolved in remission and that accordingly PPAR agonists could be of 
interest for maintenance treatment. 
4.5.3 Metallothioneins 
Metallothioneins (MTs) are small, cysteine-rich, heavy metal binding proteins. With their 
heavy metal binding properties, they function in the detoxification of toxic heavy metals, the 
utilization of essential heavy metals, and protect from oxidative stress.[94, 261] They 
furthermore modulate the activity of NF-κB and of immune cells.[94] 
Our experiments show that MTs are of decreased abundance in active UC compared to healthy 
controls. Even more interestingly, as opposed to most other proteins, their abundances do not 
increase in remission and instead remain at the levels observed in active UC. This may 
contribute to symptoms observed in the remission state or to relapses.  
Zinc homeostasis by redistribution of the intracellular zinc pool is an extensively investigated 
function of MTs. The MTs have opposite effects on the availability on zinc. They can increase 
the intracellular zinc levels to enable reactions of the acute phase response and they transport 
zinc within the cell to release it at zinc-requiring proteins, but they can also sequester zinc to 
increase the activity of enzymes that are inhibited by zinc.[261, 262] Zinc is essential for the 
normal development and function of neutrophils, macrophages, NK cells, B cells, and T cells. 
Zinc is necessary for the activation of the lipopolysaccharide induced NF-κB pathway.[263] 
On the other hand, zinc has anti-inflammatory and anti-oxidant effects. For instance, zinc 
induces protein A20 (TNFAIP3) that inhibits the pro-inflammatory NF-κB, and zinc deficiency 
can lead to an increased production of pro-inflammatory cytokines.[262, 264] Both the effects 
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of zinc on immune processes and the effects of MTs on zinc availability are ambiguous. 
Accordingly, the effects that altered zinc binding resulting from decreased MT abundances in 
UC has on the inflammation process are not clear. 
The antioxidant effects of MTs alter inflammatory processes through the sequestration of 
harmful oxygen and nitrogen intermediates and through modulation of NF-κB activity.[94] 
They are exerted by cysteine residues, which get oxidized in the process.[265] Increased levels 
of reactive oxygen species (ROS) and of oxidative damage in proteins and RNA are present in 
IBD.[266] Neutrophils and macrophages produce ROS (superoxide anion, hydrogen peroxide, 
nitric oxide) to kill bacteria and parasites during infections. However, these agents are cytotoxic 
to host cells. MTs protect host cells from these compounds. Thereby, they prevent damage and 
allow survival and growth in inflammation.[94] 
The role of MTs in IBD is obscure. Opposite findings on the expression of MTs in IBD patients 
exist, but most find decreased abundances in IBD compared to healthy controls. Results from 
animal models are similarly inconclusive. They include findings of increased, unchanged, and 
decreased abundances of MTs in response to induced colitis.[94] Two studies on MTnull and 
wild type mice found no protective or even unfavorable effects of MTs in DSS-induced 
colitis.[94, 267, 268] On the other hand, MTs showed favorable effects in other inflammation 
animal models, including Helicobacter pylori-induced gastritis [269], lipopolysaccharide 
(LPS)-induced acute lung injury [270], collagen-induced arthritis [271], and LPS-induced lethal 
shock.[272] On the other hand, MTs sensitize for TNF-induced lethal shock.[94, 273] 
An improved understanding of MTs in IBD could help in the development of new treatment 
strategies. MTs and some associated functions are compelling treatment targets, because they 
are readily addressable with existing compounds. For instance, zinc and β-hydroxybutyrate can 
induce MTs[93, 274], chelation of toxic heavy metals can contain their effects[275], 
supplementation can increase the availability of beneficial polyvalent metal ions[276], and 
antioxidants[277] could potentially replace decreased anti-oxidative capabilities from MTs. 
Waeytens et al. raised the question whether the regulation of MTs in IBD is dependent or 
independent on inflammation.[94] Our finding that the abundances remain at similarly 
decreased abundances in the absence of inflammation in remission suggests that the abundance 
changes are independent from acute inflammation. 
4.5.4 Prostaglandin metabolism 
The cyclooxygenase (COX) isoforms COX1 and the inducible COX2 generate prostaglandins 
from arachidonic acid. Prostaglandins are important mediators of inflammation, but can also 
have anti-inflammatory effects. They appear to participate in both the acute inflammation and 
the resolution of inflammation. COX2-KO mice show little resolution of the inflammation and 
higher numbers of immune cells than wild type and COX1-KO mice 7 days after induction of 
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inflammation.[278] Inhibitors of COX2 in rats decreased the initial inflammatory response at 3 
hours when injected one hour before induction of inflammation, but exacerbated inflammation 
after 48 hours when injected 24 hours after induction of inflammation. Accordingly, the study 
concludes that COX2 may be pro-inflammatory in the early phase of inflammation, but that it 
may help to resolve inflammation in later phases.[279] 
Our data showed that prostaglandin metabolizing enzymes are enriched among the proteins that 
remain at similarly decreased abundances in remission as in active UC (healthy controls > UC 
remission ≈ active UC). The proteins aldo-keto reductase family 1 member C3 (AKR1C3) and 
peroxisomal acyl-coenzyme A oxidase 1 (ACOX1) are involved in the degradation of 
prostaglandins. 15-hydroxyprostaglandin dehydrogenase (HPGD) is involved in the formation 
of prostaglandin F2α from prostaglandin D2 and prostaglandin H.[280, 281] Prostaglandin H2 
is formed from arachidonic acid and a common intermediate in the formation of prostaglandin 
D2, prostaglandin E2, prostaglandin F2, prostaglandin I2, and thromboxane A2 (TXA2). 
Prostaglandin D2 has pro-inflammatory and anti-inflammatory effects, and it may contribute to 
the resolution of inflammation. Prostaglandin F2α has a prominent role in the female 
reproductive system, but also has pro-inflammatory effects.[282] 
It should be noted that further identified metabolic proteins of prostaglandins have other 
abundance patterns. For instance, prostaglandin E synthase (PTGES) is similarly abundant in 
UC remission and healthy controls, but significantly higher abundant in active UC (healthy 
controls ≈ UC remission < active UC). PTGES forms prostaglandin E2 from prostaglandin 
H2.[283] Prostaglandin reductase 2 (PTGR2) is significantly higher abundant in healthy 
controls than in UC remission and significantly higher abundant in UC remission than in active 
UC (healthy controls > UC remission > active UC). PTGR2 is involved in the inactivation of 
prostaglandins.[284] 
Prostaglandins have long been known as a factor in IBD. Also their involvement in the 
remission state of IBD has been recognized previously.[285] Our findings show that several 
prostaglandin degradation pathways are decreased in UC remission and active UC compared to 
healthy controls. We furthermore observe differential abundances of enzymes converting 
between different prostaglandins. These results support that prostaglandins have a role in both 
active UC and UC remission and they provide additional explanations for the differential 




4.6 Prediction of 1-year outcome 
We present the first proteomic prediction model that separates mild/moderate disease courses 
from severe outcomes one year after diagnosis. Prediction of the disease course would be a 
useful tool for clinicians. For instance, it would allow for a “hit hard and early” treatment 
strategy for patients that would present a severe disease course, which has been hypothesized 
to be beneficial.[286] 
The prediction model takes the 50 most important proteins into account. These proteins form a 
major network with fibrinogens at its core (Figure 16, network A) that further comprises 
proteins that are involved in splicing and protein translation (Figure 16, network B), 
mitochondrial proteins (Figure 16, network C) and collagen metabolism (MMP2, SERPINH1). 
A smaller network contains proteins involved in gut permeability, including RAB13 and 
RAB22A (Figure 16, network D). 
Several of the 50 most important proteins have roles in inflammation, but our data suggests that 
proteins with directly inflammatory functions are only one of multiple factors determining the 
disease course. This is in line with our observation that inflammatory proteins are only one 
facet in the pathophysiology of both active UC and UC remission.
 
Figure 16 - Network of the most important proteins for separating mild or moderate from severe 1-year-outcomes 
from biopsies obtained at disease debut. From manuscript IV. 
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Despite the potential use of the model, further studies are necessary before establishing it in 
clinical applications. These studies are necessary to validate the model and characterize it in 
terms of sensitivity and specificity. A further measure to enhance the clinical use would be to 
optimize the treatment adjustment in dependence of the predictions from the model. Changes 
of the analytical method (e.g. to ELISA based approaches) and sample material (e.g. blood 
instead of colon mucosa biopsies) would benefit the usability. 
In conclusion, we present the first proteomic model to predict the 1-year outcome at UC debut. 
The model could become a useful tool, but more research is necessary to establish its use in 





4.7 Potential clinical utility 
Our results show that immune processes in the deep remission state of UC are contained, 
whereas several other functions remain unresolved or only partially resolved. Addressing these 
functions may help in both reaching and maintaining the remission state. The impaired nutrient 
utilization capacities of colonocytes imply that supplementation of readily usable energy 
sources such as β-hydroxybutyrate could be beneficial. β-hydroxybutyrate may exert further 
beneficial effects by inducing metallothioneins, even though the effects of metallothioneins in 
the context of IBD warrant further evaluation. PPAR pathways are overlapping with the nutrient 
utilization, because the fatty acid-binding FABPs are involved in PPAR signaling and because 
PPAR regulates metabolic pathways. Our data indicate that the previous hypothesis that PPAR-
γ agonists could ameliorate colitis [89, 90] may be applicable to UC. 
We observe two distinct abundance patterns among proteins with increased abundance in active 
UC. Only a minority of proteins of increased abundances in active UC follows the abundance 
pattern represented by the inflammation biomarkers lactotransferrin and calprotectin (proteins 
S100A8 and S100A9). Proteins with this abundance pattern are associated with neutrophils and 
the abundance of these proteins correlates with histological findings on neutrophil infiltration. 
The observation that they represent only a minority of proteins of increased abundance suggests 
that an additional measurement of proteins, which represent the majority of proteins of 
increased abundance, may carry further useful information. The same applies to proteins of 
decreased abundances. While the abundance changes in the minority group of proteins are 
among the highest average fold changes, the fold changes of the majority proteins are more 
consistent within the conditions active UC and healthy controls, respectively (see Figure 15). 
Knowledge on the abundance changes of these proteins in other diseases could further enhance 
their use in diagnostics. However, biopsies represent only a small area of the colon mucosa. A 
common sample type for calprotectin and lactotransferrin measurements is feces, which 
accumulates protein from a greater area and is easier to sample. Measurement in sample types 
such as feces or blood furthermore depend on the proteins leaking out of the tissue in question. 
The findings from biopsies may accordingly not reflect in feces or blood.  
The prediction of the 1-year outcome could be of great clinical use. Validation of the model is 
necessary before implementation in clinical practice. A subsequent step should be to optimize 
the treatment adjustment according to the prediction. The hypothesis that a top-down treatment 
approach could benefit patients that are prone to a severe disease course offers a straightforward 




5 Conclusion and hypothesis evaluation 
In this thesis the properties of the proteome in ulcerative colitis were elucidated, which resulted 
in a great improvement of our understanding of the pathophysiology in the active and the 
remission state of the disease. The present work suggests approaches to improve diagnostics 
and treatment, but their implementation in the clinical practice demands further research. 
The findings might help to identify and to prioritize potential treatment targets. We also showed 
that it is possible to predict the 1-year outcome of patients from the proteomic profile of 
treatment naïve patients. However, validation of this method is still needed and potentially 
transferring the biomarkers to easier accessible sample types such as feces or blood would 
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Purpose: The purpose of the study was to optimize the sample preparation
and to further use an improved sample preparation to identify proteome
differences between inflamed ulcerative colitis tissue from untreated adults
and healthy controls.
Experimental design: To optimize the sample preparation, we studied the
effect of adding different detergents to a urea containing lysis buffer for a
Lys-C/trypsin tandem digestion. With the optimized method, we prepared
clinical samples from six ulcerative colitis patients and six healthy controls
and analysed them by LC-MS/MS. We examined the acquired data to identify
differences between the states.
Results: We improved the protein extraction and protein identification number
by utilizing a urea and sodium deoxycholate containing buffer. Comparing
ulcerative colitis and healthy tissue, we found 168 of 2366 identified
proteins differently abundant. Inflammatory proteins are higher abundant
in ulcerative colitis, proteins related to anion-transport and mucus production
are lower abundant. A high proportion of S100 proteins is differently
abundant, notably with both up-regulated and down-regulated proteins.
Conclusion and clinical relevance: The optimized sample preparation method
will improve future proteomic studies on colon mucosa. The observed protein
abundance changes and their enrichment in various groups improve our
understanding of ulcerative colitis on protein level.
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1. Introduction
1.1. Inflammatory Bowel Disease
The global incidence of inflammatory
bowel disease (IBD), including Crohn’s
disease (CD) and ulcerative colitis (UC),
is increasing. In Europe 2.2 million pre-
dominantly younger people are suffering
from the disease. The immune response
is dysregulated in IBD such as in other
autoimmune diseases.[1] The cause of the
disease is unknown, but it is generally
accepted that IBD represents a dysregu-
lation of the intestinal immune tolerance
to microbiological and/or nutritional
antigens. This dysregulation results from
a combination of environmental and
genetic factors, in which dysfunctional
gene products may initiate inflammation
via signalling pathways that have been
defined to varying degrees, including
innate, adaptive and T-regulatory im-
munity systems (for a comprehensive
review, please see[2]).
1.2. The IBD Immune Response
The immune response in IBD is far from fully characterized. In
general, UC is described as an atypical Th2 and CD as a Th1 me-
diated disease.[3] Much knowledge about IBD is based on gene
transcriptional data, whereas there is a lack of data for an exten-
sive and comprehensible description of the proteomic immune
response.[4–6] One of the first more complete analyses of the pro-
teome in IBDwas reported recently,[7] describing the proteome of
CD and UC in children in comparison with each other and with
healthy controls. Another study describes the UC proteome of
uninflamed colon mucosa from adults under anti-inflammatory
treatment.[8] However, previous studies do not provide a view into
the proteome of inflamed tissue from untreated adult patients in
comparison with healthy controls, which is essential to under-
stand the underlying mechanisms.
The protein abundances are constantly changing with the state
of a tissue, in addition to the posttranslational modifications, that
can modify a protein’s function and activity. Hence, proteomic
data can reveal new insight to the pathophysiology of IBD.
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Clinical Relevance
Ulcerative colitis is, alongwithCrohn’s disease, onemajor form
of inflammatory bowel disease (IBD). IBDaffects 0.5–1.0%of
thepopulation inNorthAmerica andEurope. The colon and
rectum inulcerative colitis (UC) are in a state of chronic in-
flammation,which is accompaniedbyulceration, abdominal
pain, diarrhea, bloody stool, and further gastrointestinal and
extraintestinalmanifestations. Theunderstandingof theUC
pathophysiology is incomplete; the knowledge about proteome
changes in thedisease contributes to understanding the bio-
chemical processes associatedwithUC.We identified 168pro-
teins as differently regulated in inflamed colonbiopsies from
adultUCpatientswhen compared to samples fromhealthy
controls, andwe showwhichbiological functions aremostly af-
fectedby these changes. The findingof decreased abundances
inUC for theproteins S100A14 andS100A16, in contrast to sev-
eral other S100proteinswith increased abundances,widens
the viewon thepathophysiological role of this protein family.
The sample preparationmethod for colonbiopsies,whichwe
optimized in this study, gives reproducible resultswith high
protein identificationnumbers, thus itwill enhance the quality
of future clinical studies.
1.3. Bottom-Up Proteomics
In-depth shotgun proteomic analyses of clinically relevant sam-
ples are currently dominated by bottom-up approaches.[9]
Bottom-up proteomics is based on the mass spectrometric
analysis of a peptide solution. Regardless of the following steps,
any proteomic sample preparation protocol starts with the extrac-
tion of proteins from the tissue. Mechanical force is usually nec-
essary to break up the macroscopic structure of a tissue sample,
thereby enabling detergents and chaotropes in the lysis buffer
to solubilize the proteins. The solubilized proteins then undergo
enzymatic digestion into peptides.
The choice of detergents and chaotropes in the lysis buffer de-
termines the possibilities in the following sample preparation,
because both detergents and chaotropes need to be removed
prior to mass spectrometric analysis. Some detergent removal
methods, such as FASP, must be conducted before enzymatic
digestion.
1.4. Sample Preparation Method is Highly Determining for
Proteome Depth and Reproducibility
Chaotropes and detergents increase the solubility of proteins, as
they promote the disruption of non-covalent bonds. The disrup-
tion of these bonds facilitates the detachment of membrane con-
stituents from membrane bound proteins and reduces interac-
tions within and between proteins, which causes them to unfold.
However, several chaotropes and detergents need to be diluted or
removed prior to enzymatic digestion due to inhibition of trypsin,
introducing one ormore steps in the sample preparation that can
influence the consistency in the results.[10] A feasible method to
enable digestion into peptides in high urea and/or detergent con-
centrations without changing the tryptic digestion pattern is a
pre-digestion with the endopeptidase Lys-C.[11] As Lys-C is active
under harsh solubilisation conditions, the challenges with pro-
tein precipitation upon digestion can be reduced or avoided.
The aim of the method development in this study was to
optimize the protein extraction and enzymatic digestion for
colon mucosa biopsies. Our results achieved with SDC outper-
form other applied approaches when evaluating reproducibility
and numbers of identified peptides and protein groups. Com-
bining the tandem Lys-C/trypsin digestion with sodium deoxy-




The recruited subjects were patients newly diagnosed with mod-
erate to severe UC admitted at the University Hospital of North
Norway, not receiving any treatment for IBD. The diagnosis
was based on established clinical, endoscopic and histological
criteria.[12] Recruited were patients with active disease as de-
scribed in Table 1; one patient with total colitis, three patients
with left-side colitis, and two patients with proctitis. The degree
of illness was evaluated using the scoring system ulcerative coli-
tis disease activity index (UCDAI, score 0–12), which is based on
clinical signs and on endoscopic evaluation of the colon during
colonoscopy (grade 0–3).[13]
Samples from subjects performing a cancer screening and
with normal colonoscopy and normal colonic histological exam-
ination served as controls. All participants gave their informed
written consent. The Regional Committee of Medical Ethics of
North Norway and the Norwegian Social Science Data Services
approved the study and the storage of biological material (REK
NORD 2012/1349).
Colonic mucosal biopsies were obtained from the most in-
flamed area - the rectosigmoid - as typical for UC, and in
the controls biopsies were obtained from the rectum. Biopsies
(10–15 mg wet weight) were kept frozen at –70 °C for further
processing as described below.
2.2. Protein Identification and Quantification
The methods are described in brief here; we provide further de-
tails as supporting information.
2.2.1. Sample Preparation for the Method Development
2.2.1.1. Sample Pooling for Method Development and Tissue
Lysis. Shortly, 12 colon biopsies (six healthy, six UC) were
pooled in water and homogenized in a MagNA Lyzer instrument
(Roche) at 6500 rpm for 35 s. Protein concentrations were mea-
sured with Pierce BCA Protein Assay Kit following the vendor’s
protocol. Ten microliter aliquots of the homogenate, contain-
ing the tissue debris and 327 μg protein each, were added to
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Table 1. Demographics of 6 patients with moderate to severe ulcerative colitis (UC) at diagnosis of disease, and 6 healthy controls.
Average age (SD) Female/male (SD) UCDAI score (SD) Endoscopic score (SD) TNF-alpha (SD)
UC patients 48 (14) 1/5 9.5 (2) 2.6 (0.5) 14 188 (12390)
Healthy controls 54 (10) 1/5 – 0 2933 (1084)
UCDAI: ulcerative colitis disease activity index. TNF: tumor necrosis factor (in copies/ μg RNA).
240 μl of various lysis buffers in ceramic bead tubes to produce
the following conditions in 3 replicates each: SDC (5% sodium
deoxycholate, 8 M urea, 100 mM TEAB), SDS (1% sodium do-
decyl sulfate, 8 M urea, 100 mM TEAB), SL (5% sodium laurate,
5.7 M urea, 100 mM TEAB), Rapigest (0.25% Rapigest, 8 M urea,
100 mM TEAB), CTAB (1% cetyltrimethylammonium bromide,
8 M urea, 100 mM TEAB), NMDOA (5% N-methyldioctylamine,
6 M urea, 100 mM TEAB, adjustment to pH 6 with formic acid),
Urea (8 M urea, 100 mM TEAB). The urea concentrations with
SL and NMDOAwere reduced in order to resolve solubility prob-
lems. The samples were treated in the MagNA Lyzer instrument
at 6500 rpm for 35 s.
2.2.1.2. Reduction and Alkylation. Disulfide bridges were re-
duced with 5 mM DTT for 30 min at 54 °C, followed by alky-
lation of the cysteines with 15 mM iodoacetamide for 30 min
at room temperature in the dark. Excess iodoacetamide was
quenched by adding DTT corresponding to 5 mM for 5 min at
room temperature.[14]
2.2.1.3. Enzymatic Digestion. The samples were, where appli-
cable, diluted to 6 M urea prior to 8 h Lys-C digestion (Lys-
C:protein ratio 1:100) at 37 °C. All samples were diluted to 1 M
urea prior to tryptic digestion (trypsin:protein ratio 1:20) for 16 h
at 37 °C. The buffers contained 1 mM CaCl2 and 100 mM TEAB
during the digestions.[11]
2.2.1.4. Detergent Removal. CTAB, NMDOA and SDS were
removed prior to enzymatic digestion by modified FASP
methods.[15] SDC and SL were removed by acid precipitation, and
Rapigest by acid induced cleavage, each after enzymatic diges-
tion. A detailed description of the detergent removal methods is
provided in the supporting information.
2.2.1.5. Desalting. The samples were desalted with Omix C18
pipette tips according to the manufacturer’s protocol, except for
the use of TFA instead of heptafluorobutyric acid. The peptides
were eluted with 0.1% FA in 50% acetonitrile.
Samples were dried in an Eppendorf concentrator before being
re-dissolved in 10 μL 0.1% TFA.
2.2.2. Sample Preparation for the UC-Healthy Comparison Study
2.2.2.1. Protein Extraction. Tissue samples from six UC pa-
tients and six healthy controls were transferred to ceramic bead
tubes with 250 μL lysis buffer (8 M urea, 5% sodium deoxy-
cholate, 0.1 M TEAB) and lysed in aMagNA Lyzer instrument for
35 seconds at 6500 rpm. After dilution as described in supporting
information, the protein concentration was determined by BCA
assay according to the manufacturer’s protocol. An aliquot of 60
μg protein was taken for the following steps.
2.2.2.2. Reduction and Alkylation. Cysteines were reduced and
alkylated as described in Section 2.2.1.
2.2.2.3. Enzymatic Digestion, Labelling and Sample Mixture.
Predigestion with Lys-C was done for 8 h at 37 °C in 6 M urea,
3.75% sodium deoxycholate, 1 mM CaCl2, and 0.1 M TEAB with
0.6 μg Lys-C (Lys-C:protein ratio 1:100). Tryptic digestion fol-
lowed after dilution to 1 M urea, 0.625% sodium deoxycholate, 1
mMCaCl2, and 0.1MTEABwith 3μg trypsin (trypsin:protein ra-
tio 1:20). Processed samples from six UC patients and six healthy
controls were mixed in even peptide amounts to produce a stan-
dard. The standard and the samples were labelled with TMT as
described in the supporting information.
2.2.2.4. SDC and Acetonitrile Removal. Formic acid was added
to a concentration of 5% and the precipitated sodium deoxy-
cholate was removed by centrifugation.
The samples were dried in an Eppendorf concentrator to re-
move acetonitrile.
2.2.2.5. Desalting. Samples were dissolved in 200 μL 0.1 M
TEAB. 10.5μL 50% FA and 22.2μL 10%TFAwere added prior to
desalting with C18 pipette tips according to manufacturer’s pro-
tocol. The samples were dried in an Eppendorf concentrator and
redissolved in 8 μL 0.1% TFA.
2.2.3. Nanospray LC-MS/MS
The samples were analysed with a qExactive as described in the
Supporting Information.
2.2.3.1. Inclusion Lists for the UC-Healthy Comparison Study.
For the quantitative study, two additional LC-MS/MS analyses
with inclusion lists were conducted for each sample as described
in the Supporting Information.
2.2.4. Data Analysis
The resulting raw-files were analysed with MaxQuant version
1.5.5.1 and Perseus version 1.5.6.0 with a fasta-file containing
the human proteins (downloaded 09.09.2016 from uniprot.org,
including Swiss-Prot and TrEMBL data) and standard settings,
except for peptide spectrummatch, protein and site FDRs of 0.05
for the UC-healthy comparison.[16,17]
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Figure 1. Comparison of sample preparation methods. (A) Principal component analysis (PCA) of protein group intensities resulting from the different
sample preparation methods. CTAB = cetyl trimethylammonium bromide, NMDOA = N-methyldioctylamine, SDS = sodium dodecyl sulfate, SL =
sodium laurate, SDC = sodium deoxycholate (B) Numbers of identified protein groups and peptides with the different detergents. Shown are the mean
numbers of identifications from three technical replicates (error bars indicating the standard deviation), and the numbers of common identifications
among all three replicates. Significant differences after correction for multiple testing are indicated and the respective p-values included. The applicable
Benjamini-Hochberg critical values for an FDR of 0.05 are 0.0071 for proteins and 0.017 for peptides (Table 1, Supporting Information).
A log2(x+1) transformation of the protein intensities was
done. A principal component analysis of the detergent compar-
ison data gave Figure 1A. After transformation, the data for the
comparison of UC and healthy state was quantile normalized.
Batch effects were removed from the quantile normalized data
using the combat method.[18] The data were then analyzed by
principal component analysis (PCA), and by using the limma
package, Cluster Profiler and revigo.
3. Results and Discussion
3.1. Method Development for Sample Preparation
To optimize the number of peptides and proteins identified, we
report herein a study of different sample preparation methods
of colon biopsies and evaluate their effectiveness based on num-
bers of identified peptides and proteins. We also assess the repro-
ducibility between replicates, which is important when labelling
on peptide level.
3.2. Which Detergents were Tested, and What is the Rationale?
In this publication, we compare seven different workflows,
including two cationic (CTAB, NMDOA) and four anionic
(SDS, Rapigest, SL, SDC) detergents, as well as one workflow
without any detergent. We chose the detergent concentrations
based on previously published methods. For the detergents with
a fixed charge (SDS, CTAB) we chose 1% concentration, as pre-
viously reported for SDS.[19,20] We chose a 5% concentration, as
earlier applied for SDC,[21,22] for SDC, SL and NMDOA, which
have a pH-dependent charge. We used a Rapigest concentration
of 0.25%, since the lowest concentration recommended by the
manufacturer is 0.1%. Increasing the concentration further is un-
favorable due to the high cost of Rapigest.
Samples prepared with the same method cluster strongly in a
PCA. In addition, similarities between methods result in group-
ing (Figure 1; see supporting information for correlation data,
Figure 1, Supporting Information).
We observed no strong correlation between peptide yield
and protein identification numbers (see Figure 2, Supporting
Information).
3.3. SDC Performs Best
SDC gave the overall highest average of protein identification
numbers (Figure 1). SDC is significantly better than CTAB
and NMDOA regarding both peptide and protein identification
numbers and better than SL for peptide identification numbers
(Benjamini-Hochberg FDR< 0.05, Figure 1).[23] The high propor-
tion of missed cleavages observed with SL (Figure 4, Supporting
Information) indicates that the enzymatic digestion is strongly
impaired when both SL and urea are present. The protein and
peptide identification numbers with SDC are not significantly
higher than for urea and Rapigest when correcting for multiple
testing, but the higher numbers of commonly identified proteins
and peptides (Figure 1) make SDC preferable.
The identification numbers of SDC and SDS are not signif-
icantly different either; however, the variances of identification
numbers (Figure 1) and of correlation coefficients are higher
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for SDS than for SDC (spearman rank correlation mean ±
SD: SDCpeptides 0.889 ± 0.004; SDSpeptides 0,836 ± 0.04;
SDCproteins 0.907 ± 0,006; SDSproteins 0.883 ± 0.035; see
Figure 3, Supporting Information). For most applications, in-
cluding our clinical study, a low variance in the sample prepa-
ration is a necessity, as a high variance will decrease the mean-
ingfulness of a dataset strongly. Furthermore, the risk of misin-
terpretations affecting single samples would be detrimental for
possible clinical applications. Recurring small margins of error
are a lesser problem.
A high reproducibility in the generation of peptides is nec-
essary for reliable and precise quantifications using labelling
reagents at peptide level, such as TMT. Labelling after enzy-
matic cleavage to peptides demands that samples are processed
separately before mixing the samples. This can lead to non-
reproducible changes of the sample composition and in turn to
an imprecise determination of protein abundance ratios between
samples. In clinical samples, such shifts in the measured protein
abundance ratiosmay bemistaken for actual differences between
the investigated tissues.
We obtained the highest number of common proteins, cal-
culated as proteins identified in all three replicates, with SDC
(Figure 1). The reproducible detection of the same protein groups
over multiple LC-MS/MS experiments limits the number of
missing values in later analyses. SDC has previously been shown
to also perform very well with highly lipophilic tissues.[20]
An effortful additional sample processing such as FASP is not
required for the removal of SDC, which saves time and dimin-
ishes the risk of contaminations.
SDC is among the best under all evaluated criteria, while other
tested detergents showmajor weaknesses in at least one of these.
We conclude that SDC complements the tandem Lys-C/trypsin
digestion as a simple and cost-effective measure to enhance pep-
tide and protein identifications with high reproducibility.
3.4. Preferential Identification of Transmembrane Proteins with
Cationic Detergents
A comparably high proportion of transmembrane proteins in
the identified proteins was observed for samples prepared with
cationic detergents, especially withNMDOA (proportion of trans-
membrane proteins± SD: CTAB 15.3%± 0.8%; NMDOA 16.1%
± 0.8%; SDS 11.8%± 1.5%; urea 13.2%± 0.4%; Rapigest 13.8%
± 0.3%; SL 11.0% ± 0.3%; SDC 14.0% ± 0.4%; Figure 4 and
Table 3, Supporting Information).
These results indicated that cationic detergents could be a
promising option when targeting transmembrane proteins, but
the applied methods demand further optimization.
3.5. Comparative Study of UC-Affected and Healthy Human
Colon Mucosa
3.5.1. UC-Affected Differs Strongly from Healthy Tissue
Principal component analysis of the batch corrected data[24]
shows clear separation in principal component one between
Figure 2. Principal component analysis. The colon biopsies from patients
with ulcerative colitis separate strongly from healthy tissue samples. The
reference is a mixture of both UC and healthy tissue samples and groups
in between.
six patients newly diagnosed with UC and healthy controls
(Figure 2). The reference samples, which are a mixture of UC
and control material, lie between the two groups as expected.
2366 proteins with zero counts in fewer than five samples were
included in the PCA analysis. Component one explains 47% of
variance due to the strength of the phenotype. A normal mu-
cosa contains primarily epithelial and stromal cells, and this is
compared to a severely inflamed tissue with strong infiltration of
many types of immune cells, as reflected in the gene ontology
analysis (Figure 3). This creates a single strong biological signal.
3.5.2. Which Proteins and Functions are Affected?
Differentially expressed proteins were determined by applying
the limma package to the batch corrected counts data.[25] Pro-
teins were called as differentially expressed if they had a p-value
smaller than 0.05 after correction for multiple testing and a fold
change (log base 2) larger than |0.7|. This identified 68 proteins
that were up-regulated in UC patients and 100 that were down-
regulated (Table 2, Supporting Information).
To help interpret the biomedical significance of the differen-
tially expressed proteins, the lists were analyzed for overrepre-
sented gene ontology terms using Cluster Profiler.[26] Cluster pro-
filer allows the identification of biological processes that are over-
represented among the lists of differentially expressed genes.
The hierarchical nature of the gene ontology causes the detec-
tion of a large number of similar categories often with similar
gene memberships. We therefore used Revigo to identify non
redundant gene ontology terms to focus the interpretation on
(Figure 3).[27]
Up-regulated proteins are dominated by immune system re-
lated processes. This is unsurprising given the significant infil-
tration of immune cells into the gut lining during active UC. This
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Figure 3. Differential regulation of gene ontology categories in UC compared to healthy tissue.
Table 2. The 20 most regulated proteins in ulcerative colitis.
Protein name Gene name Fold change [intensity UC/healthy] p.adj.
Carbonic anhydrase 1 CA1 0.194 1.12E-06
Fatty acid-binding protein, liver FABP1 0.196 4.59E-07
2-oxoglutarate dehydrogenase, mitochondrial OGDH 0.218 5.59E-03
Carbonic anhydrase 2 CA2 0.222 2.03E-10
Poly(ADP-ribose) glycohydrolase PARG 0.225 1.60E-05
3-keto-steroid reductase isoform 2 HSD17B7 0.257 5.16E-08
Trefoil factor 3 TFF3 0.271 2.24E-07
Creatine kinase B-type CKB 0.277 2.71E-07
Hydroxymethylglutaryl-CoA synthase, mitochondrial HMGCS2 0.282 2.11E-06
Normal mucosa of esophagus-specific gene 1 protein C15orf48 0.305 4.88E-06
Selenium-binding protein 1 SELENBP1 0.305 4.80E-08
Cytochrome c oxidase subunit 2 COX2 0.315 8.77E-06
Neural cell adhesion molecule 2 NCAM2 0.322 1.44E-06
Calcium-activated chloride channel regulator 4 CLCA4 0.324 1.41E-04
Intelectin-1 ITLN1 0.328 1.56E-04
Protein S100-A12 S100A12 3.286 2.64E-06
Protein S100-A8 S100A8 3.875 2.95E-06
Protein S100-A9 S100A9 3.903 2.53E-06
Neutrophil defensin 1 DEFA1 3.916 3.21E-06
Myeloblastin PRTN3 5.082 1.40E-05
Fifteen proteins are lower abundant in UC compared to healthy tissue (ratio < 1), while five higher abundant inflammatory proteins (ratio > 1) are among the most regulated
proteins. Three of these are S100 proteins.
infiltration of immune cells reflects in the gene ontology terms
related to response to biotic stimulus and response to fungus.
The cell-cell communication, such as between immune cells and
epithelial cells, is involved in maintaining the inflamed state in
UC. We see this communication in gene ontology categories like
cytokine production and cell killing, the latter reflects probably
the influx of cytotoxic T cells. On the down-regulated side the
picture is less clear, but the gene ontology terms reflect ion trans-
port both of organic and inorganic ions such as SELENBP1 and
CLCA4. Other transport related proteins are also down-regulated,
such as CDH17, and epithelial cell adhesion molecules such as
EPCAM, CEACAM7 and CLDN7. Downregulation of these nor-
mal epithelial functions accommodates immune cell infiltration
andmay also reflect the dysfunction of the epithelium involved in
the UC etiology. Mucus proteins, e.g. MUC2 and TFF3, are also
lower abundant in UC.
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3.5.3. S100 Proteins
Our study found seven of in total 11 quantified S100 proteins
differently abundant in UC than in healthy tissue. Three of these
are among the five most up-regulated proteins (Table 2).
The S100 family consists of 24 proteins with EF-hand calcium-
binding properties. These proteins are further categorized into
three subgroups, which exert only intracellular, both intracellu-
lar and extracellular, andmainly extracellular effects, respectively.
The proteins of the S100 family are involved in a wide range of
functions. These functions include for instance regulatory effects
on immune response, cell migration, metabolism, and tissue re-
pair and development,[28] as well as antimicrobial effects.[29]
Our findings confirm the previously reported increased levels
in UC for S100A8 and S100A9, which form the heterodimer cal-
protectin, S100A12, S100P,[30] and S100A11.[7]
The calprotectin complex of S100A8 and S100A9, in combi-
nation with a second stimulus such as bacterial lipopolysaccha-
ride, is an endogenous ligand of Toll-like receptor 4 (TLR-4) and
induces the NF-κB-dependent expression of pro-inflammatory
proteins such as TNFα. S100A8 seems to be the active part in
the interaction with TLR-4,[31] while S100A9 stabilizes S100A8.
The latter was shown in MRP-14 (S100A9) null mice, in which
S100A8 was undetectable, even though the mRNA for S100A8
was present.[32] Fold changes for S100A8 and S100A9 provided
in Supporting Information support these findings (Figure S7).
The Receptor for Advanced Glycation Endproducts (RAGE) is
a common, but not exclusive, interaction partner of S100A11,
S100A12 and S100P.[33,34]
Conversely, our data shows that S100A14 and S100A16 are
significantly lower abundant in UC tissue. Less is known about
these proteins, and most research focused on these proteins’
roles in cancer. S100A14 seems to have the capability of both
increasing and decreasing tumor invasiveness, depending on
whether the respective tissue expresses wild type or mutant
p53. S100A16 is up-regulated in different cancers[28] and an
adipogenesis-promoting factor with negative impact on insulin
sensitivity.[35]
These findings indicate a substantial role of S100 proteins in
the pathophysiology of UC, which should be elucidated in future
studies.
3.5.4. Comparison with Previous Findings
The findings in our study are largely consistent with previ-
ous studies with different study designs and analytical ap-
proaches. The study designs comprise comparisons of macro-
scopically normal tissue from treated UC patients with healthy
controls,[8] of inflamed tissue from pediatric IBD patients with
pediatric controls,[7] and of inflamed tissue with uninflamed
tissue from the same adult UC patients.[36] Applied analyti-
cal approaches are SDS-PAGE followed by immunoblotting[37]
and peptide mass fingerprinting,[36] respectively, label-free LC-
MS/MS,[8] and SILAC.[7] Despite these differences, significantly
changes in abundances point in the same direction for 37 of
38 proteins, which were commonly identified as significantly
changed in both our dataset and at least one other study. The only
exception is thiosulfate transferase (TST); this protein was found
to be significantly down-regulated in the inflamed tissue both
in the pediatric study by Starr et al. and by us, while it was sig-
nificantly up-regulated in the comparison of inflamed and unin-
flamed tissue from the same UC patients. The differences in the
magnitude of fold-changes, especially between label-free quan-
tification and other methods, are most likely an artifact resulting
from the different analytical approaches.
Our results validate the findings from previous studies and
vice versa. The similarity in proteome changes despite very dif-
ferent study designs is remarkable.
3.5.5. Perspectives
The study identifies differences between healthy andUC-affected
tissue. This gives a deep view into the pathophysiological back-
ground and is a first step toward the identification of diagnosis
biomarkers. However, using the full potential of biomarker iden-
tification demands a larger sample basis and the investigation
of more groups and subgroups, e.g. the comparison of UC and
Crohn’s disease. This will be the focus in upcoming studies. Once
clinically relevant biomarkers are identified from biopsies, the
subsequent aim must be to quantify and validate these with tar-
geted approaches in easier accessible sample material, such as
feces and blood. Calprotectin, a complex of the proteins S100A8
and S100A9, is an example for a fecal biomarker used in IBD
management,[38] indicating that feces can be a promising sample
material for protein biomarkers.
4. Conclusions
This study reveals the so far deepest view into the ulcerative col-
itis proteome in colon biopsies from untreated adult patients
in the initial phase of the disease. The biopsy preparation was
optimized for this purpose; SDC augmentation of a urea con-
taining lysis buffer enhances both the peptide and the protein
identification. We found 68 up- and 100 down-regulated proteins
(p < 0.05, fold change (log base 2) > |0.7|) in ulcerative coli-
tis compared with healthy controls. Immune response proteins
are up-regulated in UC, while proteins involved in anion trans-
port, epithelial cell adhesion and mucus production are down-
regulated.
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TFA-NaOH solution was prepared as follows: 460 µl trifluoroacetic acid were added bit by bit with cooling periods 
in between to 350 µl water. 6 M NaOH was added slowly and interrupted by cooling until pH > 7 was reached and 
the solution was buffered with 200 µl 1 M TEAB pH 8.5 solution.  
CTAB 
After alkylation, the samples were diluted to 200 µl with 150 µl of 5 M urea in 0.1 M TEAB. The filter devices 
were equilibrated with 100 µl 8 M urea in 0.1 M TEAB and centrifuged for 20 min at 16 000 g. The diluted samples 
were added on the filter and centrifuged (30 min, 16 000 g). The samples were washed with 100 µl 5 M urea in 
0.1 M TEAB and centrifuged (20 min, 16 000 g). They were incubated with 50 µl TFA-NaOH solution for 10 min 
and centrifuged 5 min after addition of 50 µl isopropanol. 200 µl TFA-NaOH solution were immediately added, 
followed by 30 min centrifugation. The samples were incubated for 10 min with 50 µl TFA-NaOH solution, and 
centrifuged 5 min after addition of 50 µl isopropanol. Following this, washing steps with 200 µl of TFA-NaOH 
solution, 8 M urea in 0.1 M TEAB, 0.1 M TEAB, and 6 M urea in 0.1 M TEAB respectively were performed with 
30 min centrifugation each. 45 µl 8 M urea in 0.1 M TEAB were added to the filters.  
NMDOA 
After alkylation, the samples were diluted to 200 µl with 150 µl 6 M urea in water. The filter devices were 
equilibrated with 100 µl 8 M urea in 0.1 M TEAB and centrifuged for 20 min at 16 000 g. The diluted samples 
were added on the filters and centrifuged (20 min, 16 000 g). The samples were washed with 150 µl 6 M urea in 
water (20 min centrifugation), with 200 µl 8 M urea in 0.1 M TEAB (20 min centrifugation), three times with 200 
µl TFA-NaOH solution (20 min, 20 min, and 40 min centrifugation, respectively), with 200 µl 8 M urea in 0.1 M 
TEAB (30 min centrifugation), and two times with 150 µl and once with 300 µl 6 M urea in 0.1 M TEAB (20 min, 
20 min and 30 min centrifugation, respectively). 45 µl 8 M urea in 0.1 M TEAB were added to the filters. 
SDS 
After alkylation, the samples were diluted to 200 µl with 150 µl of 8 M urea in 100 mM Tris. The filter devices 
were equilibrated with 100 µl 8 M urea, 0.1 M TEAB and centrifuged for 20 min at 16 000 g. The diluted samples 
were added on the filter and centrifuged (20 min, 16 000 g). The samples were washed once with 200 µl and three 
times with 100 µl 8 M urea in 100 mM Tris (20 min, 20 min, 20 min, and 30 min centrifugation, respectively), and 
three times with 100 µl 100 mM TEAB buffer (20 min centrifugation each). 45 µl 8 M urea in 0.1 M TEAB were 




After enzymatic cleavage, FA in water (50% v/v) was added to SDC and SL samples to a final FA concentration 
of 2.5%. Detergent sedimentation was enforced by centrifugation (15 min, 16 000 g) and the peptide solutions 
were transferred to new Eppendorf tubes.  
Acid cleavage 
10 % TFA was added to a final concentration of 2% TFA. The samples were incubated at 37°C for 30 min, 
centrifuged for 15 min and the peptide solutions were transferred to new Eppendorf tubes. 
  
 
Additional statistical data for identification numbers 
 
Table S1: Average protein and peptide identification numbers from three replicates and their 












CTAB 1234 22 5699 84 
NMDOA 1420 37 6358 229 
SDS 1578 123 8156 877 
Urea 1484 60 7177 329 
Rapigest 1486 44 7128 305 
SL 1085 101 4344 643 
SDC 1652 33 7830 158 
 
Table S2: p-values for the comparisons of identification numbers. Significant changes after correcting 




compared detergents p-value rank B-H critical value 0.05 compared detergents p-value
CTAB SDC 0.00070274 1 0.002380952 CTAB SDC 0.00068614
CTAB NMDOA 0.00435248 2 0.004761905 NMDOA SDC 0.00256563
NMDOA SDC 0.00582587 3 0.007142857 SL SDC 0.00843249
SL Rapigest 0.01154641 4 0.00952381 CTAB urea 0.00947029
SL SDC 0.02180624 5 0.011904762 SL Rapigest 0.01023476
CTAB urea 0.02196687 6 0.014285714 SL Urea 0.01406103
CTAB Rapigest 0.0241305 7 0.016666667 NMDOA SL 0.01493767
urea SDC 0.02713754 8 0.019047619 CTAB Rapigest 0.02101646
NMDOA SL 0.04140153 9 0.021428571 urea SDC 0.02465533
CTAB SDS 0.06730272 10 0.023809524 NMDOA urea 0.02766078
SL Urea 0.07014393 11 0.026190476 CTAB NMDOA 0.03150387
Rapigest SDC 0.08264946 12 0.028571429 CTAB SDS 0.04356462
SL SDS 0.08605078 13 0.030952381 NMDOA Rapigest 0.04648088
CTAB SL 0.18401627 14 0.033333333 SL SDS 0.04776679
NMDOA Rapigest 0.26136542 15 0.035714286 CTAB SL 0.06656174
NMDOA SDS 0.2736621 16 0.038095238 Rapigest SDC 0.0792265
NMDOA urea 0.29595327 17 0.04047619 NMDOA SDS 0.10647926
urea SDS 0.29836417 18 0.042857143 Rapigest SDS 0.22660956
Rapigest SDS 0.49548441 19 0.045238095 urea SDS 0.27314364
SDS SDC 0.49716464 20 0.047619048 SDS SDC 0.63340622
urea Rapigest 0.98069951 21 0.05 urea Rapigest 0.88732555
Significant for Benjamini-Hochberg FDR 0.05
Correlations between the detergents 
 
Figure S1: Correlation between protein intensities [log(2)] detected in three replicates with the 
respective lysis buffers. Blue numbers indicate spearman rank correlations. 
Peptide yield and protein identification numbers 
 
Figure S2: Peptide yield from 60 µg protein (as determined by BCA) and the corresponding number of 
protein identifications. The cationic detergents show a comparably low peptide yield and low protein 
ID numbers. However, overall there is no strong correlation (r2 = 0.03). When excluding SL because 
the high missed cleavage numbers likely contribute to the low ID numbers r2 raises to 0.49. 
 
Correlation data for SDC and SDS replicates 
 
Figure S3: Correlations between peptide (A) and protein (B) intensities [log(2)] for replicates prepared with SDC 




Figure S4: Relative missed cleavages 
  
Preferential identification of transmembrane proteins with cationic detergents 
 
 
Figure S5: Average percentage of transmembrane proteins among all proteins identified with the different 
detergents. We determined the transmembrane proteins in Perseus by adding the “Keywords”-annotation 
(annotation database from http://annotations.perseus-framework.org) to the identified proteins and filtering for 
proteins with the annotation “Transmembrane”.Error bars indicating the standard deviation: 
 
 
Table S3: Absolute numbers of identified transmembrane proteins: 
 # identified transmembrane proteins  
Detergent Experiment 1  Experiment 2 Experiment 3 average 
CTAB 172 196 200 189 
NMDOA 206 246 234 229 
SDS 168 154 239 187 
Urea 185 189 215 196 
Rapi 217 202 196 205 
SL 127 132 100 120 
SDC 214 237 241 231 
 
  
Measurement of protein concentration for clinical samples in buffer containing TEAB  
The aliquots for the protein measurements were diluted 1:20 with water to yield a 5 mM TEAB concentration. 
Further solutions for the measurement were prepared by dilution with 5 mM TEAB. These solutions were 
measured against BSA standards in 5 mM TEAB. 
 
Labelling methodology 
For the 12 samples and the standard, aliquots of 25 µg peptides were labelled according to the manufacturer’s 
protocol and the following scheme with 0.4 mg of the corresponding TMT label. Aliquots of 3.3 μg peptides from 
two ulcerative colitis samples, two control samples, and the standard were mixed for each LC-MS/MS experiment. 
We alternated the labels used for UC and healthy samples between the LC-MS/MS experiments in order to reduce 
a possible bias resulting from the labelling reagents.  
Table S4: Sample labelling 
 LC-MS/MS Experiment 1 LC-MS/MS Experiment 2 LC-MS/MS Experiment 3 
• TMT6-126 Label 
Reagent standard standard standard 
• TMT6-127 Label 
Reagent healthy1  healthy5 
• TMT6-128 Label 
Reagent UC1 healthy3 UC5 
• TMT6-129 Label 
Reagent healthy2 UC3  
• TMT6-130 Label 
Reagent UC2 healthy4 healthy6 
• TMT6-131 Label 
Reagent  UC4 UC6 
 
Nanospray LC-MS/MS 
The peptide concentration was determined from the absorption at λ = 205 nm with a NanoDrop ND-1000 
Spectrophotometer. 
1 μg peptides in 0.1% formic acid was injected on a EASY-LC system connected to a qExactive (Thermo Fisher 
Scientific, Bremen, Germany). Peptides were separated on a C18 column (2 µm, 100 Å, 50 µm, 50 cm) with a 4-
40% gradient of acetonitrile in 0.1% FA over 60 min at a flow rate of 200 nl/min. The eluting peptides were 
analysed by the qExactive instrument operated in data dependent mode. 
Inclusion lists for the UC-healthy comparison study 
Inclusion lists for a second LC-MS/MS analysis of each sample were prepared with Proteome Discoverer 
software. These lists comprise the 5000 best peptide identifications among those, which did not reach high 
confidence level, and which were derived from proteins, that were identified with less than high confidence. The 
retention time window was +/- 1 min. We retained the other settings for LC-MS/MS analysis unchanged, except 
for increased Maximum IT of 200 ms for the full MS . 
We prepared inclusion lists for a third LC-MS/MS analysis from the combined data. These contained peptides, 
which were found with high confidence in at least one of the previous analyses, but were identified with at 
highest medium confidence in the corresponding sample. Peptides from proteins with a Sum PEP score >80 were 
excluded from this inclusion list. The retention time window was +/- 2 min. The experimental settings were the 
same as for the analyses with the first inclusion lists. 
Batch correction by combat method 
Figure S6: Batch correction of proteomics data. 
Raw data repeats across batches show an average correlation of r2 = 0.34. Quantile normalization of the data does 
not significantly improve this. By batch correction using the combat method[1] repeatability is improved (r2 = 
0.99). 
Comparison of S100A8 and S100A9 abundances 
 
Figure S7: The figure shows a strong interdependence of the protein abundances detected for S100A8 and S100A9. 
The data is presented as log(2) difference from the average of all samples combined. Thereby, the figure also 
visualizes the up-regulation of both proteins in UC tissue. 
  
Manufacturers 
Trypsin: Sequencing Grade Modified Trypsin, Promega Corporation, Madison, USA 
Lys –C: Wako Chemicals GmbH, Neuss, Germany 
OMIX C18 100 µl pipette tips: Agilent Technologies, Santa Clara, USA 
RapiGest™ SF: Waters, Manchester, UK 
FASP filter devices: VWR Centrifugal Filter, modified PES 30K, 500 µl; VWR International 
Pierce BCA Protein Assay Kit: Thermo Scientific, Rockford, USA 
MagNA Lyzer: Roche Diagnostics AG, Rotkreuz, Switzerland 
TMTsixplex reagent: Thermo Fisher Scientific, Rockford, USA 
qExactive: Thermo Fisher Scientific, Bremen, Germany 
  
 
[1] Johnson, W. E., Li, C., Rabinovic, A., Adjusting batch effects in microarray expression data using empirical 
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Ulcerative colitis: functional analysis 
of the in-depth proteome
Armin Schniers1, Rasmus Goll2,3, Yvonne Pasing4, Sveinung Wergeland Sørbye5, Jon Florholmen2,3 
and Terkel Hansen1* 
Abstract 
Background: Ulcerative colitis (UC) is one major form of inflammatory bowel disease. The cause and the pathophysi-
ology of the disease are not fully understood and we therefor aim in this study to identify important pathophysiologi-
cal features in UC from proteomics data.
Methods: Colon mucosa biopsies from inflamed tissue of untreated UC patients at diagnosis and from healthy 
controls were obtained during colonoscopy. Quantitative protein data was acquired by bottom-up proteomics and 
furthermore processed with MaxQuant. The quantitative proteome data was analyzed with Perseus and enrichment 
data was analyzed by ClueGO for Cytoscape.
Results: The generated proteome dataset is to-date the deepest from colon mucosa biopsies with 8562 identified 
proteins whereof 6818 were quantified in > 70% of the samples. We report abundance differences between UC and 
healthy controls and the respective p values for all quantified proteins in the supporting information. From this data 
set enrichment analysis revealed decreased protein abundances in UC for metallothioneins, PPAR-inducible proteins, 
fibrillar collagens and proteins involved in bile acid transport as well as metabolic functions of nutrients, energy, 
steroids, xenobiotics and carbonate. On the other hand increased abundances were enriched in immune response 
and protein processing in the endoplasmic reticulum, e.g. unfolded protein response and signal peptidase complex 
proteins.
Conclusions: This explorative study describes the most affected functions in UC tissue. Our results complemented 
previous findings substantially. Decreased abundances of signal peptidase complex proteins in UC are a new 
discovery.
Keywords: Inflammatory bowel disease, Ulcerative colitis, Calprotectin, Signal peptidase complex
© The Author(s) 2019. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creat iveco mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creat iveco mmons .org/
publi cdoma in/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Ulcerative colitis (UC) is a form of inflammatory bowel 
disease (IBD). The chronic inflammation of the colon in 
UC starts at the rectum and can progress continuously 
to proximal colon parts. UC affects 0.51% of the Euro-
pean and 0.25% of the North American population, with 
increasing prevalence [1]. The disease has a complex 
pathophysiology and the exact disease causes remain 
unclear. A genetic component, environmental factors, 
defects of the epithelial barrier, and dysregulated immune 
responses are involved [2].
Pathophysiological changes likely lie or are reflected in 
the abundance and state of proteins, the major functional 
units in every tissue. The proteomic analysis of colon 
biopsies affected by UC gives data on these changes at 
the main site of the disease. Advances in sample prepa-
ration, instrumentation, and analysis software allow for 
increasing proteome coverage and improved quantifica-
tion. Higher proteome coverage, growing and new path-
way databases, and improved software packages benefit 
comprehensive enrichment analyses of tissues.
Open Access
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Proteomic studies with different designs regarding sam-
ples and analytical method were previously conducted 
on colon mucosa affected by UC. Inflamed mucosa from 
untreated patients at UC debut [3] as well as macro-
scopically normal mucosa from treated UC patients [4] 
have been compared to biopsies from healthy controls 
in previous studies. A comparison of inflamed mucosa 
from untreated UC patients with mucosa from healthy 
controls as well as from Crohn’s disease patients was 
conducted on pediatric patients [5]. Another study com-
pared inflamed and non-inflamed tissue from the same 
patients [6]. Despite the differences in the study designs, 
the studies present remarkably similar proteome changes 
[3]. They revealed novel insights into the UC pathophysi-
ology, e.g. the role of neutrophil extracellular traps [4] 
and S100 proteins [3]. They also identified biomarkers for 
differentiating between UC and Crohn’s disease [5] and 
between pancolitis and partial colitis [7]. Furthermore, 
multiple studies investigated specific proteins of interest 
and their functions in UC, such as inducible nitric oxide 
synthase (NOS2) [8] and histaminase (AOC1) [9].
However, despite the challenges in extracting biologi-
cal information from omics data and the shortcomings of 
focusing on proteins with the highest fold-changes [10], 
enrichment analyses were not the main scope of previ-
ous proteomics studies on UC. Omics studies typically 
produce large amounts of data. Especially in experiments 
with strong phenotypes these datasets can contain so 
many significant findings that a sensible interpretation 
without additional statistical analyses is barely possible. 
Interpretations based on only the highest fold-changes 
in such a dataset disregard large amounts of data and fail 
to recognize functional changes as a result of multiple 
moderately different abundances. Moreover, the biologi-
cal interpretation is prone to be arbitrary, and it has fur-
ther disadvantages. Enrichment analyses can overcome 
these difficulties [10] and the enrichment factors give an 
additional indication for the importance of the respective 
functions for the disease pathophysiology.
Beside proteomics, transcriptomic approaches have 
been applied to investigate UC [11]. These studies show 
differential mRNA expressions in UC tissue. The patho-
physiological implications of these finding however are 
less clear because the correlation of mRNA and protein 
abundances is poor. The cause for that low correlation is 
that both the translation and the degradation of proteins 
are subject to several regulation mechanisms that are 
independent of mRNA levels [12].
We conducted a comprehensive enrichment analysis 
on a proteomics dataset of 8562 identified proteins from 
colon mucosa biopsies.
Materials and methods
Patients included and biopsies collection
Mucosal biopsies were collected from newly diagnosed 
treatment-naïve UC patients in Norway. The UC diag-
nosis was established upon clinical, endoscopic and his-
tological criteria defined by the European Crohn and 
Colitis Organization (ECCO) guidelines [13]. Further-
more, the degree of inflammation was evaluated during 
colonoscopy using the scoring system of ulcerative coli-
tis disease activity index (UCDAI) [14]. Moreover, TNF 
mRNA levels were measured by real-time PCR to assess 
the level of UC activity [15]. Subjects admitted for a can-
cer screening and with normal colonoscopy and histo-
logical findings served as healthy controls. None of the 
recruited subjects suffered from irritable bowel disease 
and they were not on nonsteroidal anti-inflammatory 
drug medication prior to the colonoscopy. The biop-
sies from the UC patients were obtained from the most 
inflamed area in rectum or sigmoid colon. Biopsies from 
the control group were obtained from the rectum. From 
each study participant, 3 adjacent biopsies were obtained 
from the inflamed mucosa. One biopsy was immediately 
immersed in RNAlater (Qiagen, Germany). The second 
biopsy was frozen immediately in a dry cryotube tube 
at − 70  °C until further analysis. The third biopsy was 
obtained for ordinary histological examinations (hae-
matoxylin and eosin staining). 17 patients with debut of 
UC and 15 healthy controls were recruited as shown in 
Table 1.
Table 1 Baseline characteristics in patients included at debut of ulcerative colitis and in healthy controls (see “Patients 
included and biopsies collection” and “Baseline characteristics” sections for further details)
UCDAI score and Geboes index averages calculated from available data for 15 and 16 patients, respectively
Study group Number 
of subjects
Average age (SD) Sex 
female/
male








UC patients 17 39.4 (16.7) 4/13 14,350 (16,725) 8.7 (2.2) 7.9 (3.8) 2 Proctitis
9 left sided UC
6 Extensive UC
Healthy control 15 51.9 (14.3) 5/10 4500 (2400) – – –
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Baseline characteristics
The baseline characteristics are shown in Table  1 (see 
Additional file 1: Table 1). All subjects included showed 
typical histological findings according to UC and normal, 
non-inflamed mucosa, respectively.
Sample preparation
Samples were homogenized with 250  µl cooled lysis 
buffer [8  M urea, 5% sodium deoxycholate (SDC), 
100  mM triethylammonium bicarbonate buffer pH 8.5 
(TEAB)] in MagNA Lyser Green Bead tubes (Roche Diag-
nostics AG, Rotkreuz, Switzerland) with a MagNA Lyser 
Instrument (Roche Diagnostics AG, Rotkreuz, Switzer-
land) for 35 s at 6500 rpm. Lysates were frozen at − 70 °C 
until further sample preparation. All samples and stand-
ards were diluted/produced to contain 5 mM TEAB for 
the BCA assay (Pierce™ BCA Protein Assay Kit, Thermo 
Fisher Scientific). The assay was performed according to 
the manufacturer’s protocol. Lysate aliquots of 60 µg pro-
tein were transferred to Protein LoBind tubes (Eppen-
dorf AG, Hamburg, Germany). Disulfide bridges were 
reduced with 1,4-dithiothreitol (DTT) at a concentration 
of 5 mM by incubation at 54 °C for 30 min. Cysteins were 
alkylated with 15 mM iodoacetamide (IAA) and incuba-
tion for 30  min at room temperature in the dark. DTT 
solution corresponding to a final concentration of 5 mM 
was added to remove excess IAA. Lys-C predigestion was 
performed under gentle agitation for 8  h at 37  °C with 
0.6 µg Lys-C (enzyme-to-protein ratio 1:100, w/w, Wako 
Chemicals GmbH, Neuss, Germany) in a buffer con-
taining 1 mM calcium chloride, 6 M urea, and 100 mM 
TEAB. Calcium chloride solution, 3 µg trypsin (enzyme-
to-protein ratio 1:20, w/w, Sequencing Grade Modified 
Trypsin, Promega Corporation, Madison, USA), water, 
and 1  M TEAB were added to a final concentration of 
1 mM calcium chloride, 1 M urea, and 100 mM TEAB. 
Tryptic digestion was performed under gentle agitation 
for 16 h at 37 °C.
Equal peptide amounts from each sample were com-
bined to produce a standard mixture, which was subse-
quently labelled with TMT126. Aliquots corresponding 
to 25  µg peptides were labelled with the remaining 
TMTsixplex isotopes according to the manufacturer’s 
protocol. 0.4 mg TMT reagent were used for 25 µg pep-
tides from samples with starting protein concentrations 
≥ 2200  µg/ml. Higher amounts of TMT reagent were 
used for lower starting concentrations (see Additional 
file 1: Table 2).
The differently labelled peptides were mixed in equal 
amounts to in total 100  µg peptides. The digests were 
acidified with 50% formic acid (FA) to a final concentra-
tion of 2.5% FA and pH ≤ 2. The samples were centrifuged 
at 16,000  g for 15  min and the supernatants were care-
fully transferred to fresh tubes. Acetonitrile was removed 
by evaporation in a vacuum concentrator.
Trifluoroacetic acid (TFA) was added to a concentra-
tion of 0.1%. The samples were fractionated with Pierce™ 
High pH Reversed-Phase Peptide Fractionation Kit 
(Thermo Fisher, Rockford, USA) according to the manu-
facturer’s protocol. Samples exceeding 300 µl were step-
wise loaded with 2 min centrifugation after each loading. 
The fractions were dried in a vacuum concentrator and 
redissolved in 10  µl 0.1% TFA for subsequent LC–MS/
MS analyses.
LC–MS/MS
The nano-LC–MS/MS analysis was performed on a 
Q Exactive mass spectrometer coupled to an EASY-
nLC 1000 system (Thermo Fisher Scientific, Bremen, 
Germany).
Shortly, 2.0 µg peptides, as measured with a Nanodrop 
2000 (Thermo Fisher Scientific, Bremen, Germany) at a 
wavelength of 205 nm and extinction coefficient 31 mg/
ml [16], per sample were injected. They were concen-
trated on a reversed-phase trap column and subsequently 
separated on a reversed-phase main column. A binary 
solvent gradient of 0.1% FA (solvent A) and 0.1% FA in 
acetonitrile (solvent B) was used. The ACN proportion 
was increased from 0 to 5% over 19 min, further to 30% 
at 180 min and to 100% at 200 min. A detailed descrip-
tion of the LC–MS/MS conditions can be found in the 
supporting information (see Additional file 1).
Data evaluation
The raw data was analyzed with MaxQuant against a Uni-
Prot fasta file of all human proteins (see Additional file 1) 
[17, 18]. Further analyses were performed with Perseus 
[19] and Cytoscape/ClueGO [20, 21].
The data processing and visualization in Perseus is 
partially based on a recently published protocol by the 
Perseus developers [22]. The intensities were log2-trans-
formed in Perseus, and the entries were filtered for the 
labels “potential contaminant”, “reverse” and “only iden-
tified by site”. Standard intensities were subtracted from 
the corresponding sample intensities and the resulting 
intensities Z-score transformed (matrix access: columns), 
which returns the normalized values (see Additional 
file 1).
Statistics and generation of figures and lists
Statistical analyses were performed in Perseus. The 
samples were assigned to the groups UC patients and 
healthy controls, respectively, and the groups contain-
ing the separate values for each sample were compared 
to each other with a two-sample test. Proteins were 
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annotated with gene ontology terms from the databases 
GOBP (biological process), GOMF (molecular func-
tion), GOCC (cellular component) [23], KEGG [24], 
GSEA [25], UniProt keywords [18], InterPro [26], Reac-
tome [27], and PROSITE [28]. The lists and the article 
figures were prepared in Perseus and the Cytoscape app 
ClueGO (see Additional file 1). The WikiPathways data-
base was used for the ClueGO analysis [29]. Pathways 




The proteomes of UC and healthy tissue differed strongly, 
as shown in Fig. 1. We present the 20 proteins with the 
highest abundance increases and decreases, respectively, 
in Table 2. The Pearson correlations of normalized inten-
sities (see Additional file 1) were higher when samples of 
the same group were compared (i.e. UC to UC, or healthy 
control to healthy control) than when UC samples were 
compared to healthy controls (Fig.  1a). Also the hierar-
chical clustering of the sample correlations resulted in 
Fig. 1 Exploratory analysis. a Hierarchical clustering of the correlation coefficients of 6829 protein intensities (proteins quantified in at least 70% of 
the samples) after normalization shows a clear separation between ulcerative colitis (UC) and healthy controls. The two replicates (labeled with repl) 
show the highest correlations. b Multi-scatter plot of the averaged profiles for UC2, 3, 4, 6, 7, 11, 13, 14, and 16 (UC a), UC1, 5, 8, 9, 10, 12, 15, and 17 
(UC b), H3, 4, 5, 6, 7, 8, 10, and 11 (H a), and H1, 2, 9, 12, 13, 14, and 15 (H b). The sample assignments to the groups a and b, respectively, are random. 
Blue numbers indicate Pearson correlation values. The averaged profiles show high correlations within the groups, and low correlations between 
the groups. c Principal component analysis (PCA) separates UC strongly from healthy controls in component 1 (39.9%)
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separate grouping of UC and healthy samples (Fig.  1a). 
In addition averaged profiles showed high Pearson cor-
relations (> 0.7) for comparisons within the groups UC 
and healthy, respectively, and low correlations (< 0.1) for 
comparisons of UC to healthy (Fig.  1b). Several multi 
scatter plots were investigated with random samples 
Table 2 20 proteins with highest abundance increase and decrease, respectively, in UC patients as compared to healthy 
controls
Included are only significantly different proteins as determined in the two-sample test comparing the groups UC patients and healthy controls (see Additional file 1). 
Only the first majority protein ID for each identification is given, for further IDs see Additional file 2
Ratio UC/H Protein name Gene names Majority protein ID − Log p value
Proteins of increased abundance in UC compared to healthy controls
10.12 Kinesin-like protein KIF26B B7WPD9 10.55
6.72 Protein S100-A8 S100A8 P05109 8.41
6.70 Cathelicidin antimicrobial peptide CAMP J3KNB4 9.71
6.17 Protein S100-A9 S100A9 P06702 8.07
4.95 Protein S100-A12 S100A12 P80511 8.36
4.73 Neutrophil defensin 1 DEFA1 P59665 7.02
4.47 Lactotransferrin LTF;HEL110 E7EQB2 9.42
4.39 Myeloblastin PRTN3 P24158 7.49
4.18 Neutrophil gelatinase-associated lipocalin NGAL;LCN2 B2ZDQ1 13.57
3.54 Neutrophil elastase ELANE;ELA2 P08246 7.48
3.51 Azurocidin AZU1 P20160 8.36
3.49 Cysteine-rich secretory protein 3 CRISP3 J3KPA1 6.44
3.22 Myeloperoxidase MPO P05164-2 9.05
3.20 Bactericidal permeability-increasing protein BPI A2NX48 4.31
3.18 60S ribosomal protein L14 RPL14 P50914 1.62
3.17 Bactericidal permeability-increasing protein BPI P17213 8.26
3.16 Lysozyme LYZ B2R4C5 8.50
3.12 Marginal zone B- and B1-cell-specific protein MZB1 Q8WU39 14.01
3.07 Ig heavy chain V-I region EU IGHV1-69-2 P01742 3.98
3.01 Ficolin-1 FCN1 O00602 6.65
Proteins of decreased abundance in UC compared to healthy controls
0.12 Hydroxymethylglutaryl-CoA synthase, mitochondrial HMGCS2 A0A140VJL2 14.77
0.17 Fatty acid-binding protein, liver FABP1 Q6FGL7 14.41
0.19 3-keto-steroid reductase HSD17B7;hCG_2024989 P56937-2 14.32
0.24 Sulfate transporter SLC26A2 P50443 18.52
0.26 Tumor necrosis factor alpha-induced protein 8-like protein 3 TNFAIP8L3 Q5GJ75 5.42
0.29 Carbonic anhydrase 2 HEL-76;CA2 V9HW21 12.09
0.30 Selenium-binding protein 1 HEL-S-134P;SELENBP1 V9HWG1 15.36
0.33 cAMP-dependent protein kinase inhibitor beta PKIB Q5T0Z6 7.57
0.34 Chloride anion exchanger SLC26A3;DKFZp686P10213 P40879 10.33
0.35 UDP-glucuronosyltransferase 2A3 UGT2A3 Q6UWM9 14.95
0.36 Chymotrypsin-C CTRC Q99895 5.37
0.36 Hyaluronan and proteoglycan link protein 3 HAPLN3 A0A024RC58 8.55
0.37 Calcium-activated chloride channel regulator 1 CLCA1 A8K7I4 6.68
0.37 Tissue alpha-l-fucosidase FUCA1 P04066 10.42
0.37 Phospholipase A(2) PLA2G1B F8W062 2.71
0.38 UDP-glucuronosyltransferase 2B17 UGT2B17;UGT2B15 O75795 3.10
0.38 Aquaporin-8 AQP8 Q53GF6 7.86
0.38 Mimecan OGN Q7Z532 9.66
0.39 Cadherin-17 CDH17 Q12864 17.16
0.39 Alcohol dehydrogenase 1C ADH1C P00326 10.05
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from UC patients or healthy controls in each group, and 
all showed the same trend with high correlations inter-
nally in the UC and healthy sample groups. Upon unsu-
pervised investigation by principal component analysis 
(PCA) (Fig. 1c) a strong separation of UC and healthy in 
component 1 which explains 39.9% of the variance was 
observed. To investigate possible biases we controlled for 
grouping by gender, and such grouping did not occur.
Comparison with previous proteomics studies on UC
The in total 8562 identified proteins provided the so far 
deepest view into the proteome of human colon mucosa 
and of UC. We report the abundance changes includ-
ing p values for all quantified proteins (see Additional 
file 2: Excel file). 6818 of these proteins were quantified 
in at least 70% of the samples and were subject to enrich-
ment analysis. Our data confirmed and extends previ-
ous findings, but also includes novel findings, such as 
the increased abundance of signal peptidase complex 
proteins. We searched PubMed for the terms “ulcerative 
colitis proteomics” and reviewed the titles and abstracts 
to select the relevant studies. Additionally we included 
studies previously known to the authors, totaling to 7 
studies for the comparison [3–9]. The present study was 
largely in agreement with those previous studies about 
the direction of abundance changes of differently abun-
dant proteins. However, the magnitudes of the changes 
differed.
Functional analysis
Hierarchical clustering of the 596 most differently abun-
dant proteins (8.7% of all proteins quantified in > 70% of 
samples; s0 = 2, FDR = 0.01) revealed three major clus-
ters (Fig. 2). The proteins which were higher abundant in 
UC divided into two clusters, a small cluster of 20 pro-
teins with a more pronounced abundance change in a 
subgroup of samples, and a large cluster of 247 proteins. 
The lower abundant proteins formed one cluster of 313 
Fig. 2 Clustering of the 596 most differently abundant proteins between ulcerative colitis (UC) and healthy controls. a Hierarchical clustering 
reveals three main protein clusters. Low abundances are indicated in blue, high abundances in red. b Protein abundance profiles of the three main 
clusters. 1: minor cluster of 20 proteins (including calprotectin) with increased abundance in UC, with a subgroup of UC samples showing a more 
pronounced increase. 2: major cluster of 247 proteins with increased abundance in UC. 3: Cluster of 313 proteins with a decreased abundance in UC
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proteins. In total 16 proteins were outside these three 
clusters.
The extraction of biological information from omics 
datasets is a major challenge. Enrichment analyses can 
overcome some of the difficulties [10]. Enrichment analy-
ses annotate categorical terms (e.g. functions, localiza-
tions, pathways) to proteins and subsequently determine 
which terms are overrepresented among the differently 
abundant proteins compared to the entire dataset of 
quantified proteins. Knowledge about the involved path-
ways and functions can help to understand the disease, 
understand complications, and develop new treatment 
options.
Abundance changes found in tissue proteomics could 
result from differential regulation of the protein abun-
dances in cells, but also from changes of the cell popu-
lation (e.g. from the migration of immune cells into 
inflamed tissue in UC [11]) or the extracellular matrix. 
It seems plausible that each of these factors affects all 
measured abundances in such an experiment to varying 
degrees.
Lists of the enriched gene ontology terms among pro-
teins which were found to be differently abundant in UC 
as compared to healthy tissue, and a list of the proteins 
which contributed to the functions discussed in the fol-
lowing are provided as Additional file 2: Excel file.
This article can neither cover all enriched terms we 
found, nor can it discuss the impact of each differently 
abundant protein on a function or the magnitude of 
its abundance change in detail. We therefore strongly 
encourage the reader to consult the above mentioned 
tables for further information on functions and proteins 
of interest.
Lower abundant in UC
321 proteins showed decreased abundances in UC 
as compared to healthy control samples. 313 of these 
grouped into one cluster (Fig.  2, cluster 3). Functional 
analysis revealed that metabolic pathways were overrep-
resented among the proteins with decreased abundance 
in UC. The enrichment of proteins with decreased abun-
dances in our dataset affects short-chain and long-chain 
fatty acid, ketone body and amino acid (particularly 
tryptophan) metabolism as well as the tricarboxylic acid 
(TCA) cycle (see Additional file 1: SuppPathway1–4) and 
the electron transport chain (ETC; Fig. 3a).
The observed abundance decreases of butyrate uti-
lizing proteins are in line with previous studies which 
show a decreased butyrate metabolism by UC tissue. 
Butyrate is a short-chain fatty acid (SCFA) and the main 
energy source of healthy colon mucosa [31]. It was pre-
viously hypothesized that ulcerative colitis is an energy-
deficiency disease resulting from the failure to utilize 
butyrate [31]. Colonocytes convert a part of the butyrate 
to ketone bodies [32]. Our data showed that proteins 
related to this specific utilization of butyrate were lower 
abundant in UC. Several studies have investigated 
whether butyrate has a positive effect on inflamed colon 
tissue, however the results of these studies are conflicting 
[33].
The decreased protein abundances also affected the 
transport and metabolism of the long-chain fatty acids 
(LCFA), i.e. the long carbon chain analogs of SCFAs. 
LCFAs have an ambiguous role in ulcerative colitis. Lin-
oleic acid increases the chances of developing ulcerative 
colitis [34]. Omega-3 fatty acids, such as docosahexae-
noic acid (DHA), may reduce the chance of developing 
the disease [35]. Studies on the efficacy of omega-3 fatty 
acids in the treatment of ulcerative colitis show contro-
versial results. Systematic reviews however conclude that 
large high-quality studies fail to show positive effects, 
and that there is no sufficient evidence for the efficiacy of 
omega-3 fatty acids in the treatment of UC [36, 37].
Mitochondrial enzymes involved in the metabolism of 
SCFA and LCFA as well as the tricarboxylic acid (TCA) 
and the electron transport chain (ETC) were found in our 
dataset to be low abundant in UC. These findings reflect 
a mitochondrial dysfunction which possibly contributes 
to the proposed energy deficiency [38].
Proteins related to nuclear receptors were of decreased 
abundance in UC. Peroxisome proliferator-activated 
receptor (PPAR)-inducible proteins were lower abun-
dant in UC (Fig. 3). The changes in the LCFA transport 
and the PPAR pathway are interdependent. Activation 
of the intracellular PPAR receptors by LCFA demands 
the import of the fatty acids into the cell and the trans-
port within the cell. One protein involved in the trans-
port into the cell is CD36 which is low abundant in UC 
tissue. Fatty acid binding proteins (FABP) facilitate 
the transport within the cell [39]. Four FABPs (FABP1, 
FABP2, FABP4, and FABP5) are among the proteins with 
the lowest relative abundance in UC tissue compared to 
healthy tissue. A decreased transport of LCFA might in 
turn be partially causative for the decreased abundances 
of PPAR-inducible proteins, such as ACOX1, HMGCS2, 
FABP1, and PCK1 [40]. In accordance with a previous 
study [41], we found the vitamin D3 receptor NR1i1 to be 
lower abundant in UC tissue. However, we observed no 
general abundance changes of proteins regulated by this 
receptor. Previous studies found decreased abundances 
of hepatocyte nuclear factor 4 alpha (HNF4A) in UC and 
suggested a role in the disease pathophysiology [42]. Our 
data supports these findings.
All detected metallothioneins—MT1H, MT2A, and 
MT1F—were found to be lower abundant in UC tis-
sue compared to healthy controls. Metallothioneins are 
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small, cysteine-rich proteins, which bind heavy metal 
cations. Our findings confirmed several previous stud-
ies, which concluded that the decreased metallothio-
nein abundances may result in an inefficient antioxidant 
response in the mucosa and in turn contributes to the 
IBD pathophysiology [43]. However, other studies pre-
sent conflicting results and conclusions [44].
Histamine is the major mediator of mast cells and 
contributes to the immuno-inflammatory reaction 
in IBD. Previous studies showed increased histamine 
secretion and levels in UC affected tissues [45] and 
decreased histaminase (AOC1) activity [9]. The pre-
sent study revealed that both major histamine degrad-
ing enzymes—Histaminase (AOC1) and histamine 
N-methyltransferase (HNMT)—were lower abundant 
in UC tissue compared to healthy tissue (not based on 
enrichment analysis). This finding constitutes a plau-
sible causative explanation for some of the previously 
reported findings on histamine in UC.
Fig. 3 Functional networks of differently abundant proteins in colon mucosa biopsies affected by ulcerative colitis compared to healthy controls. 
a Functional network of the 321 proteins with the strongest abundance decrease in ulcerative colitis compared to healthy tissue. Metabolic 
functions dominate this network, especially those located in the mitochondria. b Functional network of the 275 proteins with highest abundance 
increase in ulcerative colitis. Functions of the immune system characterize this network. Generated with ClueGO, Pathways: WikiPathways (updated: 
10.03.2018), pV ≤ 0.01
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Chemical compounds undergo phase I and phase II 
biotransformation reactions which make them more 
hydrophilic [46]. This allows their excretion with urine 
because the polar compounds are not reabsorbed in 
the kidneys [47]. Phase I reactions introduce or change 
functional groups by oxidation, reduction, or hydroly-
sis. In phase II reactions, enzymes attach hydrophilic 
endogenous compounds [46]. Our data showed that the 
abundances of a large proportion of both phase I and 
phase II enzymes are decreased in UC. A decrease of 
xenobiotic metabolism gene products in UC was shown 
earlier on mRNA level [48]. The affected phase II 
enzymes are involved in sulfonation, glucuronidation, 
and glutathione conjugation. Proteins related to both 
phase 1 (monoamine oxidase A, MAOA) and phase 2 
metabolism (sulfotransferases) of catecholamines were 
found in our dataset to be less abundant in UC. This 
could contribute to previously found increases of nor-
epinephrine in rectal UC mucosa [49].
Synthetic steroids are an important treatment option 
for ulcerative colitis. Our data showed impairments in 
the steroid metabolism in UC. This suggests a role of 
endogenous steroids in the pathophysiology of the dis-
ease. The hydroxysteroid dehydrogenases HSD11B2, 
HSD17B11, HSD17B2, and HSD17B7 were among the 
most down-regulated proteins in UC (HSD17B8 is 
downregulated to a lesser degree). The abundances of 
HSD17B4, HSD17B10, and HSD17B12 were not differ-
ent in UC from healthy tissue. Decreased abundances 
of HSD11B2 [50] and HSD17B7 [3] have been reported 
previously. Our data furthermore showed that pro-
teins related to the transport of bile acids are enriched 
among the lower abundant proteins, which supports 
findings of a previous study [41]. Pathway mapping 
shows abundance decreases of proteins involved in the 
neutral pathway of bile acids biosynthesis (Additional 
file  1: SuppPathway5). However, the implications of 
this finding are not clear, because bile acids are primar-
ily synthesized in hepatocytes, whereas there is no evi-
dence of bile acid synthesis in enterocytes [51].
The carbonic anhydrases CA1, CA2, CA4, and CA12 
were found to be lower abundant in UC. CA3 was the 
only quantified but not significantly lower abundant 
carbonic anhydrase. A decreased abundance in UC was 
reported earlier for CA1 [52].
Fibrillar collagens are a subgroup of collagens and 
provide three-dimensional frameworks for tissues 
and organs [53]. The fibrillar collagens were enriched 
among the proteins that were of decreased abundance 
in UC. Proteins that are involved in collagen degrada-
tion, e.g. metalloproteinases, on the other hand were 
enriched among the proteins with increased abundance 
in UC (see below). This finding is in accordance with 
a previous study on the role of collagen degradation in 
IBD [54].
Higher abundant proteins in UC
As expected, many proteins with increased abundance in 
UC are involved in inflammatory and immune processes 
(Fig.  3b). Proteins related to neutrophils (e.g. NADPH 
oxidase complex proteins which generate superoxide, 
metalloproteinases) and B cells (e.g. V and C regions 
of immunoglobulins) were highly enriched. This could 
result from a tissue infiltration by these immune cells.
The higher abundant proteins divided into two main 
clusters under hierarchical clustering (Fig.  2, clusters 1 
and 2). The UC patients with high cluster 1 protein abun-
dances (UC1, UC2, UC5, UC8, UC15, UC17) grouped 
together (Fig. 2a, b). Cluster 1 contained proteins occur-
ring in neutrophils, among these Protein S100A8 and 
Protein S100A9 which together form the calprotectin 
complex (see Additional file 1: Table 3). Several proteins 
(calprotectin, S100A12, lactotransferrin) of the minor 
cluster have been used to differentiate between IBD and 
non-IBD [55]. Interestingly, the average Geboes index in 
the patient cluster with high cluster 1 protein abundances 
is 11.0 (SD = 3.1), while it is 6.5 (SD = 3.2) for the other 
patients.
Our data showed that inducible nitric oxide synthase 
(NOS2) is higher abundant in UC tissue (not based on 
enrichment analysis). NOS2 produces nitric oxide (NO) 
which has various physiological roles as a messenger mol-
ecule. It functions most prominently as a vasodilator [56], 
but it is also involved in the immune system [57]. NO is 
directly toxic to pathogens, induces or suppresses apop-
tosis, and regulates the immune reaction [58]. Excess NO 
is cytotoxic and induces cell death. NOS2 is inducible 
by inflammation, infection and other stimuli. Increased 
NOS2 abundances in UC were shown earlier by immu-
nostaining [8] and our results confirm these findings.
Proteins with functions in protein processing in the 
endoplasmic reticulum (ER) are overrepresented among 
the proteins which were more abundant in UC. Also 
unfolded protein response (UPR) and signal peptidase 
complex (SPC) proteins are related to protein process-
ing, located in the ER, and enriched among proteins with 
increased abundances in UC. UPR has previously been 
identified as one factor in the pathophysiology of ulcera-
tive colitis [59]. The enrichment of SPC proteins among 
proteins with increased abundances in UC is a novel find-
ing from our data.
However, ER proteins were not generally higher 
abundant. For instance, many metabolic enzymes are 
located in the ER and enriched among the proteins with 
decreased abundances (e.g. UDP-glucuronosyltrans-
ferases, see “Lower abundant in UC” section).
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The SPC is not inherently inflammatory. Nonetheless 
its proteins were among those with the highest abun-
dance increases in UC. The SPC is located in the mem-
brane of the endoplasmic reticulum and cleaves the 
signal peptide cotranslationally from nascent proteins 
[60]. The SPC subunits SPCS1, SPCS2, and SPCS3 and 
the SPC catalytic subunit SEC11C were more abundant 
in UC. They furthermore showed highly similar abun-
dance profiles (Additional file 1: Figure 3). The SPC cata-
lytic subunit SEC11 however does not follow this pattern 
and was similarly abundant in UC and healthy tissue.
Accumulation of unfolded and misfolded proteins 
causes stress to the endoplasmic reticulum. The UPR 
aims to remove these proteins. To achieve this, the cell 
stops the translation of further proteins, degrades mis-
folded proteins, and produces chaperones, which correct 
the protein folding. Our data showed strong enrichment 
of proteins related to UPR, response to ER stress, and 
the ER chaperone complex among the higher abundant 
proteins in UC. Specifically, several chaperones that can 
be induced by ATF6 alpha (HSP90B1, calreticulin [61], 
and HSPA5 [62]), which plays a central role in UPR, were 
enriched. Our findings support previous assumptions 
that the UPR may play a role in the pathophysiology of 
UC.
Foreseeable applications
The functional changes we observed in the present 
study allow for hypothesis generation for treatment 
approaches.
Alterations of metabolic pathways in ulcerative coli-
tis imply that nutritional interventions directed at the 
respective metabolites could be effective in the treat-
ment of the disease. For instance, decreased metal-
lothionein abundances indicate that the detoxification of 
heavy metals and the utilization of polyvalent metal ions 
could be impaired. Considering the decreased detoxi-
fication capacities, reduced intake or chelation of toxic 
heavy metals might have beneficial effects. On the other 
hand, the supplementation of essential polyvalent metal 
ions could be advantageous. Furthermore, the decreased 
metabolic and transport capabilities related to butyrate 
contribute probably to the energy deprivation of colo-
nocytes. Previous studies investigated the treatment of 
UC with butyrate and other SCFA. But the pathophysi-
ological changes we observed related to the utilization 
of those compounds imply that supplementation with a 
later metabolite such as beta-hydroxybutyrate might be 
preferable. Beta-hydroxybutyrate is a ketone body that 
becomes systemically available after oral administration 
and has been used in the treatment of other pathophysi-
ological conditions [63, 64].
The enrichment of proteins related to signaling path-
ways such as PPAR designates the respective pathways 
as potential drug targets.
Abundance changes of single proteins may have 
similar implications, especially if they are known to 
be drugable. Proteins with high abundance differences 
between UC patients and healthy controls and high 
corresponding − Log p values are of potential interest 
as biomarker candidates. Proteins with these character-
istics are for instance SLC26A2, HMGCS2, and CD38 
(Additional file 1: Figure 4; Additional file 2).
However, further testing, clinical studies, and valida-
tion will be necessary before any clinical application.
Conclusions
Our study presents new evidence and complements 
previous findings about changes of biological functions 
in UC. The major novel findings of this study were the 
increased abundances of SPC proteins and the presence 
of two distinguished clusters of higher abundant pro-
teins, with the calprotectin complex proteins S100A8 
and S100A9 in the minor cluster 1. This cluster of 20 
proteins diverged from the abundance changes of the 
majority of proteins with increased abundances in UC 
that we observed in cluster 2.
In conclusion, abundances in UC tissue were 
increased compared to healthy controls for proteins 
related to the immune system and to protein processing 
in the ER, e.g. UPR and SPC proteins. Immune cell infil-
tration into the inflamed tissue contributes probably to 
the increased immune system protein abundances. The 
high abundance of UPR proteins indicates an ER stress 
response. Moreover, NOS2 which produces NO was 
higher abundant in UC tissue.
Lower abundant in UC were predominantly meta-
bolic proteins. These metabolic proteins comprise 
mitochondrial enzymes for the metabolization of 
SCFA and LCFA as well as proteins of the TCA cycle 
and the ETC. These changes are probably contribut-
ing to the previously reported mitochondrial dysfunc-
tion and energy deficiency of colonocytes in UC. The 
abundances of LCFA transport proteins were decreased 
which may be partially causative for the decreased 
abundances of PPAR-inducible proteins. Decreased 
abundances of histamine degrading enzymes probably 
contribute to the increased histamine levels in UC tis-
sue which were found in previous studies. Furthermore, 
abundances of proteins involved in phase I and phase 
II biotransformation were decreased, as well as the 
abundances of several metallothioneins, hydroxysteroid 
dehydrogenases, and carbonic anhydrases.
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We provide a list of all 8562 identified proteins includ-
ing the fold changes UC/H and p values as supporting 
information (see Additional file 2: Excel file).
Additional files
Additional file 1. Detailed method descriptions, additional figures and 
tables, mapping of metabolic pathways.
Additional file 2. Complete list of identified proteins including UC/
Healthy ratios and p-values, lists of gene ontology term enrichments, 
enriched functions discussed in the article and their proteins.
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LC-MS/MS was performed with an EASY-nLC 1000 coupled to a Q Exactive (both Thermo 
Fisher Scientific, Bremen, Germany).  
The LC was equipped with an Acclaim PepMap® 100 precolumn, C18, particle size 3 μm, 
pore size 100 Å, inner diameter 75 μm, length 2 cm, nanoViper,(Thermo Fisher Scientific, 
Bremen, Germany). The separation column was an EASY-Spray, PepMAP® RSLC, C18, 
particle size 2 μm, pore size 100 Å, inner diameter 75 μm, length 50 cm (Thermo Fisher 
Scientific, Bremen, Germany).  
The solvents for separation were water with 0.1% FA, and acetonitrile with 0.1% FA, 
respectively. 
LC settings 
The peptides were concentrated on a reversed-phase trap column with 0.1% formic acid (FA) 
at a flow rate of 20 µl/min. The peptides were separated on a reversed-phase main column 
with a binary solvent gradient. The column temperature was set to 60 °C and the flow rate to 
200 nl/min. The ACN proportion was increased from 2% to 5% over 19 min, further to 30% 
at 180 min and to 100% at 200 min. The column was regenerated with 100% ACN for 
additional 10 min. 
MS/MS settings 
The Q Exactive mass spectrometer was run in positive mode with the following settings: 
Chromatographic peak width 15 s, default charge state 2, full MS survey scans from 400 to 
2,000 m/z, resolution 70,000, AGC target value 3e6, maximum injection time 100 ms for MS 
scans. Subject the 10 most intense peaks to MS/MS with the following settings: resolution 
17,500, dynamic exclusion 10 s, underfill ratio 1%, charge states +2, +3 and +4, exclude 
isotopes, normalized collision energy 31, isolation window 2 m/z, AGC target value 1e5 and 
maximum injection time 50 ms, fixed first mass 120. 
MaxQuant settings 
The mass spectrometry data was searched in MaxQuant version 1.6.1.0 against a fasta file 
from https://www.uniprot.org/ (download date: 24.11.2017). This file included all human 
proteins (canonical and isoforms). The TMT reporter ion distribution was configured 
according to the manufacturer’s Certificate of Analysis. The quantification method was set to 
“Reporter ion MS2/TMTsixplex”. File names and fraction numbers were set according to the 
experimental setting. The following further parameters were applied: 
Enzyme: Trypsin/P (specific), fixed modifications: Carbamidomethyl (C), variable 
modifications: Oxidation (M) and Acetyl (Protein N-term), max. 2 missed cleavages, PSM 
FDR: 0.01, Protein FDR: 0.01 Site FDR: 0.01, Use Normalized Ratios For Occupancy: 
TRUE, Min. peptide Length: 7, Min. score for unmodified peptides: 0, Min. score for 
modified peptides: 40, Min. delta score for unmodified peptides: 0, Min. delta score for 
modified peptides: 6, Min. unique peptides: 0, Min. razor peptides: 1, Min. peptides: 1, Use 
only unmodified peptides and: TRUE, Modifications included in protein quantification: 
Oxidation (M) and Acetyl (Protein N-term), Peptides used for protein quantification: Razor, 
Discard unmodified counterpart peptides: TRUE, Label min. ratio count: 2, Use delta score: 
FALSE, iBAQ: FALSE, iBAQ log fit: FALSE, Match between runs: TRUE, Matching time 
window [min]: 0.7, Alignment time window [min]: 20, Find dependent peptides: FALSE, 
Decoy mode: revert, Include contaminants: TRUE, Advanced ratios: TRUE, Second peptides: 
FALSE, Calculate peak properties: FALSE, Main search max. combinations: 200, Advanced 
site intensities: TRUE, Max. peptide mass [Da]: 4600, Min. peptide length for unspecific 
search: 8, Max. peptide length for unspecific search: 25, Razor protein FDR: TRUE, Disable 
MD5: FALSE, Max mods in site table: 3, Match unidentified features: FALSE, MS/MS tol. 
(FTMS): 20 ppm, Top MS/MS peaks per Da interval. (FTMS): 12, Da interval. (FTMS): 100, 
MS/MS deisotoping (FTMS): TRUE, MS/MS deisotoping tolerance (FTMS): 7, MS/MS 
deisotoping tolerance unit (FTMS): ppm, MS/MS higher charges (FTMS): TRUE, MS/MS 
water loss (FTMS): TRUE, MS/MS ammonia loss (FTMS): TRUE, MS/MS dependent losses 
(FTMS): TRUE, MS/MS recalibration (FTMS): FALSE. 
Perseus 
Data normalization 
The proteinGroups file generated by MaxQuant was loaded into Perseus version 1.6.1.1. The 
“Reporter Intensity Corrected” columns were loaded as main columns. These intensities were 
log(2) transformed. The respective standard intensities were then subtracted. The intensity 
columns were renamed according to the respective sample name and categorical annotations 
were added (UC and H, respectively). Rows were filtered to remove proteins labelled as 
“Only identified by site”, “Reverse” and “Potential contaminant”. The intensities were then Z-
score normalized (matrix access: column). 
The Z-score normalized values were used for all analyses, except the determination of the 
UC/H ratio. 
Creation of lists and figures 
Figures 
For figure 1A the rows were filtered to have at least 70% values and column correlations were 
calculated for the normalized protein intensities with standard settings. The results were 
visualized by hierarchical clustering. The replicates were only included for this figure and 
were removed for all other analyses. 
For figure 1B, the Z-score transformed dataset was filtered for 70% valid values. The 
intensities of each protein for UC2, 3, 4, 6, 7, 11, 13, 14, and 16 (UC a), UC1, 5, 8, 9, 10, 12, 
15, and 17 (UC b), H3, 4, 5, 6, 7, 8, 10, and 11 (H a), and H1, 2, 9, 12, 13, 14, and 15 (H b), 
respectively, were averaged. This was done by assigning the respective groups to the samples, 
followed by the function “Annot. rows → Average groups, Average type: mean”. The 
averaged intensities were visualized in a multi scatter plot. 
For figure 1C, the dataset without replicates was filtered for 100% valid values before the 
PCA was generated. 
Figure 2 was generated by filtering the normalized dataset without replicates for 70% valid 
values. A two-sample test was performed to determine significant differences between the UC 
samples and healthy controls with standard settings, except for s0 = 2 and FDR = 0.01. The 
dataset was then filtered for significantly changed proteins. The figure was prepared by 
hierarchical clustering of the resulting dataset, and setting the number of clusters to 17. 
For figure 3A and B, the lower abundant proteins and higher abundant proteins, respectively, 
which were identified in the previous two-sample test were selected. Their gene identifiers 
were loaded into the Cytoscape app ClueGO and analyzed against WikiPathways (updated 
07.02.2018), showing only pathways with pV ≤ 0.01. GO term grouping was activated for the 
higher abundant proteins, but not for the lower abundant proteins. The ClueGO Layout was 
selected and manually refined. All other parameters were at the standard setting. 
Metabolic pathways (suppPathway1-5) were mapped at 
https://humancyc.org/overviewsWeb/celOv.shtml# (date: 01.01.2019) with Gene IDs and 
logaritmized UC/H ratios of all quantified proteins. 
   
List of enriched GO terms 
To generate the enrichment lists provided with the supporting information, annotations were 
added to the unfiltered matrix resulting from the two sample test (see preparation of Figure 2). 
Lists of more and less, respectively, abundant proteins were generated, based on the two-
sample test. These lists were separately matched back to the matrix with the added annotations 
with the function “matching rows by name” and the option of an indicator in the new matrix. 
Fisher exact tests with the categorical column indicating the respective matrix of enriched 
proteins and standard settings gave the enrichment lists. 
List of proteins in enriched terms 
For the ratio UC/H, the normalized intensities before Z-scoring (i.e. after log(2) 
transformation and subtraction of the respective standard intensity) were used. The mean of 
the sample intensities (matrix acces: column) was subtracted. The difference between the 
normalized log(2) intensities of UC and H was calculated in a two-sample test. The resulting 
log(2) differences were transformed back by a 2^x operation which gives the ratio of the 
normalized protein intensities. 
The UC/H ratio column was then matched with the function “Matching rows by name” to the 
column “majority protein” into a matrix of the 6818 proteins which were quantified in >70% 
of the samples, including two-sample test results (after Z-scoring) and GO annotations. 
A volcano plot was created from this list. The rider “categories” allows the selection of all 
proteins in a given category by clicking on the category name in the list. The respective 
proteins were subsequently exported into a separate matrix (Rider: “Points” → “Export 
selection (reduce matrix”), which was then exported into a tab delimited text file (Right-click 
→ “Plain matrix export”). 
List of all proteins 
The Z-score difference and the –log p-value were determined in a two-sample test from the 
normalized values after Z-scoring from all 8562 identified proteins. The corresponding Ratio 
UC/H was calculated and implemented as described in “List of proteins in enriched terms”. 
The indicators for whether a difference is significant (as generated for figure 2) were matched 





Grade Average SD Range 
Architectural changes (0-3) 1.06 0.66 0-3 
Chronic inflammatory 
infiltrate (0-3) 1.31 0.46 1-2 
Eosinophils in lamina 
propria (0-3) 0.88 0.60 0-2 
Neutrophils in lamina 
propria (0-3) 1.06 0.83 0-2 
Neutrophils in epithelium  
(0-3) 1.69 0.68 1-3 
Crypt destruction (0-3) 1.31 1.04 0-3 
Erosions and ulcerations 
(0-4) 0.63 1.36 0-4 
Total (0-22) 7.94 3.77 3-16 
 




Starting protein concentration [µg/ml] 
in sample as determined in BCA assay 
TMTsixplex for 25 µg 
peptides 
≥ 2200  0.4 mg 
1530 to 2200 0.5 mg 
1173 to 1530 0.6 mg 
952 to 1173 0.7 mg 
800 to 952 0.8 mg 
 
Suppl. table2: Used TMTsixplex amounts in dependence of starting concentration of samples. 
The TMTsixplex amount was adjusted for low concentrated samples, because poor labeling 








Protein names Gene names Majority 
protein IDs 
10.1177 10.5488 Kinesin-like protein KIF26B B7WPD9 
6.7208 8.40544 Protein S100-A8 S100A8 P05109 
6.69903 9.70578 Cathelicidin antimicrobial peptide CAMP J3KNB4 
6.16675 8.07071 Protein S100-A9 S100A9 P06702 
4.94808 8.35806 Protein S100-A12;Calcitermin S100A12 P80511 
4.72862 7.01854 Neutrophil defensin 1 DEFA1 P59665 
4.47297 9.41786 Lactotransferrin LTF;HEL110 E7EQB2 
4.39275 7.48579 Myeloblastin PRTN3 P24158 
4.17913 13.5737 Neutrophil gelatinase-associated lipocalin NGAL;LCN2 B2ZDQ1 
3.5434 7.48418 Neutrophil elastase ELANE;ELA2 P08246 
3.50704 8.35501 Azurocidin AZU1 P20160 
3.49049 6.43954 Cysteine-rich secretory protein 3 CRISP3 J3KPA1 
3.21954 9.05008 Myeloperoxidase MPO P05164-2 
3.2025 4.30977  BPI A2NX48 
3.16036 8.49697 Lysozyme LYZ B2R4C5 
3.01386 6.64713 Ficolin-1 FCN1 O00602 
2.85388 6.53514 Resistin RETN Q9HD89 
2.72326 6.35354   B7Z507 
2.53399 6.33617 Matrix metalloproteinase-9 MMP9 P14780 
2.43248 5.56569 Neutrophil collagenase MMP8 P22894 
 
Suppl. table3: Proteins from the minor cluster of the proteins which are more abundant in UC 
(cluster 1, see article figure 2). Given for each protein is only the first Majority protein ID 
states (see Excel file, Supplementary Data Content 2, which lists all 8562 identified protein, 
for further IDs and data on these proteins (labeled there with “Cluster 1 (minor cluster 




Suppl. figure1: Profile plot of the minor cluster (orange and red) of higher abundant proteins 
in UC in comparison with the major cluster of more abundant proteins (grey). The profile 





Suppl. figure2: Profile plot of the averages of the normalized protein intensities from the 
minor (top) and major (bottom) cluster of upregulated proteins in UC. 
 
 
Ratio UC/H p-value UC_H Gene name 
1.63153 9.60672 SPCS1 
1.66381 11.2304 SPCS3 
1.70966 10.7076 SPCS2 
2.252 10.7787 SEC11C 
1.26938 12.2656 SPC18 
 
Suppl. figure3: Profile plot and statistics of signal peptidase complex protein abundances. 
SPCS1, SPCS2, SPCS3, and SEC11C present similar abundance profiles. SPC18 does not 





Suppl. figure4: Profile plot of normalized abundances of three proteins which differ strongly 
between UC and healthy tissue (SLC26A2, sulfate transporter; HMGCS2, 
Hydroxymethylglutaryl-CoA synthase; CD38, ADP-ribosyl cyclase/cyclic ADP-ribose 
hydrolase 1). These were selected based on p-value and the difference between the group 
averages. Calprotectin (S100A8 and S100A9) is shown for reference. It shows a large 
difference between the UC and healthy average intensities, but it presents with low 
significance. Overlaps occur in which single healthy tissue samples show higher calprotectin 



















































































































































































































































































































































SuppPathway4: Protein abundance changes in tricarboxylic acid (TCA) cycle. Arrow colors 




SuppPathway5: Protein abundance changes in bile acid synthesis, neutral pathway. Arrow 
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